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ABSTRACT 
As a result of the enormous clinical need, cardiac tissue engineering has become a prime 
focus of research within the field of tissue engineering. In this project, Poly(3-
hydroxyoctanoate), P(3HO), a medium chain length (mcl-PHAs) biodegradable, 
biocompatible and elastomeric polyhydroxyalkanoate, was studied as a potential material for 
cardiac tissue engineering. Mcl-PHAs are an alternative source of polymers produced by 
Pseudomonas sp. As Gram-negative bacteria, Pseudomonas sp. contains lipopolysaccharides 
in the membrane, which are co-purified with PHAs and may cause immunogenic reactions. 
This limits the biomedical applications of the mcl-PHAs in several cases. In this work, the 
Pseudomonas mendocina PHA synthase gene (phaC1) was expressed in the LPS free, GRAS, 
Gram-positive microorganism, Bacillus subtilis so as to produce LPS-free mcl-PHAs. Our 
results showed that the recombinant Bacillus subtilis containing the phaC1 gene produced 
poly(3-hydroxybutirate), P(3HB), with a maximum yield of 32.3 % DCW, an unexpected 
result. This result thus revealed the unusually broad substrate specificity of the PHA synthase 
from P. mendocina, which is able to catalyse both medium and short chain length PHAs 
biosynthesis depending on the metabolic pool available in the host organism. Sequence 
comparison of this PHA synthase with stringent mcl-PHA synthases revealed possible 
residues influencing the substrate specificity of PHA synthases.  
As studies on mcl-PHAs remain limited mainly because of the lack of availability of mcl-
PHAs in large quantities, the capacity to scale-up P(3HO) production from 2 L to 20 L and 
72 L pilot plant bioreactors, based on constant oxygen transference, was studied.  
The interaction of freshly isolated rat cardiomyocytes with the P(3HO) polymer, during 
contraction, was studied when cells were stimulated at a range of frequencies of electrical 
pulses or calcium concentrations. These results showed that P(3HO) did not have any 
deleterious effects on the contraction of adult cardiomyocytes.  P(3HO) cardiac patches non-
porous, porous or with P(3HO) electrospun fibres deposited on their surface were developed. 
Our results showed that the mechanical properties of the final constructs were close to that of 
the cardiac structures, with a Young’s modulus value of 0.41±0.03 MPa. Myoblast (C2Cl2) 
cell proliferation was studied on the different constructs showing an enhanced cell adhesion 
and proliferation when both porous and fibrous structures were incorporated together.   
Finally, for further enhancement of the cardiac patch function, VEGF and RGD peptide were 
incorporated. Results obtained in this project showed that the P(3HO) multifunctional cardiac 
patches were potentially promising constructs for efficient cardiac tissue engineering.  
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Cardiovascular diseases (CVDs) are the leading cause of death throughout the world 
(Morosco et al., 2002, Perry et al., 2003). According to the World Health Organization, an 
estimated 17.3 million people died from CVDs in 2008 and it is predicted that by 2030 
almost 25 million people will die from CVDs. CVDs, including coronary heart disease, 
hypertension, peripheral artery disease, rheumatic heart disease and congenital heart disease 
among others, are caused by disorders in the cardiac tissue and blood vessels. Myocardial 
infarction is the main cause of death in patients with CVDs. Myocardial infarction is an 
irreversible necrosis of the cardiac tissue produced by an imbalance in the oxygen and 
nutrient supply to a portion of the myocardium. The acute loss of myocardium triggers a 
cascade of cell signals activating a ventricular remodelling process, which can be divided in 
two phases: early remodelling and late remodelling. The early ventricular remodelling 
process includes the formation, thinning and elongation of a fibrotic scar that cause elevation 
of diastolic and systolic wall stresses. An increased wall stress leads to a late remodelling 
characterized by myocytes hypertrophy and production of interstitial collagen with an 
increased wall mass and chamber enlargement (Figure 1.1) (Sutton and Sharpe 2000). 
Myocardial infarction may eventually lead to the deterioration of systolic or diastolic function 
and to increased predisposition to arrhythmias and other long-term complications. 
Figure 1.1. Schematic representation of post-myocardial infarction remodelling. The 
infarction of a specific part of the tissue leads to the formation, thinning and elongation of a 
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fibrous scar followed by myocytes’ hypertrophy and production of interstitial collagen with 
an increased wall mass and chamber enlargement (Konstam et al., 2011). 
 
1.2. Anatomy of the heart 
The heart is the organ responsible for blood supply by repeated rhythmic contractions to all 
parts of the body. The heart cavity is divided into a right and a left heart, which are further 
subdivided into two chambers. The upper chambers are called right and left atrium and they 
receive the blood entering the heart. The lower chambers are called right and left ventricle 
and they pump the blood out of the heart. The right and left heart are considered as two 
separate pumps as they are in charge of the pulmonary and peripheral circulation, 
respectively. As each chamber contracts, blood is forced into the ventricles and out of the 
heart for re-circulation. In particular, the right atrium receives blood from the different organs 
via the vena cava and blood passes through the tricuspid valve to the right ventricle where it 
is pumped out through the pulmonary artery to the lungs. Blood is oxygenated in the lungs 
and returned via the pulmonary veins to the left atrium. Oxygenated blood is passed to the 
left ventricle responsible for pumping blood around the whole body (Laizzo et al., 2009). 
Figure 1.2 illustrates the anatomy of the heart. 
 
 
Figure 1.2. Schematic representation of the heart anatomy (Taken from Mader 1999). 
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The heart wall is composed of the endocardium, myocardium, and epicardium layers 
(Kierszenbaum et al., 2002). The myocardium is the tissue responsible for the alternating 
contractions and relaxations cycles induced by electrical impulses, allowing pumping of 
blood. The myocardium consists of cardiomyocytes, extracellular matrix and blood vessels.  
The cardiomyocytes are terminally differentiated cells responsible for the contraction and 
relaxation cycles. On the other hand, the extracellular matrix, mainly composed of type I and 
type III collagen, provides a framework that couples and aligns adjacent myocytes to 
optimize and distribute force development in the ventricular walls and avoids deformation 
(Sutton and Sharpe 2000). The epicardium, also known as the visceral pericardium, is mainly 
composed of connective tissue and it provides an outer protective layer to the heart. The 
endocardium is a thin layer of endothelium and connective tissue that lines the chambers of 
the heart (Kierszenbaum et al., 2002). 
 
1.3. Cardiac contraction 
Cardiac excitation–contraction cycle is initiated by an action potential. Here, the 
cadiomyocytes’ membrane is depolarized when ions enter through connexin channels from 
an adjacent cadiomyocyte inducing the entry of Na+ through voltage gated-sodium channels. 
After a rapid depolarization of the membrane, inactivation of Na+ channels and activation of 
Ca2+ and K+ channels occur. Ca2+ influx triggers Ca2+ release from the sarcoplasmic 
reticulum (SR) through the ryanodine channels (RyR). Both Ca2+ influx and Ca2+ released 
from the sarcoplasmic reticulum raises cytosolic free Ca2+, which binds to the troponin 
complex (TnC) that switches on the myofilaments in a cooperative manner, activating the 
contraction. Cardiomyocyte relaxation occurs when Ca2+ dissociates from troponin after Ca2+ 
is removed from the cytosol by calcium uptake pumps in the sarcoplasmic reticulum and by 
Na+/Ca2+ exchange pumps present in the cell membrane (Knollmann et al., 2008). Figure 1.3 





Figure 1.3. Schematic representation of cardiac contraction and relaxation mechanisms 
(Bers, 2000). 
1.4. Cardiac therapies 
As cardiac tissue lacks significant regenerative capacity to replace lost cells, the cardiac 
tissue injury is permanent. Different pharmacological or interventional therapies are currently 
applied to patients with cardiac failure. Pharmacological therapies aim to reduce the load of 
the cardiac tissue or to increase the strength of the heart muscle contraction. Among the most 
common drugs utilized are: angiotensin-converting enzyme (ACE) inhibitors, β-blockers, 
aldosterone antagonists and angiotensin II receptor antagonist (ARB). Interventional 
therapies include the implantation of pacemaker/defibrillator devices to synchronize the 
electrical and mechanical pulses of the heart or surgery to replace the infarcted tissue with a 
“cardiac patch” that reinforce the organ. Although in some patients these therapies have 
served to achieve a significant prolongation of life, additional improvement is needed to 
adequately control the progression of the disease to the end stage, in majority of the patients 
(Krumholz et al., 2000). Cardiac transplantation has become the last viable treatment option 
for patients with end stage cardiac disease. However, due to the lack of organ donors and the 
post-operative complications including infection, sepsis, organ rejection and side effects of 
the immunosuppressive medication, new strategies need to be developed to treat infarcted 
hearts (Bishay, 2011). 
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1.4.1. Cardiac tissue engineering 
Recently, cardiac tissue engineering has provided a promising alternative method to treat 
heart disease. Much research has been carried out in the development of engineered tissues 
that can replace the infarcted myocardium. In a first approach, studies involving the injection 
of several cell sources directly into damaged areas or intravenously were carried out. To this 
end, several cells types were explored including cardiomyocytes, embryonic stem cells and 
bone marrow-derived mesenchymal stem cells (Ye et al., 2011). Although some studies 
reported significant improvement in myocardial function, this improvement was not clinically 
relevant and only transient (D’Alessandro et al., 2010). Investigations to date have shown 
that the main limitations of this technique include poor cell integration, cell loss and cell 
death. Additionally, some cell sources showed a negative effect by inappropriate electrical 
integration leading to occurrences of arrhythmia (Prabhakaran et al., 2011). Fernandes et al., 
(2010) studied the effect of intramyocardial injection of embryonic stem cell-derived 
cardiomyocytes after chronic infarction in rats for three months. Results showed that 
implanted cells were insufficient to restore heart function or alter adverse remodelling. 
Additionally, different groups have focused on the integration between host and injected cells 
by studying cell junctional expression molecules, including connexin 43 and cadherin. 
Results showed no significant cell integration after injection (Nunes et al., 2011). 
In a second approach several naturally derived and synthetic polymers were proposed to 
replace the non-contractile infarcted tissue. Among the natural derived biomaterials were 
collagen, fibrin, chitosan, gelatine and decellularized extracellular matrix (Pok et al., 2011). 
One of the major advantages of many naturally occurring polymers is the non-immunogenic 
nature as they mimic the native extracellular matrix well, facilitating cell adhesion, growth 
and proliferation. However, most of these materials fail as cardiac patches due to their poor 
mechanical properties or high degradation rates. One example is collagen, the most abundant 
constituent of the extracellular matrix, which as expected, showed good cell adhesion 
properties but poor mechanical support (Atala et al., 2001). Among the decellularized 
extracellular matrix are porcine small intestine submucosa (SIS) and bovine pericardium. 
Badylak et al., (2002) showed promising results with good myocardial cell infiltration and 
spontaneous contraction after SIS membrane implantation in pigs and dogs. However, other 
studies showed difficulty in finding large portions of SIS with homogeneous properties and in 
vivo xenogenic rejection after implantation (Keith et al., 2005, Tottey et al., 2011). On the 
other hand, although bovine pericardium showed reliable consistency, durability, easy 
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handling, good cell migration and proliferation, xenogenic rejection was observed due to the 
transplantation of bovine proteins/DNA along with the membrane into the host (Li et al., 
2011). In contrast, several synthetic biomaterials were developed. Among the most used are: 
poly(lactic acid) (PLA), poly(glycolicacid) (PGA), polycaprolactone (PCL), poly(lactic-
glycolic acid) (PLGA) and poly(glycerol-sebacate) (PGS). The main advantages of synthetic 
polymers are the capacity to produce them in large quantities and the ability to regulate the 
microstructure, mechanical properties and degradation rate. However, many of these 
materials present acidic degradation products and showed reduced cell adhesion properties in 
contrast to naturally derived materials (Pok et al., 2011). For instance, the intermediate 
degradation products of PLGA are lactic and glycolic acid, which reduce the local pH, 
causing not only an inflammatory reaction but also accelerating the polymer´s degradation 
rate (Liu et al., 2006). 
The combination of a natural or synthetic biomaterial with relevant cells and growth factors 
ex vivo is currently receiving much attention as an alternative for cardiac tissue engineering 
treatments (Giraud et al., 2007) (Figure 1.4). The final goal will be the selection of an 
appropriate cell type and the development of a biocompatible flexible material that stimulates 
cell growth and guides and supports tissue regeneration in order to replace formed scar tissue 
with functioning cardiac muscle tissue. The material’s physical and mechanical 
characteristics should be similar enough to those of the natural myocardium in order to 
support the organ during the regeneration process, and its composition should allow it to 
degrade as the new tissue takes over its function (Jawad et al., 2008). Bioabsorbable 
polymeric materials provide an extracellular matrix where growing cells can localize and 
interact to form new tissue. An ideal biomaterial should possess five special characteristics. 
First, the material should be biocompatible. Second, the material mechanical properties 
should be similar to the host tissue to provide mechanical support to the cells until new 
extracellular matrix is synthesized by the cells. As previously described, myocardial 
infarction normally results in wall thinning and ventricular dilatation that cause a significant 
stress in the heart wall. Overstressed wall leads to a progressive ventricular remodelling with 
an end stage of heart failure (Sutton and Sharpe 2000). In order to prevent an overstressed 
wall with a negative ventricular remodelling, the material’s mechanical properties should 
allow reducing the heart wall stress (Chen et al., 2007). Third, the material should possess an 
appropriate shape and size to guide and organize the cells and to repair at the implant site. 
Fourth, the chemistry of the material’s surface should allow cell attachment, differentiation 
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and proliferation. Fifth, the composition of the material should allow biodegradation in vivo 
at rates appropriates for tissue regeneration (Williams et al., 1999).     
Figure 1.4. A schematic diagram illustrating the principle of myocardial tissue engineering 
1.4.1.1. Biomaterials used in myocardial tissue engineering 
Several synthetic and naturally occurring materials combined with different cell sources have 
been explored for myocardial tissue engineering applications. Among the natural polymers, 
collagen, gelatine and alginate have been under intensive investigation. Kofidis et al., (2002a) 
seeded neonatal rat cardiomyocytes in vivo in a commercially available collagen matrix. 
Results showed good cell attachment and continuous rhythmic contractions for up to two 
weeks. However, insufficient size, inadequate geometry, low viability, weak physical 
properties such as elasticity, integrity and plasticity, low biocompatibility and high 
production costs were reported. Li et al., (1999) also observed good cell proliferation and 
spontaneous and regular contraction of the grafts after subcutaneous implantation of a 
gelatine mesh seeded with cells derived from foetal rat ventricular muscle. However, grafts 
underwent significant degradation and showed high thrombogenicity. Leor et al., (2000) 
isolated and grew foetal cardiac cells within 3D porous alginate scaffolds for the implantation 
in rat myocardial scar tissue in vivo. Although results showed that the grafts attenuated left 
ventricular dilatation and heart function deterioration, presence of macrophages, lymphocytes 
infiltration and low myocardial mass in the graft was observed. In addition to natural 
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polymers, among the most investigated synthetic polymers were PGA, PCL, PLA and PLGA. 
Xing et al., (2012) developed myocardial grafts by seeding bone marrow mesenchymal stem 
cells on scaffolds consisting of 50% polylactic acid (PLA) and 50% polyglycolic acid (PGA). 
Results showed that PLGA scaffolds implanted in rat peritoneal pocket could form 
engineered myocardial tissue with structural and functional features resembling those of 
native tissue. However, the function of the engineered graft in the ischemic heart model 
should be studied to determine the construct capacity to regenerate and support the organ 
during regeneration. Shinoka et al., (2005) seeded bone marrow cells in PCL/PLLA scaffolds 
and resulting constructs were implanted as patches to repair congenital heart defects in 19 
patients, ages from 1 to 24 years. No complications such as thrombosis, stenosis, or 
obstruction of tissue engineered autografts were observed. However, long term analysis is 
needed to determine the capacity of the graft to support the organ in the long term. Several 
studies on creating beating engineered synthetic constructs have been reported recently 
showing that the stiffness of the scaffold impeded the contractions (Shin et al., 2004). 
Additionally, due to the myocardial tissue cyclic and constant beating, a plastic deformation 
and failure is expected when thermoplastic polymers such as PGA, PLA and PCL and their 
copolymers are exposed to long term cyclic strain. Table 1.1 shows the most important 
mechanical properties of some materials explored for myocardial tissue engineering. These 
data show that most natural materials are weaker than myocardial structures in contrast to 
synthetic materials, which are much stiffer than the human myocardium.  
Table 1.1. Mechanical properties of materials proposed for myocardial tissue engineering 
Polymer Young’s modulus Tensile strength References 
Collagen 2-22 KPa 1-9 KPa Roeder et al., 2002 
Alginate 10-50 KPa 10-40 KPa Drury et al., 2004 
PGA 7-10 GPa 70 MPa Webb et al., 2004 
PCL 343.9-364.3 MPa 10.5-16.1MPa Eshraghi et al., 2010
PLA 1-4 GPa 30-80 MPa Garlotta et al., 2001 
PLGA 67 MPa 4 MPa Lin et al., 2011 
Myocardium (human) 0.2-0.5 MPa 3-15 KPa Watanabe et al., 2006 
Nagueh et al., 2004 
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1.4.1.2. Cells applied in myocardial tissue engineering 
As the type and source of cells will have an enormous influence on the success of the tissue 
engineered constructs, much research has been carried out to determine the most suitable 
cells to use in myocardial tissue engineering applications. Based on the cell source, cells can 
be classified into autologous (patient origin), allogeneic (human origin, not patient) and 
xenogeneic (animal origin). Autologous cells are preferred since no immunosuppressive 
therapy is required compared to allogeneic and xenogeneic cells. However, difficulty in 
harvesting a sufficient amount of cells, mainly from aged or diseased patients leads to the use 
of allogeneic or xenogeneic cell sources (Ikada et al., 2006). Additionally, cells can be 
classified according to the extent of differentiation (Figure 1.5). Fertilized ovum creates a 
totipotent cell, zygote, which is capable of developing into all the specialized cells that make 
up the body. As cells proliferate, they differentiate into two lineages, the pluripotent inner 
cell mass and the trophoectoderm. Pluripotent cells can be isolated and propagated in vitro in 
an undifferentiated state as embryonic stem cells. Pluripotent cells proliferate into the three 
major germ layers: endoderm, mesoderm or ectoderm. These three multipotent layers 
proliferate and differentiate to progenitor cells, which form the organs (Shoukhrat et al., 
2009). Adult stem cells, which reside in organs, are defined as multipotent as they have the 
capacity to differentiate into restricted number of cell lineages. 
Figure 1.5. A schematic diagram illustrating the different stages of cells differentiation 
(Taken from Ikada et al., 2006). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  INTRODUCTION	  
	  
11	  
The optimal cell source to create a myocardial patch should be non-immunogenic, easy to 
isolate, proliferative, and with the capacity to differentiate into functional cardiomyocytes 
(Leor et al., 2005). Different cells were proposed for myocardial tissue engineering including 
foetal cardiomyocytes, skeletal myoblasts, mesenchymal stem cells, smooth muscle cells, 
endothelial progenitor cells, bone marrow cells, fibroblasts and human embryonic stem cells 
(Li et al., 1999, Kamelger et al., 2004, Krupnichk et al., 2001, Matsubayashi et al., 2003, 
Ryu et al., 2005, Kadner et al., 2004, Levenberg et al., 2003). It is expected that the most 
suitable cells for myocardial tissue regeneration are cardiomyocytes, due to their natural 
electrophysiological, structural, and contractile properties. However, healthy cardiomyocytes 
capable of contracting at high pacing rates are difficult to obtain, to expand, and can be 
maintained in culture for only up to 36–48 hr (Pinz et al., 2011). The alternatives to 
cardiomyocytes are cardiac adult stem cells or embryonic stem cells, which are able to 
differentiate to cardiomyocytes in vitro under appropriate conditions. One of the problems 
associated with adult stem cells is the difficulty in harvesting a sufficient amount of cells, 
especially when the patient is aged or diseased. On the other hand, it was demonstrated that 
embryonic stem cells could generate spontaneously contracting engineered heart tissue 
(Eschenhagen et al., 2005). For this reason, embryonic stem cells are one of the best 
alternatives for myocardial tissue engineering applications. Table 1.2 shows some advantages 












Table 1.2.  Advantages and disadvantages of different cell types proposed for myocardial 
tissue engineering applications (adapted from Chen et al., 2010, Galvez-Monton et al., 2013 
and Leor et al., 2005). 
Cell type Advantages Disadvantages 
Fetal 
cardiomyocytes 
Cardiomyocytes phenotype Limited availability 
Low survival 

























High rate of proliferation 
Hypoxia-resistant 
Autologous 
High incidennce of 
arrhythmias 
Fibroblasts Easily isolated 
High rate of proliferation 
Autologous 
No cardiac myogenesis 




High rate of proliferation 
Autologous 
No cardiac myogenesis 
No clinical experience 
1.4.1.3. Active molecules used in myocardial tissue engineering 
There are a range a proteins produced by the cells in the body that play key role in cell 
adhesion, proliferation, migration and differentiation. Several reports have shown an 
enhanced response of the engineered construct by the addition of these bioactive agents 
(Epstein et al., 2001, Richardson et al., 2001, Yamoto et al., 2003). Among the most 
frequently used growth factors are basic fibroblast growth factor (bFGF), vascular endothelial 
growth factor (VEGF) and transforming growth factor-b (TGF-b) (Ikada et al., 2006). These 
growth factors assist cellular proliferation, differentiation, migration and vascularization 
(Jakowlew et al., 2006, Neufeld et al., 1999). As the contractile nature of the cardiac tissue 
demands readily available high oxygen and nutrient concentrations, delivery of angiogenic 
growth factors from the engineered graft is a key factor to encourage the rapid development 
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of the vascular network. Several studies have confirmed the capacity of these angiogenic 
factors to facilitate blood vessel growth when they are incorporated into bioengineered 
tissues. Perets et al., (2003) proved that the local release of bFGF incorporated into alginate 
scaffolds enhanced the rate and extent of vascularization, when implanted into rat 
peritoneum. Singh et al., (2012) showed that VEGF simulated angiogenesis, after 
encapsulation in PCL scaffolds, when implanted subcutaneously in mouse.  
One critical aspect in the application of these angiogenic growth factors in tissue engineering, 
due to their short biological half-life and high tumorigenic potential, is the delivery of these 
factors to the site of action in a sustained and controlled manner (Faranesh et al., 2004). 
Shankha et al., (2004) investigated the effect of intramyocardial and intracoronary 
administration of bFGF in chronically ischemic porcine myocardium. Results showed that 
direct intramyocardial injection results in significant improvement in regional myocardial 
blood flow, in contrast to intracoronary perfusion. In order to allow direct release at the site, 
several groups have been working towards the incorporation of growth factors in 
biodegradable polymers to provide localized and sustained release. The incorporation of these 
growth factors in biodegradable polymers not only allows a localized release but also allows 
adjusting the magnitude of the release by altering the polymer degradation rates. Growth 
factors can be incorporated into engineered constructs by two main approaches. The first 
approach involves the mixing of the factor before processing the polymer into the final 
construct. The second approach involves pre-encapsulation of a factor in microspheres and 
the incorporation of these microspheres in the final construct. Richardson et al., (2001) 
showed a much-controlled release when VEGF was incorporated into PLGA microspheres 
than direct incorporation into the engineered PLGA constructs. 
One important problem in the application of different biomaterials in tissue engineering is the 
inadequate interaction of the construct with the cells, leading to foreign body reactions, 
infections, implant encapsulation, thrombosis and embolization (Thull et al., 2001). In order 
to address this issue much research is been carried out in the immobilization of cell 
recognition motifs to obtain controlled interaction between the cells and the material 
(Hubbell, 1999). Among the most explored proteins that allow efficient host cell recruitment 
and adhesion are fibronectin and arginine-glycine-aspartic tripeptide sequence (RGD peptide) 
(Hersel et al., 2003, Ota et al., 2005, Yoon et al., 2003). Matsuzaka et al., (2004) showed that 
the number of rat bone marrow cells adhering to a fibronectin immobilized polystyrene disk 
increased after 1 or 2 hr incubation compared with non-immobilized surfaces. Shachar et al., 
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(2011) investigated the effect of neonatal rat cardiac cells on RGD-immobilized or 
unmodified alginate scaffolds. Results showed that RGD immobilized surfaces promoted cell 
adherence to the matrix accelerating cardiac tissue regeneration and that within 6 days 
myofibres composed of multiple cardiomyocytes in a typical myofibre bundle were formed. 
 
1.4.1.4. Techniques for the fabrication of engineered constructs 
The main goal in tissue engineering is the fabrication of a matrix that restores and maintains 
the lost biological function of the host tissue (Langer et al., 1993). Much research is carried 
out to design engineered structures that can mimic the natural extracellular matrix of the 
tissue to support the native tissue until host cells can repopulate and resynthesize a new 
natural extracellular matrix. A number of fabrication technologies were developed for the 
production of engineered structures including: (I) Porogen leaching such as solvent cast 
particle leaching (SCPL), compression moulding (Wu et al., 2005) and gas foaming (Leatrese 
et al., 1998); (II) Phase transitions, including solvent evaporation (Park et al., 2011), phase 
separation (Tu et al., 2003) and gel casting (Chopra et al., 2012); (III) Rapid prototyping such 
as stereolithography (Dhariwala et al., 2004) and fused deposition modelling (Zein et al., 
2002) and (IV) fibre deposition, including electrospinning (Zong et al., 2005) and bonded 
fibre meshes (Mikos et al., 1993). Figure 1.6 shows an example of some of the structures 
obtained with the most used methods from the four mentioned processing techniques. 
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Figure 1.6. SEM images of the different structures obtained by SCPL, freeze drying 
emulsions, stereolithography and electrospinning (Flaibani et al., 2012, Lu et al., 2004, 
Sultana et al., 2012).  
1.4.1.4.1. Solvent cast particle leaching 
The SCPL method is a technique widely used in the design of constructs for tissue 
engineering to incorporate porous structures due to its easy operation and capacity to 
precisely control number and size of pores. The particle leaching technique involves the 
addition of water-soluble particles to a polymer solution follow by casting of the films and 
porogen removal (Ikada et al., 2011). This technique is simple, low cost and can be used for 
many soluble polymers. The size of porous structures can vary from 30-300 µm and the 
porosity that can be obtained is 20-50% (Chen et al., 2007). Figure 1.7 illustrates the different 
steps involved in the solvent cast particle leaching technique.   
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Figure 1.7. Schematic diagram of the solvent cast particle leaching technique (adapted from 
Chung et al., 2007) 
1.4.1.4.2. Freeze-drying emulsions 
In the freeze-drying emulsions method water is emulsified in a polymer solution until 
homogeneity is achieved (Figure 1.8). The obtained emulsion is immediately poured into a 
metal mould, frozen and freeze-dried, creating porous structures. This technique was 
developed by Whang et al., (1995) for the fabrication of porous biodegradable scaffolds with 
PLGA. The resulting scaffolds porosities obtained were greater than 90% with median pore 
diameters ranging from 15-35 µm and larger pores greater than 200 µm. 
Figure 1.8. A schematic diagram of the freeze-drying emulsions method (adapted from 
www.powderpro.se). 




The stereolithography method requires a computer model of the desired scaffold architecture 
for the production of an accurate structure (Figure 1.9). In this technique an ultraviolet laser 
bean guided by a computer is focused on the surface of a liquid photopolymer tank drawing a 
slice of the structure and converting the thin layer of liquid plastic to a solid piece. The layer 
is immersed in the tank and covered with liquid photopolymer and in the following step the 
laser beam draws a layer over the previous one (Lanza et al., 2011). This technique allows 
the production of 100% interconnected porous structures ranging from 45-150 µm pore sizes 
(Chen et al., 2007).  
 
 




Electrospinning allows the fabrication of micro- and nano- structures that recreate the natural 
three-dimensional environment of the tissue for better cell organization, survival and function 
(Zong et al., 2005). Micro- or nano- fibres based matrix are fabricated for multiple 
biomedical applications, including production of scaffolds in tissue engineering, drug 
delivery and medical implants (Boland et al., 2001, Min et al., 2004, Khil et al., 2003). In this 
technique, a polymer solution is loaded and pumped through a syringe fitted with a nozzle 
connected to a voltage source. The suspended droplet created by gravity and mechanical 
pumping at the tip of the nozzle, is electrically charged creating a repulsion force directly 
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opposite to the surface tension. As the intensity of the electric field is increased, the surface 
of the droplet elongates to form a conical shape called Taylor cone (Taylor 1969). When the 
electric charges overcome the surface tension of the droplet a charged jet is ejected from the 
tip of the Taylor cone. As the jet is ejected from the droplet and travel through the air, the 
solvent evaporates and fibre is deposited on a grounded collector. Figure 1.10 shows the 
experimental setup for the electrospinning technique. 
 
Figure 1.10. Schematic diagram of the electrospinning technique (adapted from Khan et al., 
2008) 
Electrospinning is a simple, low cost technique, suitable for many soluble polymers. Fibrous 
structures are obtained with pores ranging from 20-100 µm and porosity higher than 95% 
(Chen et al., 2007). Different parameters were described to have an effect in the size and 
shape of the produced fibres including the solution properties, the controlled variables and the 
ambient parameters. Among the solution properties are viscosity, conductivity and surface 
tension. On the other hand, the controlled variables include pump flux, electric potential and 
the distance between the nozzle tip and the collector. Finally, the ambient parameters are 
temperature, humidity and air velocity (Doshi et al., 1995). By appropriately varying one or 
more of the above parameters different non-woven, porous and nano/micro-scale fibre based 
matrix were obtained with different synthetic and natural materials. Among the most used 
materials are PLGA, PLLA, poly(vinyl alcohol) (PVA), poly(ethylene oxide) (PEO), 
poly(caprolactone) (PCL), collagen, silk protein and fibrinogen (Smith et al., 2009). Duan et 
al., (2007) observed good cell attachment of fibroblast cells to a 275 ± 175 nm PLGA–
chitosan/PVA composite fibers. Chen et al., (2007) found that cell adhesion and growth are 
significantly affected as a function of fibre diameter and that in the range of 428-1051 nm 
fibres, cell adhesion and growth decreased with increasing fibre diameter. On the other hand, 

















Lu et al., (2012) studied the effect of Poly(3-hydroxybutyrate-co-3-hydroxyvalerate), P(3HB-
co-3HV), fibre orientation on the growth behaviour of bone-marrow-derived mesenchymal 
stem cells, showing that random-oriented nanofibrous scaffold are most favourable for cell 
growth, compared to aligned fibre scaffold. 
 
1.5. Polyhydroxyalkanoates 
In this project we proposed Poly-3-hydroxyoctanoate, P(3HO), a medium chain length 
biodegradable and biocompatible polyhydroxyalkanoate, as the biomaterial to deliver cells to 
the injured tissue and to support the organ during its regeneration process. PHAs are 
polyesters composed of several units of hydroxyalkanoate monomers linked to each other 
through ester linkages. Figure 1.11 represents the PHA’s general formula where ‘n’ is the 
number of monomer units in each polymer chain, which varies between 100 and 30000, ‘R1’ 
and ‘R2’ the side chain that includes alkyl groups with 1 to 13 carbons and ‘x’ in the main 
chain which ranges from 1 to 4. 
 
 
                                                                                                                                n 
Figure 1.11. General formula for PHAs. R1/R2: Alkyl groups C1-C13, x: 1-4, n: 100-30000.  
Numerous microorganisms synthesize PHAs by the fermentation of a carbon source and then 
accumulate them as intracellular carbon reserve inclusion bodies. In order to accumulate 
PHAs in most bacteria an excess supply of carbon and limitation of nitrogen, phosphorus, 
oxygen or magnesium is required. These elements are essential for the cell growth i.e. 
nitrogen is one of the main constituents of aminoacids, nucleic acid, nucleotides and 
coenzymes, phosphorous constitutes nucleic acids, nucleotides and phospholipids and 
magnesium is cofactor for certain enzymes reactions. These unfavorable growth conditions 
result in a decrease in cell growth and division, and a redirection of their metabolism towards 
the biosynthesis of the PHAs (Jurasek et al., 2004). The stored PHA can be degraded by 
intracellular depolymerases and metabolized as carbon and energy source when needed 
(Byrom et al., 1994). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  INTRODUCTION	  
	  
20	  
The properties of PHAs vary depending on the distance between ester groups in the molecule, 
the structure of the side groups and the number of monomer units in the polymer chain. For 
example, the length of the side chain and its functional group has a direct effect on the 
polymers physical properties such as flexibility, crystallinity, melting point and glass 
transition temperature (Volvoa et al., 2004). The nature and proportion of the PHA 
monomers are influenced by the type and relative quantity of carbon sources supplied to the 
growth media, the organism used and the culture conditions provided (Ojumu et al., 2004).  
For instance, based on growth conditions and the used microorganism, the molecular weight 
of the polymers can vary from 2 × 105 to 3×106 Daltons (Byrom et al., 1994). 
PHAs can be either thermoplastic or elastomeric materials with variable mechanical, thermal 
stability and durability properties. They are water insoluble and impermeable to oxygen 
(Chen et al., 2010). Due to the stereospecificity of the PHA synthase, all the 
hydroxyalkanoate monomers incorporated in the polymer are in the R(-) configuration, 
resulting in an optically pure polymer (Zinn et al., 2005). Additionally, they are 
biodegradable; hence, they can be degraded and metabolized by microbes and by enzymes 
within the human body; biocompatible, they do not generate toxic by-products and some of 
them are piezoelectric, a property known to stimulate cell growth (Philip et al., 2007).  
Based on the number of carbon atoms in the monomer units PHAs can be divided in two 
main different groups: the short chain length polyhydroxyalkanoates (scl-PHAs), which 
consist of C3-C5 atoms, and the medium chain length polyhydroxyalkanoates (mcl-PHAs) 
consisting of C6-C14 atoms (Ojumu et al., 2004). Also, it has been observed that some 
organisms produce copolymers including both scl and mcl monomers, these are referred to as 
scl-mcl PHAs. These groups are a consequence of the PHA synthase substrate specificity, 
which accepts precursors of a certain range of carbon length (Rehm et al., 2001).  
Poly(3-hydroxybutyrate), P(3HB), the simplest and most common example of the scl-PHAs, 
is a highly crystalline, brittle, stiff and piezoelectric material with a melting temperature of 
177 °C, glass transition temperature of 4 °C, tensile strength of 40 MPa and elongation at 
break of 6 %. Its biological properties include, complete biodegradability, water resistance, 
high biocompatibility and a suitable substrate for tissue engineering which enhances cell 
adhesion, migration, proliferation and differentiation functions (Saad et al., 1999). The mcl-
PHAs such as poly(3-hydroxyhexanoate), P(3HHx), or P(3HO) are thermoplastic elastomers 
with melting point, Tm, ranging between 40-60 °C and glass transition temperature, Tg 
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ranging between -50 to -25 °C. The mcl-PHAs have lower crystallinity with higher flexibility 
and softness. They are more thermally stable than scl-PHAs, with an elastomeric nature, 
which increases with the length of the side chain. These are also biodegradable, water 
resistant and biocompatible, which could be utilized in medical implants, such as scaffolding 
for the regeneration of arteries and nerve axons (Witholt et al., 1999). Table 1.3 describes the 
physical properties of P(3HB), a scl-PHA, P(3HO), a mcl-PHA, and polypropylene, a 
commonly used synthetic polymer. The crystallinity and tensile strength of P(3HB) are 
similar to those of propylene, however, the elongation to break is significantly lower than that 
of propylene. On the other hand, the Young’s modulus and elongation to break values for, 
P(3HO) are comparable to those of propylene and dissimilar in terms of crystallinity and 
tensile strength. The scl-mcl PHA copolymers have properties intermediate between scl and 
mcl PHAs (Nomura et al., 2004). Nowadays, most of the studies focus in the development of 
different types of copolymers for the production of tailor made materials to suit different 
applications. For example, one of the most commonly produced copolymers that is 
commercially available is P(3HB-co-3HV). This copolymer is more ductile, elastic and 
flexible than P(3HB), due to the presence of the hydroxyvalerate groups (El-Hadi et al., 
2002). Moreover, it has been reported that the increment in hydroxyvalerate units results in a 
melting temperature, crystallinity and tensile strength reduction, but an increment in 
flexibility, impact strength and ductility of the material (Conti et al., 1996). These approaches 
make PHAs suitable for a wider range of applications and a promising class of new emerging 
biomaterial (Akaraonye et al., 2010).  
Table 1.3. Comparison of the physical properties of P(3HB), a scl-PHA, P(3HO), a mcl-PHA 
and polypropylene (Ojumu et al., 2004, Rai et al., 2010). 
Properties scl –PHAs (P(3HB)) mcl-PHAs (P(3HO)) Polypropylene 
Melting point (°C) 175 49 176 
Glass-transition temp (°C) 15 -36 -10 
Crystalline (%) 81 30 70 
Young’s modulus (GPa) 3.5 0.01 1.7 
Tensile strength (MPa) 40 1.8 34.5 
Elongation to Break (%) 6 276 400 
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1.5.1. Biodegradability of PHAs 
One of the most valuables properties of PHAs is their biodegradability in natural 
environments. PHAs are degraded completely to carbon dioxide and water under aerobic 
conditions and lead to methane formation under anaerobic conditions (Volvoa et al., 2006). 
PHAs can be degraded by depolymerases present in microorganisms and enzymes present in 
the blood and animal tissues (Jendrossek et al., 2002). It has been demonstrated that the main 
factors that influence PHA biodegradation are the stereoconfiguration of the monomers, the 
crystallinity, the molecular mass and the chemical composition of the polymer. Only ester 
linkages of monomers in the (R)- configuration are hydrolysed by the depolymerases (Volvoa 
et al., 2004). In terms of the molecular mass, high molecular mass polymers are degraded 
more slowly than low molecular mass polymers. For instance, Quinteros et al., (1999) studied 
the relation between alkyl side chain length and biodegradability, showing an increment in 
the degradation rates with the polymer length. Additionally, Abe et al., (1999) reported that 
an increment in the polymer crystallinity resulted in a reduction of the degradation rate and 
that the depolymerases first hydrolyse polymer chains in the amorphous phase, followed by 
crystalline phases, with a depolymerisation rate 20 times higher in amorphous than the 
crystalline phase. Volvoa et al., (2004) described PHA biodegradation based on data obtained 
from different PHAs as follows: In the first week, the amorphous phase of the polymer is 
eroded. Then, a disruption of the polymer chain results in the formation of tetramers, dimers 
and monomers with a decrease in the molecular mass. Finally, the polymer loses it mass and 
this process can take from months up to 2-3 years, depending to the polymer properties and 
environmental conditions. Weng et al., (2011) studied the influence of chemical structure on 
the biodegradability of P(3HB-co-3HV). Results showed that an increment in the 
hydroxyvalerate subunits resulted in an increment in the biodegradation and that the 
biodegradation occurred by enzyme catalysed erosion from the surface to the interior. Rai et 
al., (2011a) studied the degradation behaviour of the P(3HO) homopolymer films. In contrast 
to other amorphous polymers such as PLGA, which showed bulk degradation, P(3HO) films 
showed only around 15% of degradation on DMEM media after 3 months and this could be 
due to the semicrystalline structure of the polymer .    
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1.5.2. Biocompatibility of PHAs 
One of the fundamental requirements for a material to be suitable for medical applications is 
that it should display adequate biocompatibility. In response to the material composition and 
degradation products, the host body can release either pro- or anti-inflammatory mediators, 
which can eventually cause initial acute inflammation, followed by chronic inflammation and 
possible ultimate rejection of the biomaterial. In addition to the chemical and molecular 
structure, different parameters were reported to have an influence on the biocompatibility of 
the material such as the size, porosity, shape and surface topography of the material (Zhao et 
al., 2003). Among the different parameters, the haemocompatibility of the material is one of 
the main aspects that will determine the suitability of the material for medical applications. 
The material should not cause thrombosis, embolisms, antigenic response and destruction of 
plasma proteins. The haemocompatibility of a material can be evaluated by the haemostasis 
system, which can be studied by different parameters such as the morphology of the attached 
platelets and complement activation. Sevastianov et al., (2001) studied the 
haemocompatibility of P(3HB) and P(3HB-co-3HV) films produced from R. eutropha 
through the determination of relative number and morphology of adherent platelets, 
complement activation and coagulation system activation. PHA films in contact with blood 
did not activate the haemostasis system at the level of cell response, but they did activate the 
coagulation system and the complement reaction. Further experiments, which included 
purification of the produced polymers showed that resulting P(3HB) and P(3HB-co-3HV) 
were suitable to be used in contact with blood and that the presence of lipopolysaccharides 
from the producer bacteria was the factor activating the haemostasis systems ((Sevastianov et 
al., 2003). One of the main reasons of PHA biocompatibility is the presence of some PHA 
monomer units in human blood and tissues. It has been demonstrated that the monomer 
present in the P(3HB) polymer, (R)-3-hydroxybutanoic acid, is present at concentrations of 3-
10 mg in 100 ml of blood in healthy humans. Additionally, the presence of low molecular 
weight forms of P(3HB) have also been detected in lipoprotein fractions of human tissues 
(Hocking et al., 1994, Nelson et al., 1981). However, although a material can be 
biocompatible, the presence of impurities derived from the method of production and 
extraction can affect the final biocompatibility of the material, as previously described by 
Williams et al., (1996). Several reports have shown that cell adhesion and proliferation are 
highly affected by the surface structure of the polymers. Bellino et al., (2013) demonstrated 
that it is possible to modify cell adhesion and proliferation of a human osteoblastic cell line 
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by modifying the nanopore size of titania and silica film coating. Rebollar et al., (2008) 
showed that surface laser modification of polystyrene films resulted in a significant 
enhancement of human embryonic kidney cell adhesion and proliferation compared to 
unmodified structures. 
 
1.5.3. Biosynthesis of PHAs 
PHA biosynthesis has been intensively studied over the years. Different metabolic pathways 
were described and the particular pathway used for PHA production was found to depend on 
the particular metabolic pathways that are operating in a particular microorganism and the 
carbon source provided. PHA biosynthesis can be divided in two main steps. The first step 
involves the synthesis of hydroxyacyl-CoA, the PHAs activated monomer units for PHAs. 
The second step involves a reaction catalysed by the PHA synthase, which use the 
hydroxyacyl-CoA units as substrates and catalyse their polymerization into PHAs with the 
concomitant release of CoA (Rehm et al., 2001). The synthesis of the 3-hydroxyacyl CoA 
units can occur mainly by three different pathways (Figure 1.12) (Kim et al., 2007, Doi et al., 
1990, Poirier et al., 1995, Steinbüchel et al., 1991). Two of the pathways involve the 
production of PHAs using carbohydrates as a carbon source and a third using fatty acids.  
In the first pathway, PHA biosynthesis occurs from carbohydrates unrelated in structure to 
the final PHA monomer unit (Kazunori et al., 2001). Three key enzymes are implicated: β-
ketothiolase, NADPH-dependent acetoacetyl-CoA reductase, and PHA synthase. The β-
ketothiolasecatalyses the condensation of two acetyl-CoA molecules from the tricarboxylic 
acid cycle. The resulting acetoacetyl-CoA subunits are then converted to 3-hydroxybutyryl-
CoA and the PHA synthase catalyzes the esterification of these subunits leading to the 
formation of P(3HB) (Philip et al., 2007). This pathway can also be utilised for the synthesis 
of P(3HB-co-3HV). 
The second pathway involves the production of PHAs via the fatty acid degradation pathway. 
In this case, the resulting monomers in the polymer chain were similar in structure to the 
carbon source or shortened by 2, 4 or 6 carbon atoms (Huisman et al., 1989). In this pathway 
the fatty acids are first converted to the corresponding acyl-CoA which are then oxidised by 
the ß-oxidation pathway via enoyl-CoA, (S)-3-hydroxyacyl-CoA and 3-ketoacyl-CoA 
precursors. Finally, enzymes like the enoyl-CoA hydratase, hydroxyacyl-CoA epimerase, and 
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β-ketoacyl-CoA reductase connect the β-oxidation pathway to the medium-chain length PHA 
biosynthesis through the PHA synthase (Rehm et al., 2009).  
The third pathway involves mcl-PHA production via the fatty acid de novo biosynthesis 
metabolic pathway. This pathway is of significant interest due to the ability of producing 
mcl-PHAs from carbohydrates that are structurally unrelated to the carbon source and are 
inexpensive (Kazunori et al., 2001). In this pathway, the carbohydrates are first oxidized to 
acetyl-CoA molecules that enter into the fatty acid de novo biosynthesis. The fatty acid de 
novo biosynthesis leads to the formation of R-3-Hydroxyacyl-ACP precursor, which is then 
linked to the PHA synthase for the mcl-PHA biosynthesis via the (R)-3-hydroxyacyl-ACP-















Figure 1.12. Metabolic pathways involved in the biosynthesis of PHAs from related and 
unrelated carbon sources (adapted from Kazunori et al., 2001). 
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1.5.4. PHA biosynthetic genes 
The PHA synthase gene and the genes encoding other proteins related to the metabolism of 
PHAs have been studied in a variety of microorganisms. In particular, PHA synthases are the 
key enzymes of PHA biosynthesis. They are encoded by the phaC gene and use coenzyme A 
(CoA) thioesters of HA as substrates to catalyse the polymerization of HAs into PHAs with 
the release of CoA (Rehm et al., 2002). According to their primary structure, substrate 
specificities of the enzymes and subunit composition, PHA synthases can be divided into four 
major classes. Class I and class II PHA synthase enzymes consisting of only one type of 
subunit (phaC), and class III and class IV PHA synthases include two subunits, phaC, similar 
to class I and II PHA synthases, and one subunit with no similarity (phaE and phaR, 
respectively). In vivo substrate specificity studies showed that class I PHA synthases (e.g. 
present in C. necator) preferably utilize coenzyme A thioesters of scl-3-hydroxyalkanoate 
subunits (containing from 3 to 5 carbon atoms in the alkyl side chain). On the other hand, 
class II PHA synthases (e.g. present in P. aeruginosa) preferentially utilize coenzyme A 
thioesters of mcl-3-hydroxyalkanoate subunits (containing more than 5 carbon atoms in the 
alkyl side chain). Finally, class III (e.g. present in Aeromonascaviae) and class IV PHA 
synthases (present in Bacillus megaterium) include enzymes consisting of two subunits. Both 
subunits preferably utilize coenzyme A thioesters of scl-3-hydroxyalkanoate subunits 
(containing from 3 to 5 carbon atoms in the alkyl side chain) (Rehm et al., 2003). Table 1.4 
illustrates the four different classes of polyester synthases.  
Table 1.4.The four classes of PHA synthases (Rehm et al., 2003). 
Class Subunits Size Substrate Species 
I (60-73 KDa) 3HASCL C. necator 
II (60-65 KDa) 3HAMCL P. aeruginosa 
III (40 KDa)-(40KDa) 3HASCL A. caviae 
IV (40 KDa)-(22KDa) 3HASCL B. cereus SPV 
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The PHA genes that encode for the biosynthetic proteins, and genes related to the PHA 
metabolism are often clustered together in the bacterial genomes. For instance, Steinbuchel et 
al., (1991) showed that C. necator contains PHA synthase gene (phaC), β-ketothiolase 
(phaA) gene and NADPH-dependent acetoacetylo-CoA reductase (phaB) gene, which 
comprise the three individual steps in the P(3HB) biosynthetic pathway, organized in a single 
operon. Rehm et al., (1999) reported that Pseudomonas sp. possess two different PHA 
synthase genes (phaC), separated by another gene, phaZ, that encodes an intracellular PHA 
depolymerase. Downstream of the second phaC gene are the phaD, phaI and phaF genes. 
PhaD plays a role in the regulation of the size and number of PHA granules formed, phaF 
codes for a regulatory protein which is associated with PHA granules and controls the 
expression of the phaC and phaI genes and phaI codes for a newly identified granule-
associated protein (Prieto et al., 1999). Hein et al., (2002) compared both PHA synthases 
(phaC1 and phaC2) from Pseudomonas mendocina by creating knock-out mutants. Results 
provide evidence that phaC1 is the major enzyme for PHA synthesis, whereas phaC2 
contributes to the accumulation of PHAs to only a minor extent. Levergiesell et al., (1992) 
showed that C. vinosum and all bacteria that possess two component PHA synthases (phaC 
and phaE) contain both enzymes and all PHA metabolism genes in the same operon.  
 
1.5.5. PHA producing microorganisms 
1.5.5.1. Wild type producing microorganisms 
More than 250 strains were described as PHAs producers, however, only a few of them are 
usually employed for PHA production. Among the most used are Cupriavidus necator, 
Alcaligenes latus, Bacillus megaterium, Pseudomonas oleovorans and Pseudomonas putida 
due to their capacity to grow in a range of substrates and their ability to synthesize a wide 
range of PHAs depending on the carbon source and the cultivation condition utilized (Chen et 
al., 2010). P(3HB) is the most common and widely studied PHA (Lemoigne et al., 1926). 
Since then, various bacterial strains among Gram positive and Gram negative bacteria have 
been identified to accumulate P(3HB) both aerobically and anaerobically. Awareness of the 
cost of production of PHAs and the need of industrialization encouraged several groups to 
work intensively in reducing production costs. In 1990, Hangii reported A.latus as the main 
candidate for P(3HB) production due to the fast growth and the ability to use cheap carbon 
sources. However, since then, many different strains and strategies were developed for the 
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P(3HB) production. Yu et al., (2008) achieved a 57% P(3HB) dry cell weight (DCW) yield 
under appropriate C/N ratios in C. Necator. Omar et al., (2001) reported P(3HB) content of 
cells of up to 50% when B. megaterium was fed with date syrup and beet molasses. 
Akaraonye et al., (2011) obtained 67% DCW yield of P(3HB) using Bacillus cereus SPV in 
the presence of sugarcane molasses. 
Among the mcl-PHA producer microorganisms P. oleovorans was the first bacteria reported 
to produce a mcl-PHA copolymer containing P(3HO) when grown on n-octane as the sole 
carbon source (De Smet et al., 1983). After this finding, Haywood et al., (1989) examined 
various Pseudomonas species for grow and polymer accumulation with different alkanes, 
alcohols and alkanoic acids as the sole carbon source and proved that mcl-PHA production 
were not only restricted to P. oleovorans but also to P. aeruginosa, P. putida, P. fluorescens, 
and P. testosterone. Later, it was found that mcl-PHAs are accumulated mainly by 
Pseudomonas belonging to rRNA-DNA homology group I and that a number of strains in this 
group were able to produce scl- and mcl-PHA copolymer (Kabilan et al., 2012). Mcl-PHAs 
and copolymers attracted a lot of attention due to their flexible and elastomeric properties for 
industrial and particularly biomedical applications, where flexible biocompatible biomaterials 
are required. Liu et al., (2011) produced Poly(3-hydroxydecanoate-co-dodecanoate), P(3HD-
co-HDD), copolymer when P. putida was grown on dodecanoic acid as a single carbon 
source. Mechanical characterization of the polymer properties showed the flexible nature of 
the material. Rai et al., (2011a) reported the production of an absolute homopolymer of 
P(3HO) when P. mendocina was grown in octanoate, in contrast to other well studied 
organisms such as P. putida, P. oleovorans, P. aeruginosa, P. resinovorans and P. stutzari, 
which accumulate copolymers. Mechanical, thermal, and chemical analysis carried out on the 
P(3HO) produced homopolymer revealed the flexible, elastomeric and semicrystalline 
structure of the material (Rai et al., 2011a).   
1.5.5.2.     Recombinant PHA producer microorganisms 
One of the most popular strategies for enhancing the type, quality or quantity of the produced 
PHAs consists in the homologous or heterologous expression of the PHA biosynthetic 
enzymes in different microorganisms including PHA or non-PHA producers. Several used 
strategies aim to reduce the cost of the polymers by developing recombinant strains able to 
utilize cheap carbon sources and free of PHA degradative pathways to accumulate high 
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amounts of PHAs. For example, Park et al., (1997) over expressed the PHA biosynthetic 
genes from a plasmid on C. necator showing increased levels of P(3HB) and reduced 
fermentation times. Povolo et al., (2010) converted C. necator, a strain unable to grow on 
lactose, into an organism capable of growing on lactose contained in waste material, by 
cloning the Escherichia coli lac genes into the PHA depolymerase gene. Higher PHA yield 
was obtained compared to the wild type strain. 
Other strategies have focused on the development of novel PHAs by introducing new PHA 
biosynthetic pathways or genes into different strains. Li et al., (2011) cloned PHA 
biosynthetic genes from Aeromonas caviae into P. putida allowing the recombinant bacteria 
to produce a scl-mcl-PHA copolymer consisting of 3HB, 3-hydroxyvalerate, 3HV, and 3-
hydroxyheptanoate, 3HHp. The resulting copolymer, P(3HB-co-HV-co-3HHP), was shown 
to have highest tensile strength and stiffness compared with other commercially available 
PHAs. Ma et al., (2009) showed that when the 3-hydroxyacyl-CoA dehydrogenase gene was 
partially or completely deleted in P. putida, the produced copolymer composed of P(3HD-co-
3HDD) showed the highest melting temperature and Young’s modulus among all the studied 
PHAs.   
Escherichia coli is one of the most widely used hosts for the production of heterologous 
PHAs as it has shown outstanding results in standard recombinant expression applications 
and a capacity for large scale production, to meet commercial demands (Sorensen et al., 
2005). Zheng et al., (2011) worked on the development of an E.coli capable of synthesising 
PHAs and succinate from a mixture of glycerol, glucose and fatty acids (by-products of the 
biodiesel production process) by overexpressing the phaC1 gene from P. aeruginosa. The 
resulting strain was able to synthesize succinate and a copolymer composed of P(3HO) and 
P(3HD). However, the presence of toxic lipopolysaccharides present in all Gram-negative 
stains, which are co-purified with PHAs, limited the use of these polymers in medical 
applications.  
Singh et al., (2009) described Bacillus subtilis as a potential host for the production of PHAs. 
Gram-positive bacteria lack LPS and hence they are preferred hosts for the production of 
PHAs for biomedical applications (Valappil et al., 2007). In particular, B. subtilis is generally 
recognized as a safe (GRAS) organism by Food and Drug administration (FDA) and is 
among the most studied and widely used microbes for large-scale production of recombinant 
proteins, amino acids and chemicals. In addition, B. subtilis subsp. subtilis was described as a 
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non-PHA producer like E.coli, and hence it can also be used for the expression and study of 
PHA biosynthetic genes (Singh et al., 2009). Wang et al., (2006) have worked on the 
expression of the phaC1 gene from Pseudomonas aeruginosa in B. subtilis DB104, in the 
presence of glucose as a carbon source. Results showed that recombinant bacteria were able 
to produce P(3HD-co-3HDD). Furthermore, the incorporation of the phaA gene, encoding the 
β-ketothiolase and the phaB gene encoding the acetoacetyl-CoA-reductase from R. eutropha 
resulted in the production of a Poly(3-hydroxybutyrate-co-3-hydroxydecanoate-co-3-
hydroxydodecanoate, P(3HB-co-3HD-co-3HDD), when malt waste was used as carbon 
source. 
1.5.6. Production of PHAs by fermentation 
PHA production in bioreactors was carried out in batch, fed-batch and continuous processes 
(Jung et al., 2001, Sun et al., 2007, Suwannasing et al., 2011). In a batch process, the 
bioreactor is supplied with fresh media and inoculum. At the end of the fermentation process, 
the content of the bioreactor is harvested and the polymer is extracted. In fed-batch processes, 
fresh nutrient is continuously supplied in the bioreactor during the fermentation process. In 
this case, cells are allowed to grow exponentially until stationary phase. At this point, specific 
substrates were added to promote the production of specific PHAs. In some cases, when cells 
grow exponentially and nutrients start to be consumed, specific carbon sources are supplied 
to allow an increment in the cell concentration, the production phase and the final product.  
Continuous processes are based on a continuous feed and withdrawal of nutrients and culture 
from the system. In this case, a high cell concentration is achieved by a continuous 
circulation of media, allowing to maintain a substrate concentration at one desirable level, 
followed by a product formation phase with nutrient depletion (Rehm et al., 2009). 
Based on the culture conditions required for PHA synthesis, bacteria can be divided into two 
major groups. One group requires an excess supply of carbon and limitation of nitrogen, 
phosphorus, oxygen or magnesium such as C. necator and P. oleovorans, while the second 
group do not require nutrient limitation for PHA accumulation such as A. latus, A. vinelandii 
and recombinant E. coli. These characteristics are important to be considered for deciding the 
fermentation strategy for PHA production. The fermentation condition should be designed to 
allow cells to grow to a high density for high productivity and then to stop growing or 
dividing and redirect their metabolism to the accumulation of PHAs (Jurasek et al., 2004). 
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Generally, when processes involve a complete depletion of a nutrient, fed-batch 
fermentations were utilized with PHA accumulation occurring during the nutrient depletion 
stage (Kim et al., 1997; Lee et al., 2000; Diniz et al., 2004). 
As different strains require different growth conditions, the fermentation strategy used for 
PHA accumulation varies with the organism used. Additionally, physiological conditions 
used have a direct effect in PHA subunit composition, cellular PHA content, specific PHA 
synthesis rate and overall volumetric productivity (Sun et al., 2007). Page et al., (1989) 
reported that when A. vinelandii was grown in batch culture, under an oxygen limiting 
condition, a reduction in the activity of the tricarboxylic acid cycle, and the redirection of 
acetyl-CoA molecules resulted in P(3HB) production. Later, Chen et al., (1997) reported 
higher yield of PHAs when A. vinelandii was growth in fed-batch cultures, with high aeration 
during the first stage and low aeration in the second stage, prompting P(3HB) formation. 
Presuting et al., (1991) studied the mcl-PHA production with P. oleovorans showing that the 
specific mcl-PHA accumulation rate is strongly dependent on the specific growth rate of the 
strain and is highest when it grows at 0.2 h-1, which is less than half of the maximum specific 
growth rate. Jung et al., (2001) worked on the production of mcl-PHAs in two-stage 
continuous cultivation with a dilution rate of 0.2 and 0.16 h-1 in the first and second stage, 
respectively. Under these conditions, P. oleovorans cells contained 63% DCW PHAs, which 
was one of the highest PHA yield obtained in P. oleovorans. Hence, as optimal conditions for 
PHA production are not the same in all the cases, it is necessary to assess the optimal 
condition for different bacteria, carbon source or media composition employed.  
One of the main limitations in the PHA production is the production cost. For example, it has 
been reported that PHA production is 10 times more expensive than polyethylene production 
(Kasemsap et al., 2007). The most important limitation factors in the production of PHAs are 
the special growth conditions required, the media utilized, the fermentation process and the 
PHA recovery. Hence, several groups have focused in developing systems that allow a high 
volumetric productivity. This parameter will define the size of a product needed to meet 
market demands. Currently, one of the main PHA produced at industrial scale, is the 
copolymer P(3HB-co-3HV) by C. necator, due to the cost effectiveness of the process 
(Verlinden, 2007).  
It is well known that trying to reproduce results obtained in shaken flask, in bioreactors is a 
difficult task and in many cases the variables involved are not very well understood. For this 
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reason, there is a need to find the optimal growth conditions when bioreactors are used (Peña 
et al., 2011). Once the optimal growth condition for a specific strain and media composition 
is achieved, PHA production can be scaled-up. Scale-up studies based on the constant power 
input or constant oxygen transfer parameters have been carried out. The constant power input 
scaling-up criteria is based on a constant amount of energy required to maintain fluid motion 
within a vessel, in a given period of time. Power input is often referred to as volumetric 
power consumption and is representative of the turbulence degree and media circulation in 
vessels, and influences heat and mass transfer, mixing and circulation times (Marques et al., 
2010). On the other hand, the constant oxygen transfer technique is based on keeping the 
same oxygen transfer rate (OTR) at different scales. The dissolved oxygen concentration in a 
suspension depends on the rate of the oxygen transfer from the gas phase to the liquid phase, 
the rate at which oxygen is transported into the cells and on the microorganism oxygen 
uptake rate. In stirred tank bioreactors, different variables affect the mass transfer, however, 
the main ones are the stirrer speed, type and number of stirrers and gas flow rate used. The 
correct measurement of the OTR is a crucial step for the prediction of the conditions for 
larger scales (Garcia-Ochoa et al., 2009).    
 
1.5.7. Applications of PHAs 
As discussed earlier, PHAs are a family of biodegradable polyesters produced by the bacterial 
fermentation of a carbon source. According to the monomer content, PHAs properties can 
range from rigid and stiff to flexible and elastomeric material. Several bacterial strains, 
carbon sources and growth conditions have been explored and more than 150 PHA monomer 
subunits have been incorporated into PHA polymers allowing the development of a range of 
PHAs (Chen 2010). As a result, tailor made materials have been developed for different 
applications ranging from packaging material to biomedical applications.  
 
1.5.7.1. Bulk applications 
PHAs have attracted a lot of attention as materials for various applications for substitution of 
oil-derived polymers, due to their capacity to be produced from a renewable source, their 
biodegradable characteristics which allow them to degrade without generation of toxic by-
products and the ample range of monomer compositions appropriate for different kinds of 
applications. Initially, PHAs were used in packaging films such as bags, containers, paper 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  INTRODUCTION	  
	  
33	  
coatings and disposable items including razors, utensils, diapers, feminine hygiene products 
and cosmetics. The first consumer product made from PHAs was shampoo bottles launched 
by Wella® (Germany) in 1990 (Chen 2010). However, they have not had a wide application 
mainly because of their production costs. For this reason, currently, only a few PHAs are 
available in the market. Although, at present, petrochemical plastics are a more economically 
feasible choice than biodegradable ones, future lack in oil supply will result in a drastic 
increase in the petrochemical plastic production costs. On the other hand, further research on 
microbial strains, inexpensive substrate sources, diverse fermentations strategies, polymer 
recovery and purification can substantially reduce the production cost and make PHAs 
commercially relevant.  
 
1.5.7.2. Medical applications 
PHAs are attractive materials for biomedical applications because of their natural origin, 
enhanced biocompatibility, biodegradability, and their ability to support cell growth and 
proliferation (Valappil et al., 2006). The biological response of a biomaterial in vivo is the 
main property that will determine the material use in the medical field. For example, 
Shishatskaya et al., (2002) tested the toxicity of P(3HB) and P(3HB-co-HV) threads 
implanted in Wistar rats during a period of six months. Results showed no adverse changes in 
physiological and biochemical parameters. Williams et al., (1999) reported the effect of a 
subcutaneous poly(3-hydroxyoctanoate-co-3-hydroxyhexanoate),P(3HO-co-HHx), implant 
for 40 days in mice with no infiltration of macrophages and a minimal reaction to the 
implants, which were encapsulated, with a thin layer of fibroblasts during the 40 days 
experiment. From all the produced PHAs, only some of them are currently in sufficient 
quantities to be evaluated as potential material for different applications, including P(3HB), 
P(3HB-co-3HV), poly-4-hydroxybutyrate, P(4HB), poly(3-hydroxybutyrate-co-3-
hydroxyhexanoate), P(3HB)-co-HHx, and P(3HO) (Byrom, 1992, Chen et al., 2001, Hrabak, 
1992). These PHAs have been utilized to develop devices for different biomedical 
applications such as wound dressing, orthopaedic pins, slings, adhesion barriers, stents, 
articular cartilage, bone marrow scaffolds, nerve guides, tendon repair devices and 
cardiovascular patches (Chen et al., 2005). In addition to this, the potential use of PHAs in 
drug delivery has been evaluated in a number of studies as subcutaneous implants, 
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compressed tablets for oral administrations and microparticulate carriers for intravenous use 
(Williams et al., 1996). 
 
1.5.7.2.1. Cardiovascular applications 
As many synthetic materials were unable to repair and regenerate cardiac tissue and some of 
them show high risks of immune responses, several groups have been focused on finding 
alternative materials for cardiac tissue engineering applications (Smaill et al., 2000).  Malm 
et al., (1992) studied the effect of P(3HB) as a pericardial patch after the pericardium was 
excised and replaced with the polymer in 18 sheep. Patches were removed between 2 and 30 
months after operation and examined for adhesions, infection and inflammatory responses. 
No adhesion was observed between the heart and the sternum in 14 of the treated animals. 
After 24 months post-operation, polymer remnants were still present on the animals. 
Although some macrophages were still found at 30 months, no platelet aggregates were 
detected. Duvernoy et al., (2007) evaluated the effect of P(3HB) patches in 50 human 
patients admitted for bypass surgery or valvular replacement. Results showed a low incidence 
of postoperative adhesions between the patch and the cardiac surface in patients treated with 
the patches. Malm et al., (1994) worked on the implantation of P(3HB) transannular patches 
into the right ventricular outflow tract and pulmonary artery of 13 sheep. Dacron patches 
were implanted in the control groups. Implanted patches were analyzed 3 to 24 months later 
showing no aneurysm formation. Comparable amounts of native arterial tissue of neointima 
and neomedia were obtained with the test group but not with the control group. Dacron 
implants presented a collagen layer and dense lymphocytes infiltration due to the 
inflammatory reaction of the material. In contrast, P(3HB) patches were phagocytated by 
macrophages and no platelet aggregates were observed. Furthermore, the P(3HB) regenerated 
vessel showed structural and biochemical qualities in common with the native pulmonary 
artery. Shum-Tim et al., (1999) evaluated the elastomeric polymer P(3HO-co-3HHx) as a 
copolymer with PGA for the production of tissue engineered vascular grafts seeded with 
autologous cells. Resulting constructs were placed in lambs aortic segments. Results showed 
no aneurysms formation and an insignificant inflammatory response, with increased cell 
density, collagen formation and mechanical properties that resemble those of the native aorta. 
Stock et al., (2000) showed good vascular cell growth, no thrombus formation and good 
mechanical properties when P(3HO-co-3HHx) films were blended with PGA and used to 
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replace pulmonary valve leaflet in lambs, in contrast to results obtained with PGA-PLA 
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AIMS AND OBJECTIVES 
The aim of this project was to synthesise P(3HO), a unique mcl-PHA homopolymer and its 
use in the production of cardiac patches.       
The specific objectives to be met in order to fulfil the above overall aim include: 
 
1- An attempt towards the development of a Gram-positive recombinant strain for the 
production of LPS-free P(3HO). At present, Gram-negative bacteria are the only industrial 
source of mcl-PHAs. However, the membrane of Gram-negative bacteria species contain 
lipopolysaccharides (LPS), which are co-purified with PHAs and cause immunogenic 
reactions. Consequently, part of this study was aimed to express the Pseudomonas mendocina 
PHA synthase gene (phaC1) in the LPS-free Gram-positive microorganism Bacillus subtilis. 
The produced polymer was characterized in terms of mechanical, thermal, wettability and 
surface topography properties. 
2- Production and characterization of P(3HO) using Pseudomonas mendocina. P(3HO) 
homopolymer was produced from P. mendocina in 2 L bioreactors. The obtained polymer 
was fully characterized in terms of mechanical, thermal, wettability and surface topography 
properties. Its effect on contraction and viability of fresh rat isolated cardiomyocytes was 
assessed.  
3- Large scale production of P(3HO). Optimization of P(3HO) production was carried out in 
2 L bioreactors. Optimized conditions were scaled-up for the production of P(3HO) in the   
20 L bioreactor and the 72 L pilot plant bioreactor.   
4- Construction of P(3HO) cardiac patches. P(3HO) cardiac patches were designed using the 
solvent casting, particle leaching technique and electrospinning. Resulting constructs were 
characterized in terms of mechanical, thermal, wettability and surface topography properties. 
Biocompatibility of the P(3HO) cardiac patches was assessed using C2C12 myoblast cell 
line.  
5- Functionalisation of the cardiac patches. The arginine-glycine-aspartic acid (RGD) 
tripeptide sequence was immobilized on the surface of the P(3HO) films to allow efficient 
host cell recruitment and adhesion. Vascular endothelial growth factor (VEGF) was 
incorporated in the films to assist cellular proliferation, differentiation, migration and 
vascularisation. Additionally, VEGF was incorporated in P(3HB) microspheres produced 
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using the recombinant B. subtilis created in the first part of the project. The VEGF release 
profile was assessed. In vitro cell culture work was carried out with C2C12 myoblast cell line 


















2.1.1. Bacterial strains 
Pseudomonas mendocina was obtained from the National Collection of Industrial and Marine 
Bacteria (NCIMB) and the Bacillus subtilis 1604 was bought from Bacillus Genetic Stock 
Centre (BGSC). All the Escherichia coli strains were obtained from the culture collection of 
University of Westminster, London, UK.  
 
2.1.2. Cell line and cell culture materials 
C2C12 myoblast cell line was purchased from Sigma-Aldrich, Dorset UK. 
 
2.1.3. Plasmid vector used for cloning and expression 
The pHCMC04 vector, extracted from Escherichia coli ECE 189, is 8089 base pairs in size.  
It is a B. subtilis-E. coli shuttle vector that replicates as theta circles and it contains a PxylA 
promoter, which is functional in the presence of xylose in the media (Nguyen et al., 2005). 
The genes that compose the pHCMC04 are described in Table 2.1. 
 
 
Figure 2.1. Genetic and restriction map of the pHCMC04 expression vector (taken from 
Bacillus Genetic Stock Centre manual). 
 
 






Table 2.1. pHCMC04 genetic map description 
GENE FUNCTION 
Rep replication initiation protein from theta replication plasmid pBS72. 
Cat encodes chloramphenicol acetyl transferase; selectable in either E. coli or  
B. subtilis (chloramphenicol 5 µg/ml) 
Bla encodes β-lactamase; selectable in E. coli only (ampicillin 100 µg/ml) 
ORF unknown function 
xylR represses transcription from the PxylA promoter; xylose relieves repression 
 
2.1.4. Chemicals proteins and kits 
The chemicals used in this study were purchased from Sigma-Aldrich (Dorset, England) and 
VWR (Poole, UK). The Wizard Genomic DNA Purification Kit, the 1-Kb step ladder, the Pfu 
DNA polymerase master mix and all the primers were purchased from Promega 
(Southampton, UK). The gel extraction and miniprep kits were obtained from QIAGEN 
(Sussex, UK). The restriction enzymes were acquired from New England Biolabs 
(Hertfordshire, UK). The VEGF ELISA kit was purchased from Invitrogen (Paisley, UK). 
 
2.1.5. Reagents 
2.1.5.1. Agarose gel 
• Tris-borate-EDTA buffer (g/L) (5X): 54 g of Tris-Base, 27.5 g of Boric acid and 20 ml of 
0.5 M EDTA (pH=8). 
• Loading dye (6X): 30 % Glycerol, 0.25 % Bromophenol blue and 0.25 % Xylene Cyanol 
FF. 
 
2.1.5.2. Miniprep plasmid extraction 
• Solution I: 50 mM Glucose, 25 mMTris-HCl pH 8 and 100 mM EDTA 
• Solution II: 0.2 N NaOH and 1% SDS 
 





• Solution III: 60 % of 5 M Potassium acetate and 11.5 % Acetic acid glacial. 
 
2.1.5.3. SDS-PAGE 
• Resolving gel (12%): 4.9 ml of 1.5 M Trizma base pH 8.8, 100 µl 10 % SDS, 3 ml of     
40 % Acrylamide, 100 µl of 10 % Ammonium persulfate, 20 µl of TEMED and 4.9 ml 
water.  
• Stacking gel (4%): 625 µl of 0.5 M Trizma base pH 6.8, 50 µl 10 % SDS, 500 µl of 40 % 
Acrylamide, 50 µl of 10 % Ammonium persulfate, 10 µl of TEMED and 3.6 ml water. 
• Sample buffer (4x): 6 ml of Trizma base 0.5 M pH 6.8, 9.6 ml of 10 % SDS, 2.4 ml of β-
mercaptoethanol, 2.4 ml of 10 % Bromophenol blue, 4.8 ml of Glycerol and 4.8 ml of 
water. 
• Running buffer (10x): 25 mM of Trizma base, 192 mM of Glycine and 0.1 % of SDS. 
• Staining solution: 0.25 g/L of Brilliant Blue R and 10 % of Acetic acid glacial. 
• Destaining solution: 10 % Acetic acid. 
 
2.1.5.4. Krebs-Henseleit solution (mmol/L): NaCl 119, KCl 4.7, MgSO4 0.94, KH2PO4 1.2, 
NaHCO3 25 and glucose 11.5. 
 
2.1.6. Bacterial growth media composition 
2.1.6.1. Pseudomonas mendocina growth media 
• Mineral salt medium production media (MSMPM) (g/L): (NH4)2SO4 0.50, MgSO4 0.40, 
Na2HPO4 3.80, KH2PO4 2.65 and trace elements (PM) solution 1 mL/L. 
• Mineral salt medium production media (MSM2nd seed) (g/L): (NH4)2SO4 0.50, MgSO4 
0.40, Na2HPO4 3.80, KH2PO4 2.65 and trace elements (PM) solution 1 mL/L. 
• Trace elements (PM) (g/L): CoCl2 0.22, FeCl3 9.70, CaCl2 7.80, NiCl3 0.12, CrCl6.H2O 
0.11, CuSO4.5H2O 0.16. 
 
2.1.6.2. Bacillus subtilis growth media 
• Ramsay media (g/L): Na2HPO4.7H203.7, KH2PO40.83, (NH4)2SO4 2.0, MgSO4.7H2O 0.2, 
ferrous ammonium citrate 60, CaCl2 .2H2O 10 and trace elements (BS) solution 1 mL/L. 
• Trace elements (BS) (g/L): 0.3 g/L H3BO3, 0.2 g/L CoCl2.6H2O, 0.1 g/l ZnSO4.7H2O,  
 





• 30 mg/L MnCl2.4H20, 30 mg/L NaMoO4.2H2O, 20 mg/L NiCl2.6H20, and 10 mg/L 
CuSO4.5H20). 
• Kannan and Rehacek media (g/L): Yeast extract 2.5, Potassium chloride 3, Ammonium 
sulphate 5 and Soybean dialysate 100 mL/L 
• Soybean dialysate: Dialysis of 10 g of defatted soybean flour in 1L of distilled water for 
24 hr at 4oC. 
 
2.1.7. Bioreactors 
2.1.7.1. 2 L Bioreactor 
The 2 L bioreactor used in this study was a stirred tank with 2 Rushton turbine impellers and 
buffers. The vessel was a 200 series Fer mac® (Electrolab) and total volume was 2 L. The 
ratio of impeller to vessel was 2. The vessel temperature was controlled with a wrap-around 
heating belt and the pH and dissolved oxygen tension (DOT) were controlled with Bradley 




Figure 2.2. The 2 L stirred tank bioreactor used in this study 
 
2.1.7.2. 20 L Bioreactor 
The 20 L bioreactor was a stirred tank with 2 Rushton turbine impellers and buffers. The 
vessel was a 2000 series LH® and total volume was 20 L. The ratio of impeller to vessel was 
3.28. The vessel temperature was controlled with a heat exchanger and the pH and dissolved 
oxygen tension (DOT) were controlled with Mettler Toledo® electrodes. The bioreactor 
sterilization was carried out in place with live steam at 132 ºC for 30 minutes.  
 







Figure 2.3. 20 L stirred tank bioreactor used in this study 
 
2.1.7.3. 72 L Bioreactor 
The 72 L bioreactor was a stirred tank with 2 Rushton turbine impellers and buffers. The 
vessel was a 1075 series LH® and total volume was 72 L. The ratio of impeller to vessel was 
3.09. The vessel temperature was controlled with a heating jacket and the pH and dissolved 
oxygen tension (DOT) were controlled with Mettler Toledo® electrodes. The bioreactor 











Figure 2.4. 72 L stirred tank bioreactor used in this study 
 





2.2. EXPERIMENTAL METHODS 
2.2.1. Construction of recombinant Bacillus subtilis strain 
For the construction of the recombinant Bacillus subtilis strain containing the phaC1 gene,   
P. medocina genomic DNA was extracted and the phaC1 gene was amplified by PCR. The 
phaC1 gene was ligated to the pHCMC04 B. subtilis-E. coli shuttle vector and E. coli XL1 
blue competent cells were transformed with ligation products for plasmid amplification. The 
phaC1-pHCMC04 plasmid was isolated and the phaC1 sequence integrity was confirmed by 
sequencing. B. subtilis 1604 was transformed with the phaC1-pHCMC04 plasmid. Figure 2.5 
shows a schematic representation of the steps followed for the cloning of the phaC1 gene into  

















Figure 2.5. Schematic representation of the strategy used for the cloning of phaC1 into        
B. subtilis 1604. 
 





2.2.1.1. P. mendocina phaC1 amplification 
A Pseudomonas mendocina single colony was used to inoculate 10ml of nutrient broth and 
the culture was grown at 30 ºC and 200 rpm overnight. After the centrifugation at 2500 g for 
10 minutes, the bacterial genomic DNA was extracted from the pellet using the Wizard 
Genomic DNA Purification Kit. The phaC1 gene from P. mendocina was amplified in an 
Eppendorf® Mastercycler PCR using the P. mendocina genomic DNA as template and 04F 
and 04R primers (Table 2.2). The product size was 1.68 Kbp.  
 
Table 2.2. Primers designed for the cloning of phaC1 into pHCMC04 vector 












The primers were designed using the known sequence of P. mendocina to include EcoRV and 
BamHI restriction sites and to facilitate the cloning of the PCR product. PCR was carried out 
with the Phusion Flash high-Fidelity PCR master mix and the mix consisting of primers, 
template and master mix was made up to 100µl with MiliQ water. The PCR program used is 
shown in Table 2.3.  
Table 2.3. PCR program used for the amplification of the phaC1 gene 
 Temperature (ºC) Time (min) 
Initial denaturation 95ºC 2 
Denaturation 95ºC 1 
Annealing 60ºC 1.4 
Extension 72ºC 1 










2.2.1.2. phaC1 purification  
The phaC1 gene was isolated by electrophoresis and purified from the agarose gel. For 
electrophoresis, the phaC1 PCR product was loaded onto a 0.8 % agarose gel and run in Tris-
borate-EDTA buffer (2.1.5.1.) at 100V for 1 hour. The resulting band was excised from the 
gel and purified using a QIAGEN gel extraction kit. 
 
2.2.1.3. pHCMC04 purification  
An E. coli ECE 189 single colony was used to inoculate 10 ml of Luria Broth (LB) media and 
the culture was grown at 37 ºC and 200 rpm, overnight. The resulting culture was centrifuged 
at 2500 g for 10 minutes and the plasmid DNA was extracted from the pellet by the miniprep 
plasmid extraction protocol. For this, the cells were lysed with 350 µl of Solution I (2.1.5.2), 
following by the addition of 5 µl of RNase and 300 µl of Solution II (2.1.5.2). After 
incubating the sample on ice for 5 minutes, 300 µl of Solution III (2.1.5.2) were added and 
the sample was centrifuged for 5 min at 7000 g. The supernatant was isolated and the same 
amount of Phenol-Chloroform was added. After vortexing, the sample was centrifuged at 
7000 g for 12 min and the upper phase was kept. For the DNA precipitation, 600 µl of 
isopropanol was added followed by centrifugation at 7000 g for 20 minutes at 4 ºC. The 
resulting pellet was washed twice with 500 µl 70 % ethanol and dissolved in 30 µl of MiliQ 
water.  
 
2.2.1.4. phaC1 and pHCMC04 restriction enzyme treatment 
Restriction enzyme digests were carried out to prepare the purified vector pHCMC04 and 
PCR amplified phaC1 insert for the ligation. For this, 25 µl of each product were double 
digested with BamH1 and EcoRV enzymes in NEB restriction buffer 3, containing BSA, for 
2.5 hours at 37 ºC. The final volume of the reaction was 70 µl. In order to avoid self-ligation 
the vector was treated with 0.5 µl of Calf intestine phosphatase (CIP), 20 minutes prior to the 










2.2.1.5. phaC1 and pHCMC04 ligation 
For the phaC1 and pHCMC04 ligation reaction, one part of restricted phaC1 product and 
seven parts of the restricted pHCMC04 vector were ligated together using T4 DNA ligase in 
ligase buffer for 4 hours at room temperature. 
 
2.2.1.6. Transformation of the Escherichia coli XL1 blue competent cells 
The phaC1-pHCMC04 construct was used for E.coli XL1 blue heat shock transformation. 
Competent Escherichia coli XL1 blue cells were designed for high efficiency transformation. 
For this, E. coli XL1 blue was grown at 37 ºC and when the OD600 reached 0.3-0.4, 10 ml of 
the culture were centrifuged at 2500 g for 10 minutes. The resulting cell pellet was 
resuspended in 0.1 M ice-cold MgCl2 solution and centrifuged at 2500 g for 10 min at 4 ºC. 
Then, the obtained pellet was resuspended in 0.1 M ice-cold CaCl2 solution and again 
centrifuged at 2500 g for 10 min at 4ºC. The cell pellet was dissolved in 6 ml of a 50 % 
glycerol solution in 0.1 M CaCl2 and stored at -80 ºC. 
The E.coli XL1 blue heat shock transformation was carried out by mixing 7 µl of the phaC1-
pHCMC04 ligation product with 50 µl of competent Escherichia coli XL1 blue cells. After 
the reaction was incubated on ice for 5 minutes, 750 µl of LB broth were added. The cells in 
LB broth were incubated at 37 ºC for 1 hour with shaking and the transformed colonies were 
selected in LB agar containing 100 µg/ml of ampicillin. 
 
2.2.1.7. phaC1-pHCMC04 plasmid purification and sequencing 
Ampicillin resistant colonies were grown in LB broth containing 100 µg/ml of ampicillin at 
37 ºC and 200 rpm. The overnight culture was centrifuged and plasmid DNA was extracted 
using the QIAGEN miniprep kit. Digests were carried out using EcoRV and BamHI enzymes 
and phaC1 gene presence was confirmed by running the resulting product in a 0.8 % agarose 
gel. In order to confirm the lack of sequence changes in the phaC1 insert due to PCR, the 
pHCMC04-phaC1 product was sequenced using the automated DNA sequencer at the 









2.2.1.8. Transformation of Bacillus subtilis 1604 
Bacillus subtilis 1604 was transformed with pHCMC04-phaC1 plasmid by electroporation.  
B. subtilis 1604 was grown in 10 ml of LB broth at 30 ºC and when the OD600 reached 0.8, 
the culture was incubated on ice for 20 minutes and centrifuged at 2500 g for 15 minutes. 
Following centrifugation, the cell pellet was resuspended in 10 ml of chilled water and 
centrifuged for 5 minutes at 2500 g at 4ºC. Then, the cell pellet was resuspended in 10 ml of 
10% glycerol and again centrifuged for 5 minutes at 2500 g at 4 ºC. This procedure was 
repeated thrice. The cell pellet was incubated on ice for 15 minutes and 200 µl were 
transferred into a cold eppendorf. After the addition of 1 µl of the phaC1-pHCMC04 plasmid, 
the reaction was transferred into a cold 2 mm Bio-rad® Gene-pulser cuvette and the cells 
were transformed in a Bio-rad® Micro Pulser electroporator with a pulse of 2.5 KV. 
Following the transformation, 500 µl of LB broth were added and the cells were incubated at 
37 ºC for 1 hour. Transformed colonies were selected in LB agar containing 5µg/ml of 
chloroamphenicol. The plasmid was extracted and the presence of the phaC1 insert was 
confirmed by PCR with primers flanking the phaC1 sequence.  
 
2.2.2. Expression of phaC1 in B. subtilis phaC1-pHCMC04 
2.2.2.1. Determination of early mid-log phase, mid-log phase and late mid-log phase for 
xylose induction in LB broth media 
Transformed Bacillus strains were grown in LB media containing 5 µg/mL of 
chloramphenicol at 30 °C and 200 rpm and the early mid-log phase, mid-log phase and late 
mid-log phase were determined by measuring the absorbance at 600 nm in a standard 
Novaspec II® visible spectrophotometer at different time points. At these time points, cultures 
were induced with different xylose solutions, i.e. 0.2%, 0.5%, 0.8% and 1.1%. Samples were 
taken at 15, 30, 60, 120 and 180 minutes after induction and centrifuged at 2500 g for 15 min. 
The obtained pellets were prepared for SDS-PAGE. 
 
2.2.2.2. SDS-PAGE 
The phaC1 protein expression profile was analysed using SDS-PAGE. The cell pellet was 
disrupted in 4x Sample buffer (2.1.5.3.), boiled for 10 minutes and allowed to cool down. 
Samples were loaded on a 12%/4 % resolving/stacking acrylamide gel (2.1.5.3.) and 
 





electrophoresis was carried out at a constant voltage of 200 V in Running buffer (2.1.5.3.) 
using a Bio-Rad®Mini-Protean II electrophoresis system. For protein size estimation, a Bio-
Rad® reference protein ladder was used. In order to add a reference band closer to the sample 
size, to facilitate the size estimation, Bovine serum albumin (BSA) was added to the marker. 
The gels were stained with Staining solution (2.1.5.3) to fix and stain proteins, destained and 
stored in destaining solution (2.1.5.3). 
 
2.2.3. PHA production from B. subtilis phaC1-pHCMC04  
The PHAs production in recombinant B. subtilis was carried out using a two stage seed 
culture preparation. Briefly, the first culture was inoculated with a single colony of the 
recombinat strain. The culture in mid-log phase was then used for inoculating the PHAs 
production media. PHAs production was induced with a xylose solution when the culture in 
PHAs production media reached mid-log phase. After 30 hr cells were harvested and cells 
pellet was dried by freeze-drying. PHAs were extracted from lyophilised cells. Figure 2.6 
shows a schematic representation of the steps followed for PHAs production in recombinant 
B. subtilis strain. 
 
Figure 2.6. Schematic representation for the PHA production in B. subtilis phaC1-
pHCMC04. 
 
2.2.3.1. Production of PHAs in B. subtilis 1604 phaC1-pHCMC04 from carbohydrates 
The PHA polymer production was carried out in Ramsay media (2.1.6.2.) in two stages using 
sucrose as a sole carbon source. To this end, a B. subtilis 1604 phaC1-pHCMC04 single 
colony was used to inoculate LB broth and the culture was grown at 30 ºC and 200 rpm until 
mid-log phase was reached. This culture was then used to inoculate the PHA production 
media with 20 g/l of sucrose. The growth of the organism was monitored by measuring the 
OD at 600 nm and a solution of 0.5 % xylose was used to induce the culture when mid-log 
phase was reached. The culture was grown for 30 hr at 30 ºC and 200 rpm.  
 





2.2.3.2. Production of PHAs in B. subtilis 1604 phaC1-pHCMC04 from fatty acids 
The PHA production was also carried out with a range of oils (groundnut oil, corn oil and 
coconut oil) and fatty acids (from 3 to 12 carbons) in Ramsay media and Kannan and 
Rehacek media (2.1.6.2.). The fatty acid concentration used in this study was always 20 mM. 
The procedure used was the same as described in section 2.2.3.1. 
 
2.2.3.3. Extraction of PHAs in B. subtilis 1604 phaC1-pHCMC04 
The PHA extraction was carried out using the dispersion of chloroform and sodium 
hypoclorite method (Rai et al., 2011). For this, the cells were harvested and the cell pellet 
lyophylised. Dried cell were incubated at 30 ºC and 150 rpm with a solution of 80 % sodium 
hypochlorite and chloroform (1:4).  After 2 hours of incubation, the solution was centrifuged 
for 18 min at 3680 g and the lower layer containing the polymer and chloroform was 
concentrated in a Bűchi®rota vapour (R-114) and precipitated in cold methanol.  
 
2.2.4. Structural characterization of PHAs from B. subtilis 1604 phaC1-pHCMC04 
The structural characterization of the polymer obtained from B. subtilis phaC1-pHCMC04 
was carried out by FTIR, GC-MS and NMR. 
 
2.2.4.1. Fourier transform infrared spectroscopy (FTIR) 
FTIR analysis was carried out to determine the presence of the PHA functional groups in the 
sample. A Perkin Elmer series 2000 FTIR spectrometer with a spectral range 4000 to         
400 cm-1 was used at the Department of Biomaterials and Tissue engineering, Eastman 
Dental Institute, University College London, UK. For both, the whole cell analysis and 
extracted PHA polymer, 2 mg of lyophilised cells or polymer were used. 
 
2.2.4.2. Gas Chromatography-Mass spectroscopy (GC-MS) 
The monomer content of the extracted PHA was identified by GC-MS. Before the analysis, 
the polymer was methanolysed as described by Wang et al., (2006). For this, 15 mg of 
polymer were added to 1 ml of the esterification solution containing 3 ml of 95–98% H2SO4, 
0.29 g of benzoate, and 97 ml of methanol. Then, 1 ml of chloroform was added and the 
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mixture was heated at 100 °C for 4 hr. After the 4 hours, the mixture was cooled and 1 ml of 
MiliQ water was added and vortexed for phase separation. The lower phase was extracted, 
dried over anhydrous Na2SO4, neutralized by Na2CO3, filtered and sent to the School of 
Chemistry, University of Southampton, UK, for the GC-MS analysis.   
2.2.4.3. Nuclear magnetic resonance (NMR) 
The extracted PHA monomer structure was confirmed by NMR. The analysis was carried out 
on 30 mg of polymer dissolved in 1 mL of the deuterated chloroform (CDCl3). The 1H and 
13C spectra were obtained in a Bruker® AV400 (400 MHz) spectrometer at the Chemistry 
Department, University College London, UK. 
2.2.5. Sequence analysis 
Protein sequences for phaC1 from P. mendocina (phaC1P.mendocina) and 9 other Pseudomonas 
sp. were retrieved from NCBI or UniProt database.    
2.2.5.1. Sequences alignment 
Multiple sequence alignment of the protein sequences were performed using Clustal Omega 
(Goujon et al., 2010) and pair wise alignments were performed on Jalview (Waterhouse et 
al., 2009), a fast Java based multiple alignment editor and analysis tool. 
2.2.5.2. Phylogenetic analysis 
A phylogenetic tree based on the multiple sequence alignment of the 10 phaC1 amino acid 
sequences was constructed using ClustalW Phylogeny from the ClustalW2 package at the 
EBI using the neighbour joining clustering method. 
2.2.6. Production of mcl-PHAs from Pseudomonas mendocina 
2.2.6.1. Cell growth 
P. mendocina was used for the production of poly-3-hydroxyoctanoate, a mcl-PHA. The 
polymer production was carried out in three steps according to Rai et al., 2011. For the seed 
culture production, a P. mendocina single colony was grown in nutrient broth at 30 ºC at 
 





200 rpm for 24 hr. The second seed was produced by inoculating the Mineral salt medium 
production media (MSM2nd seed) (2.1.6.1) containing 20 mM of sodium octanoate as a carbon 
source with the seed culture and grown at 30 ºC at 200 rpm until the OD450 was 1.6. The 
resulting culture was used to inoculate the PHA Mineral salt medium production media 
(MSMPM) (2.1.6.1) containing 20mM of sodium octanoate. The volume of the inoculums 
used in all the cases was 10 % of the final production media working volume.  
 
2.2.6.2. P(3HO) extraction  
The P(3HO) polymer extraction was carried out as described in section 2.2.3.3. 
 
 
2.2.6.3. P(3HO) purification 
The P(3HO) polymer purification was carried out by dissolving and precipitating the polymer 
in a series of solvents (Rai et al., 2011). In the first step, the polymer was dissolved in 
chloroform and precipitated in an ice-cold methanol: ethanol solution (50:50). In the second 
step the polymer was dissolved in acetone and precipitated in ice-cold methanol. For the last 
step, the polymer was again dissolved in chloroform and precipitated in ice-cold methanol. 
 
2.2.7. Production of mcl-PHAs in Bioreactors 
The P(3HO) production was optimized in 2 L bioreactors and scaled-up to 20 L and 72 L. In 
all cases the MSMPM (without magnesium) was sterilized with the bioreactors and the 
sterilized magnesium, trace elements and sodium octanoate solution were added to the 
bioreactor before the inoculation. The bioreactor was inoculated with 10 % of second seed 
inoculum. 
 
2.2.7.1. Optimisation in a 2 L Bioreactor 
The P(3HO) polymer production was optimised by varying the carbon:nitrogen ratio and pH 
in the production media. The working volume in the 2 L bioreactor was 1.4 L. The pH of the 
medium was maintained using 2 M NaOH and 2 M H2SO4. Table 2.5. shows the four 
conditions tested in this study.  
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Table 2.5. Fermentation conditions tested for the optimisation studies 
2.2.7.2. Scaling-up 
The P(3HO) production was scaled-up from the 2 L to the 20 L and 72 L bioreactors. The 
scaling up was based on a constant oxygen transfer coefficient, kLa. By employing the 
gassing out method, the kLa values were calculated at different sets of impeller speeds and 
airflow rates. Briefly, the bioreactor was filled with distilled water and the concentration of 
O2 in the water was lowered by gassing the liquid out with nitrogen gas. Aeration was then 
initiated at a constant airflow rate and the increase in dissolved oxygen tension (DOT) was 
recorded at different time points.  The rate of oxygen transfer from the air bubble to the liquid 
phase can be described by the equation 2.1: 
dC/dt = kLa (C*-C) (2.1) 
where C* is the saturated dissolved oxygen concentration, C is the recorded concentration of 
dissolved oxygen in the bioreactor and dC/dt is the change of the oxygen concentration over a 
period of time. The kLa of each bioreactor at each stirrer speed and airflow rate was 
determined from the slot of the plot of ln (C*-C) vs. time. 
In a stirrer tank reactor, the efficiency of oxygen absorption in a liquid is expressed in terms 
of kLa and it is a measure of the aeration capacity of a reactor. In this case, the kLa is 
dependent on the airflow rate and stirrer speed, and the relation is described by the equation 
2.2: 
kLa = FxNy (2.2) 
Where F is the airflow rate, N is the stirrer speed and x and y are constants. 
C:N pH Stirrer speed (rpm) 
Condition 1 20:1 7.15 200 
Condition 2 15:1 7.5 200 
Condition 3 15:1 6.8 200 
Condition 4 10:1 7.15 200 
 





The kLa of the 2 L bioreactor at the optimized C:N condition, pH and stirrer speed was 
determined. As it was not possible to keep the pH constant in both 20 L and 72 L bioreactors, 
the optimised pH was used to initiate the fermentations in the scaling-up study. To determine 
the kLa, the 2 L bioreactor was filled with 1.4 L of distilled water and the oxygen was 
lowered with nitrogen supply. When the DOT reached 10, the air supply was switched on and 
the DOT was recorded every 30 seconds until 90 seconds. The obtained kLa was the chosen 
parameter to be kept constant as the scale increases. The kLa of the 20 L and 72 L bioreactor 
was determined in a similar way at a range of stirrer speeds and airflow rates. The total 
volume vs. working volume ratio used in the 2 L bioreactor was kept constant in the 20 L and 
72 L bioreactors (for the 20 L and 72 L bioreactor the working volume used was 14 L and 50. 
4 L, respectively). Due to the fact that the stirrer speed can be regulated with more precision, 
the aeration rate was kept constant and the estimation of the stirrer speed for a constant 
oxygen transfer in the 20 L and 72 L bioreactors was obtained from the extrapolation of the 
Log kLa vs. Log rpm. 
	  
2.2.8. P(3HO) characterization 
2.2.8.1. Fourier transform infrared spectroscopy (FTIR) 
The sample preparation and analysis was carried out as described in section 2.2.4.1. 
 
2.2.8.2. Gas Chromatography-Mass spectroscopy (GC-MS) 
The sample preparation and analysis was carried out as described in section 2.2.4.2. 
 
2.2.8.3. Nuclear magnetic resonance (NMR) 
The sample preparation and analysis was carried out as described in section 2.2.4.3. 
 
2.2.9. P(3HO) cardiac patches 
2.2.9.1. Plain and porous film fabrication 
The plain and porous films fabrication was carried out by dissolving 0.5 g of P(3HO) in 10 
ml of chloroform and casting the solution on 60 mm diameter glass petridishes. For the 
 





porous film, 50 mg of sucrose particles between 250 and 300 µm of size were added to the 
dissolved polymer. The polymer was dried at room temperature for 7 days and then freeze 
dried for 10 days.  
 
2.2.9.1.1. Porosity measurements 
The porosity of the films was determined using equation 2.3.      
Porosity (%) =    Vm-Vp  x 100 = Vm-(Wρ/ρ) x 100                                                          (2.3) 
                               Vm                        Vm 
where Vm is the volume of the plain films (cm3), Vρ is the volume of the porous film (cm3), 
and Wρ and ρ is the mass and density of the porous film, respectively. Porosity 
measurements were taken in quadruplicates. 
 
2.2.9.2. Electrospinning 
The electrospinning technique was used for the fabrication of P(3HO) microfibres. For this, 
the following P(3HO) solutions were produced in acetone: 0.2 wt%, 0.5 wt%, 0.6 wt%, 0.7 
wt%, 1 wt% and 1.2 wt%. A syringe was loaded with the polymer solution and pumped by a 
Harvard® syringe pump through silicone tubing connected to a 330 µm inner diameter nozzle. 
The conductive steel nozzle was connected to a positive terminal of a Glassman Europe® high 
voltage supply source. The electric potential and the pump speed were adjusted for each 
concentration until a stable cone-jet was obtained. A distance of 15 cm between the needle 
and collector was used in all the conditions tested. A range of collection times were assessed 
in each condition (from 1 second to 10 minutes) and one collection time was selected in each 
case. The fibre collection was carried out on plain and porous P(3HO) films and glass slides.  
 
2.2.9.2.1. Fibre measurements 
The size and shape of the fibres obtained by electrospinning was assessed by optical 
microscopy. Image tool® software was used to measure the size of the fibres. An average of 
the fibres size was calculated in each condition from the measurement of 30 fibres. 
 
 





2.2.9.3. Human vascular endothelial growth factor (VEGF) incorporation within the 
P(3HO) film 
The VEGF film fabrication was carried out by dissolving 0.5 g of the P(3HO) polymer in 10 
ml of chloroform. Then, 2 µl of a 1 µg/µl human VEGF solution in MiliQ water were added 
into the polymer solution. The resulting solution was vortexed for 5 minutes and cast in 60 
mm petridishes. Films were dried at 4 ºC for 21 days. 
 
2.2.9.4. Arg-Gly-Asp (RGD) peptide film immobilization 
The RGD peptide immobilization protocol used in this project was adapted from Yoon et al., 
(2003). The immobilization was carried out in two stages. First, the P(3HO) material was 
aminated and films were cast. Then, the surface immobilization of the RGD peptide was 
carried out on one side of the aminated solvent cast films. Figure 2.7 shows the synthetic 
scheme for the RGD peptide immobilization in PHAs. 
 
Figure 2.7. Synthetic scheme of the RGD peptide immobilization. 
 
 





2.2.9.4.1. Preparation of aminated P(3HO) 
In order to attach a terminal amine group to the P(3HO), the carboxylic acid terminal group 
was activated and reacted with hexaethyleneglycol-diamine. For this, 1 g of P(3HO) was 
dissolved in 10 ml of methylene chloride. 0.22 mmol of dicyclohexylcarbodiimide (DCC) 
and 0.22 mmol of N-hydroxysuccinimide was added into the polymer solution with stirring. 
The reaction was stirred for 12 hr at room temperature. Insoluble dicyclohexylurea was 
removed by filtration, and the carboxylic group activated polymer was isolated by 
precipitation in DMSO and dried for two days at room temperature. The activated P(3HO) 
was reacted with an excess of  hexaethyleneglycol-diamine (75 mg) in 10 ml of methylene 
chloride for 12 hr at room temperature with stirring. The aminated P(3HO) was precipitated 
into cold ethanol. 
 
2.2.9.4.2. Surface immobilization of RGD peptide on aminated P(3HO) films 
The film casting was carried out by dissolving 0.25 g of aminated P(3HO) with 0.25 g of 
non-aminated P(3HO) (50:50) in 10 ml of methylene chloride. After 5 minutes of vortexing, 
the solution was cast in a glass petridish and dried for 4 days at room temperature. Dried 
films were pre-wetted in 70 % ethanol and washed in distilled water. Resulting films were 
hydrated in PBS for 4 hr. In order to introduce amine reactive groups onto the film surface, 
films were soaked in 20 ml of PBS containing 100 nM ethyleneglycol-bis-
succinimidylsuccinate (EGS) and agitated for 4 hr at room temperature. Films were washed 
with PBS three times and soaked into 20 ml of PBS containing 30 nmoles of the RGD 
peptide. The solution was stirred for 12 hr at 4 ºC. The peptide immobilized films were 
washed with PBS and distilled water and then freeze-dried.   
 
2.2.9.4.3. Confirmation of the RGD peptide immobilization on P(3HO) films 
The presence of the RGD peptide on the constructs surface was confirmed by FTIR (2.2.4.1.), 









2.2.10. P(3HO) films characterization 
2.2.10.1. Dynamic mechanical analysis (DMA) 
The mechanical properties of the polymer were analysed using a Perkin–Elmer®dynamic 
mechanical analyser at the Department of Biomaterials and Tissue engineering, Eastman 
Dental Institute, University College London, UK. The analysis was carried out under static 
conditions on polymer strips of 10 mm length and 4 mm width. The initial load was set to 1 
mN and then increased to 6000 mN at the rate of 200 mN min-1 and the stress and strain were 
measured. The Young’s modulus, tensile strength and elongation at break were calculated 
from the stress vs. strain plot. 
 
2.2.10.2. Differential scanning calorimetry (DSC) 
The thermal properties of the polymer were determined using a Perkin Elmer®Pyris Diamond 
DSC at the Department of Biomaterials and Tissue Engineering, Eastman Dental Institute, 
University College London, UK. For the analysis, approximately 8 mg of sample were placed 
in aluminium pans and the samples were cooled down to -57 ºC. Then, samples were heated, 
cooled and heated again at a heating rate of 20 ºC min-1 from -57 ºC to 175 ºC, and the glass 
transition temperature (Tg), melting temperature (Tm) and crystallization temperature (Tc) 
were determined.     
 
2.2.10.3. Contact angle analysis  
The water contact angle of the fabricated films was analysed on a KSV Cam 200® optical 
contact angle meter at the Department of Biomaterials and Tissue Engineering, Eastman 
Dental Institute, University College London, UK. For this, a Hamilton® syringe was loaded 
with MiliQ water and a drop of water was dispensed on the film. A series of photos were 
taken every second to record the shape of the drop over 20 seconds. The water contact angle 
was measured using a KSVCam® software. 
 
2.2.10.4. Scanning electron microscopy (SEM) 
The surface of the films was examined under a JEOL 5410LV Scanning electron microscope 
(Hertfordshire, UK) at the Department of Biomaterials and Tissue Engineering, Eastman 
 





Dental Institute, University College London, UK. The samples were placed on Agar 
Scientific® Carbon conducting tabs and then coated with gold-palladium using a Quorum 
Technologies® Polaron E5000 Sputter Coater (East Sussex, UK) for 2 minutes. The SEM 
images were taken with an acceleration voltage of 10 kV at 15 cm working distance. 
 
2.2.10.5. Surface roughness analysis 
Surface roughness studies were carried out on a UBM laser scanning profilometer at the 
Department of Material Science and Engineering, University of Erlangen-Nuremberg.  An 
area of 2 mm x 2 mm (± 500 µm) was scanned by the machine in two directions. Graphic 
representation of the scans and average roughness values were recorded.  
 
2.2.10.6. Protein adsorption study 
The protein adsorption study was carried out by measuring the protein concentration after 
soaking the P(3HO) films in Foetal Bovine Serum (FBS). To this end, 1 cm2 films were 
incubated with 400 µl of FBS at 37 ºC for 24 hr. For a negative control, films were incubated 
only in PBS. For the collection of the adsorbed proteins, films were washed three times with 
PBS and incubated in 1 ml of 2 % SDS in PBS for 24 hr, at room temperature, with shaking. 
The amount of protein in the solution were quantified using a ThermoScientific® 
bicinchoninic acid (BCA) reagent kit. The experiment was carried out in triplicates of each 
sample. 
 
2.2.11. In vitro cell culture studies 
2.2.11.1. Cardiomyocytes viability 
In vitro biocompatibility studies were performed using adult fresh rat isolated cardiomyocyte 
cells. The cell viability on the P(3HO) UV sterilized films were studied over a period of 0, 1, 
2, 3, 24, 25 and 26 hours. The number of live vs. dead cells was determined by counting the 
cells with rod shape (live cells) vs. cells with round shape (dead cells) under the optical 
microscope. The viability studies were also carried out on standard tissue culture plastic as a 
control. The study was carried out in triplicates for each sample. 
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2.2.11.2. Cardiomyocyte contraction experiments 
Fresh adult rat beating cardiomyocytes were seeded on a P(3HO) coated cover slip. The 
cardiomyocytes were superfused at 37 ◦C in a Krebs-Henseleit solution (2.1.5.4) containing 
1 mM CaCl2 and bubbled with a mixture of 95 % O2 5 % CO2. For the study, rod shaped 
cardiomyocytes with regular and no spontaneous contraction without stimulation were 
selected. Cells were stimulated with pulses of 50 V for 2 ms with 2 second intervals. 
Contraction amplitude (% shortening), ‘time to peak 90 %’ and ‘time to relaxation 50 %’ 
were recorded with a IonOptix® video based system. Figure 2.8. shows an illustration of the 
time to peak and time to relaxation parameters analysed for each peak during the 
cardiomyocyte contraction. 
Figure 2.8. An illustration of the time to peak and time to relaxation of a cardiomyocyte. 
Arrows in red show the time to peak 90% and time to relaxation 50% assessed during the 
contraction measurements.   
The myocyte contraction was studied at a range of frequencies of electrical pulses of 50 V for 
a period of 2 ms. Starting from 2 second interval pulses, the intervals were increased to 5 
seconds, and then decreased to 2 seconds, 1 second and 0.5 seconds. Following this, the 
effect of the calcium increment was studied. With a 2 second interval pulse of 2 ms at 50 V, 
the CaCl2 concentration of the solution was increased from 1 mM to 2 mM, and then 3 mM 
and 4 mM. A stabilization period was allowed in each condition. The contraction studies 
Time to peak 
Time to relaxation 
Time to peak 90% Time to relaxation 50% 
 





were also carried out on uncoated cover slips as controls. The contraction experiments were 
carried out in quadruplicates. 
 
2.2.11.3. C2C12 myoblast proliferation 
The C2C12 myoblast cell line was used to assess cell proliferation in the P(3HO) constructs 
by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric 
assay and SEM.  
 
2.2.11.3.1. C2C12 cell growth 
C2C12 myoblast cells were grown in DMEM supplemented with 10 % of foetal calf serum, 
1% w/v penicillin and 1 % w/v streptomycin solution and grown at 37 ºC with 5 % of CO2. 
Media was pre-warmed at 37 ºC and filter sterilized prior to use. Cell passages were carried 
out before confluence, every one or two days. For the passages, cells were detached from the 
flask using a 5 % trypsin at 37 ºC for 2.5 minutes and the reaction was stopped by adding 
equal volume of supplemented DMEM. Samples were centrifuged at 400 g for 10 min and 
the resulting pellet was dissolved in freshly supplemented DMEM. Cells were seeded in 
sterile 75 cm2 tissue culture flasks.  
 
2.2.11.3.2. Sample preparation 
P(3HO) film constructs were cut in to 1 cm2 squares and sterilized under the UV light for 30 
minutes each side. P(3HO) films were soaked in supplemented DMEM for 12 hr prior to cell 












2.2.11.3.3. C2C12 cell seeding 
C2C12 myoblast cells in 70 % confluence were used for the cell seeding. Scaffdex® cell 
crowns were used to hold the cells on the well’s surface. Around 20,000 cells were seeded on 
the pre-wetted constructs in a 24 well plate. As a positive control, cells were seeded in the 
wells without films. For the negative control, films were incubated in supplemented DMEM 
without cells. Plates were incubated at 37 ºC with 5 % of CO2 and media was changed every   
2 days. Cell proliferation was assessed at 24 hr.  
 
2.2.11.3.4. C2C12 MTT assay 
The MTT assay was performed on the constructs containing the cells at 24 hr. For this,      
100 µl of a 5 mg/ml MTT solution in distilled water were added to each well at 24 hr and the 
plates were incubated for two hours at 37 ºC with 5 % of CO2. After this, films were 
transferred to new 24 well tissue culture plates and 500 µl of DMSO were added. After a 5 
minute incubation, 100 µl of the resulting solution were transferred to 96 well plates and the 
absorbance at 540 nm was measured on a Thermomax®microtitre plate reader. The 
absorbance of the samples were normalised with respect to the positive control. The 
difference in the surface areas of the tissue culture plate wells and the films were considered 
for the calculation of the % cell viability on the films. 
 
2.2.11.4. C2C12 myoblast SEM 
At 24 hr constructs containing the cells were visualized using SEM. To this end, cells were 
fixed in 0.1 M cacodylate buffer containing 3 % glutaraldehyde for 12 hr at 4 ºC and 
dehydrated in a series of ethanol solutions (50 %, 70 %, 90 % and 100 %) for four times, 
incubating 10 minutes in each solution. Samples were air dried, coated and examined under 










2.2.12. P(3HB) microspheres 
2.2.12.1. P(3HB) microsphere production 
The microspheres were produced using the P(3HB) polymer obtained from B. subtilis phaC1-
pHCMC04 as described by Francis et al., 2011. Briefly, 1 g of polymer was dissolved in 8 ml 
of chloroform. The polymer solution was slowly added in the form of drops into 40 ml of 1 % 
polyvinylalcohol (PVA) water solution, stirred at 1000 rpm for 3 minutes. The solution was 
then poured into a second 0.5 % PVA solution stirred at 800 rpm for 4 hours. The resulting 
microspheres were isolated by centrifugation at 3680 g for 5 minutes, washed with distilled 
water three times and air dried.   
 
2.2.12.2. Microspheres porosity 
The porosity of the microspheres was measured using the liquid displacement method (Chen 
et al., 2005). For this, 5ml of ethanol were weighed in a measuring cylinder. Then, the 
microspheres were immersed in the ethanol and sonicated to ensure the ethanol penetration 
through the pores. The sample porosity was calculated according to equation (2.4). 
Porosity =    Vf__   =   W2 –W3-Ws_x 100                                                                       (2.4) 
                     Vs+Vf            (W1-W3) 
Vf =          W2 –W3-Ws_  
                        ρe 
Vs =         W1 –W2+Ws_  
                        ρe 
where W1 is the weight of the cylinder + ethanol, W2 is the weight of the 
cylinder+ethanol+sample after removing the excess of ethanol above 5 ml, W3 is the weight 
of ethanol+ cylinder after removing the microspheres sample saturated with ethanol and Ws is 
the weight of the microsphere sample used in the experiment. 
 
 
2.2.12.3. Encapsulation of VEGF in P(3HB) microspheres 
VEGF was encapsulated within P(3HB) microspheres. For this, 5 µl of a 1 µg/µl VEGF 
solution in water were added to 1 g of polymer dissolved in 8 ml of chloroform. The solution 
 





was vortexed for 5 minutes and the microsphere production was carried out as described in 
section 2.2.13.1. 
 
2.2.12.3.1. Determination of VEGF encapsulation efficiency 
The encapsulation efficiency (EE%) of the protein encapsulation was determined using 
equation (2.5). 
EE%=          actual amount of VEGF                 x 100                                                         (2.5) 
          experimental amount of VEGF loaded 
 
The actual amount of VEGF loaded into the microspheres was determined by dissolving 5 mg 
of VEGF loaded microspheres in 1 ml of chloroform and 5 ml of water and the water phase 
was then analysed for the VEGF content by the the invitrogen®VEGF human ELISA kit 
(R&D Systems, Minneapolis, USA). 
 
2.2.12.4. P(3HB) microsphere characterization 
Microspheres were characterized by FTIR (described in section 2.2.4.1.), DSC (described in 
section 2.2.5.3.) and SEM (described in section 2.2.5.5.). 
 
2.2.12.5. VEGF release kinetics from P(3HB) microspheres and P(3HO) films  
The in vitro VEGF release from the microspheres and films was studied for 30 days 
(Sipahigil et al., 2012). In this experiment, 10 mg of microspheres or 10 mg of films were 
incubated in Eppendorf tubes containing 1 ml of PBS at 37 ºC with constant agitation at 100 
rpm. 500 µl of PBS were periodically withdrawn from the tubes and replaced with fresh PBS 
at the following time points (days): 1, 3, 5, 7, 10, 13, 17, 21, 25 and 30. The amount of VEGF 
released in the medium was measured using the Invitrogen®VEGF human ELISA kit (R&D 









2.3. DATA ANALYSIS 
Data are reported as mean ± STDEV. Statistical significance was assessed using ANOVA 
with the Newman-Keuls' test. Differences were considered statistically significant when 
*p<0.05, very significant **p<0.01 and highly significant when ***p<0.001. 
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3.1. INTRODUCTION 
Polyhydroxyalkanoates (PHAs) are an alternative source of polymers produced by bacterial 
fermentation of sugar or lipids. Due to their outstanding properties, including 
biocompatibility, biodegradability, and their adjustable mechanical properties, PHAs are 
gaining importance as potential candidates for medical applications. In particular, medium 
chain length-PHAs (mcl-PHAs) have flexible and elastomeric properties that make the 
material unique for soft tissue engineering applications (Rai et al., 2011a).  
Mcl PHAs are commonly produced by Pseudomonas belonging to rRNA homology group I 
(Lageveen et al., 1988). The Pseudomonas sp. PHA synthesis gene cluster consists of two 
different phaC genes encoding class II PHA synthases separated by another gene, phaZ, that 
encodes an intracellular PHA depolymerase. Downstream of the second phaC gene are the 
phaD, phaI and phaF genes, which encode structural and regulatory proteins (Figure 3.1). 
Knock-out mutants in Pseudomonas mendocina studied previously provided evidence that 
phaC1 is the major enzyme for PHA synthesis (Hein et al., 2002).  
 
 
Figure 3.1. The PHA-related gene cluster of Pseudomonas sp., which encodes the proteins 
involved in PHA metabolism. 
 
The Pseudomonas sp. has been widely studied due their capacity to grow on different carbon 
sources, and their ability to produce mcl-PHAs using a related or an unrelated carbon source. 
P. mendocina has been recently found to be a source of the homopolymer P(3HO), an 
unusual observation (Rai et al., 2011a). The P(3HO) homopolymer is flexible and 
elastomeric in nature. In addition, it has the capacity to support cell attachment, 
differentiation, and maturation, making the material a promising candidate for soft tissue 
engineering (Rai et al., 2011b). However, Gram-negative bacteria have LPS, which are co-
purified with the PHAs. The presence of this endotoxin is responsible not only for the 
pyrogenicity, but also for complement activation, which stimulates an undesirable immune 
response. This limits the biomedical applications of the PHAs in several cases. 
Gram positive bacteria, which lack LPS, are the focus for polymer production for medical 
and pharmaceutical applications (Valappil et al., 2007). Among Gram-positive bacteria, 
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Bacillus subtilis is one of the most well studied organisms for heterologous expression due to 
its versatility in the acceptance of varied growth conditions, capacity of growth at a very high 
cell density and their non-pathogenic nature, essential for medical applications (Zweers et al., 
2008). Thus, B. subtilis is an ideal microorganism for the expression of heterologous genes 
(Singh et al., 2009). In this work, the P. mendocina PHA synthase gene (phaC1) was 
expressed in the LPS free Gram-positive microorganism, B. subtilis, so as to produce LPS-
free mcl-PHAs. B. subtilis is a GRAS organism widely used in industry that has not yet been 
explored as a PHA producer at a commercial scale. To this end, P. mendocina phaC1 gene 
was amplified and cloned in B. subtilis 1604 through the pHCMC04 expression vector. 
Sequence analysis of the cloned phaC1 gene was carried out to confirm the integrity of the 
gene. The phaC1 expression was induced and analysed with SDS-PAGE. B. subtilis was 
grown in PHA production media with sucrose as the sole carbon source and the produced 
polymer was quantified and analysed by FTIR, GC-MS and NMR.  
PHA biosynthesis can be divided in to two main steps. The first step involves the synthesis of 
hydroxyacyl-CoA, the PHA monomer units. The second step involves a reaction catalysed by 
the PHA synthase which use the hydroxyacyl-CoA units as substrates and catalyses their 
polymerization into PHAs with the concomitant release of CoA (Rehm et al., 2002). The 
synthesis of the 3-hydroxacyl-CoA units can occur mainly by three different pathways and 
the particular pathway used for PHA production depends on the specific metabolic pathways 
operating in a particular microorganism and the carbon source provided (Steinbüchel et al., 
1991; Doi et al., 1990, Poirier et al., 1995). In the first pathway, P(3HB) or P(3HB-co-3HV) 
are produced from carbohydrates through a precursor from the tricarboxylic acid cycle. The 
second pathway involves the production of mcl-PHAs via the fatty acid oxidation pathway 
from fatty acids related to the final polymer structure. The third pathway involves mcl-PHA 
production via the fatty acid de novo biosynthesis using carbohydrates structurally unrelated 
to the final polymer structure. To assess the capacity of the recombinant B. subtilis to produce 
mcl-PHAs through the fatty acid biosynthesis and degradation pathways, production of PHAs 
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3.2. RESULTS 
3.2.1. Construction of recombinant Bacillus subtilis 
P. mendocina was grown in nutrient agar and a single colony was used to inoculate nutrient 
broth. The P. mendocina genomic DNA was isolated from an overnight bacterial culture by 
using the Wizard Genomic DNA Purification Kit. The integrity of the isolated DNA was 
confirmed by electrophoresis (Figure 3.2). 







Figure 3.2. P. mendocina genomic DNA. Lane MK represents the 1Kb ladder. The arrow in 
the figure shows the integrity of P. mendocina genomic DNA obtained in Lane 1. 
 
The PHA synthase gene (phaC1) was amplified by PCR as described in section 2.2.1.1 using 
specific primers flanking the complete phaC1 sequence and including BamH1 and EcoRV 
restriction enzyme sites present in the plasmids, to be used later for cloning. The resulting 
product was run using a 0.8% agarose gel after gel purification (Figure 3.3). 
  
 
Figure 3.3. The P. mendocina synthase gene phaC1 containing the BamH1 and EcoRV sites 
(1692bp). Lane MK represents the 1Kb ladder and lanes 1-4 correspond to elutions 1-4 
obtained from the column used to purify the product from the gel. The arrow in the figure 
indicates the phaC1 amplified sequence.  
Escherichia coli ECE 189 was grown overnight and pHCMC04 plasmid (a Bacillus-E. coli 
shuttle vector, described in section 2.1.3) was isolated by miniprep as described in section 
MK     1     2      3     4 
MK     1      
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2.2.1.3. Digests were carried out to prepare the vector and inserts for ligation (section 
2.2.1.4). The pHCMC04 plasmid and PCR insert were digested using EcoRV and BamHI 
enzymes. Figure 3 shows a 0.8% agarose gel with both digested insert and vector (Figure 
3.4). 
 
                                                                
Figure 3.4. Digested insert and pHCMC04 vector with BamH1 and EcoRV enzymes. MK 
represents the 1Kb ladder. Lane 1: digested pHCMC04 (8089bp); Lane 2: The digested 
phaC1 PCR product (1692bp). The arrows in the figure indicate the digested insert and 
vector. 
The pHCMC04 vector was ligated with the phaC1 fragment and transformed into 
Escherichia coli XL1 blue cells using heat shock (section 2.2.1.6). The transformed cells were 
grown and selected in 100 µg/mL ampicillin LB agar plates. Restriction digestion of 
plasmids, isolated from randomly chosen ampicillin-resistant colonies was carried out (Figure 
3.5). Note that both plasmids contained an upper band representing the vector, pHCMC04 
and a lower band representing the insert, which confirmed the successful cloning of the 




Figure 3.5. Restriction Digestion of the pHCMC04-phaC1 clones. MK represents the 1Kb 
ladder. Lane 1 and Lane 2: Double digestion of pHCMC04-phaC1 plasmid obtained from 
ampicillin resistant colony 1 and 2, respectively, using BamH1 and EcoRV. The arrows in the 
MK     1      2       
MK      1       2       
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figure show the upper bands corresponding to the vector pHCMC04 (8089bp kb) and the 
smaller bands corresponding to the phaC1 insert (1692bp kb).  
E.coli XL1 blue containing pHCMC04-phaC1 plasmid was grown overnight and the plasmids 
were extracted using the Qiagen Kit (Sussex, UK). The resulting constructs were sequenced 
to confirm that no undesirable mutations were introduced by the PCR reaction (section 
2.2.1.7). The sequence obtained is shown in Figure 3.6. The sequence of phaC1 cloned into 
pHCMC04 vector shows only one mistake at the highlighted position, which results in a 
thymine instead of a cytosine.  
 
            atgagtgacaagaataacgaagacctgaaacgccaggcctcggaaaacacgctgggcctc 
M  S  D  K  N  N  E  D  L  K  R  Q  A  S  E  N  T  L  G  L 
aacccggtgattggcatccgcggcaaggatcttttgacctctgcccgcatggtgctcgcc 
N  P  V  I  G  I  R  G  K  D  L  L  T  S  A  R  M  V  L  A 
caggcactcaaacaatccttccacagcgccaagcatgtcgcccatttcggcctcgaactg 
Q  A  L  K  Q  S  F  H  S  A  K  H  V  A  H  F  G  L  E  L 
aagaacgtcatgctcggccagtccgcgctaaagcccgaagacggtgaccgccgctttgcc 
K  N  V  M  L  G  Q  S  A  L  K  P  E  D  G  D  R  R  F  A 
gatccggcctggagccagaacccgctgtaccgccgctacctgcagacttacctggcctgg 
D  P  A  W  S  Q  N  P  L  Y  R  R  Y  L  Q  T  Y  L  A  W 
cgcaaggagctgcacgactgggtcgagcacagctcgctgtccgagcaggacgccagccgc 
R  K  E  L  H  D  W  V  E  H  S  S  L  S  E  Q  D  A  S  R 
ggcaccttcgtgatcaacctgatgaccgaagacatggcaccctccaacagcatggccaac 
G  T  F  V  I  N  L  M  T  E  D  M  A  P  S  N  S  M  A  N 
ccggcagcggtcaaacgcttcttcgaaaccggcggcaagagcctgctcgacggcctgtcg 
P  A  A  V  K  R  F  F  E  T  G  G  K  S  L  L  D  G  L  S 
cacctggccaaggacatggtgcacaacggcggcatgccgagtcaggtgaatatggaggcc 
H  L  A  K  D  M  V  H  N  G  G  M  P  S  Q  V  N  M  E  A 
ttcgaggtcggcaagaacctggccaccaccgacggcgccgtggtgtttcgcaacgatgtg 
F  E  V  G  K  N  L  A  T  T  D  G  A  V  V  F  R  N  D  V 
ctggagctgatccagtacaagccgatcaccgagagcgtgcatgagcgcccgttgctagtg 
L  E  L  I  Q  Y  K  P  I  T  E  S  V  H  E  R  P  L  L  V 
gtgccgccgcagatcaacaagttctatgtcttcgacctgtcgccggacaagagcctggcg 
V  P  P  Q  I  N  K  F  Y  V  F  D  L  S  P  D  K  S  L  A 
cgcttcctcctgcgcagccaggtgcagaccttcgtggtcagctggcgcaacccgaccaag 
R  F  L  L  R  S  Q  V  Q  T  F  V  V  S  W  R  N  P  T  K 
gcgcagcgcgagtggggcctgtccacctacatcgaggcgctcaaggaagccatcgacgtc 
A  Q  R  E  W  G  L  S  T  Y  I  E  A  L  K  E  A  I  D  V 
atctgcgccatcaccggcagcaaagacgtgaacatgctcggcgcctgctccggtggcctg 
I  C  A  I  T  G  S  K  D  V  N  M  L  G  A  C  S  G  G  L 
accactgcttcgctgctcggccactacgccgcgctcggccaacctaaagtcaatgccctg 
T  T  A  S  L  L  G  H  Y  A  A  L  G  Q  P  K  V  N  A  L 
Continues on the following page 
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accttgctggtcagcgtgctcgacacccagctcgacacccaggtagcgctgttcgccgac 
T  L  L  V  S  V  L  D  T  Q  L  D  T  Q  V  A  L  F  A  D 
gagaagaccctggaacgcggccaacgccgctcctaccaggccggagtgctggaaggcagc 
E  K  T  L  E  R  G  Q  R  R  S  Y  Q  A  G  V  L  E  G  S 
gacatggccaaggttttcgcctggatgcgccccaacgacctgatctggaactactgggtc 
D  M  A  K  V  F  A  W  M  R  P  N  D  L  I  W  N  Y  W  V 
aacaactacctgctcggcaacgagccgccggtgttcgacattctctactggaacaacgac 
N  N  Y  L  L  G  N  E  P  P  V  F  D  I  L  Y  W  N  N  D 
accacacgcctgccggctgcgctgcacggcgagttcatcgaaatgttccagaccaacccg 
T  T  R  L  P  A  A  L  H  G  E  F  I  E  M  F  Q  T  N  P 
ttgacccgtcccggcgcgctggaagtgtgcggtacgccgatcgacctcaaacaggtcacc 
L  T  R  P  G  A  L  E  V  C  G  T  P  I  D  L  K  Q  V  T 
tgcgacttcttcgtcgtcgccggcaccaccgaccacatcacgccatgggattcctgctac 
C  D  F  F  V  V  A  G  T  T  D  H  I  T  P  W  D  S  C  Y 
aaatcggctcatctgttcggcggcaaatgcgagttcgtgctctccaacagcggccatatc 
K  S  A  H  L  F  G  G  K  C  E  F  V  L  S  N  S  G  H  I 
cagagcattctcaacccgccgggcaaccccaaggcgcgctacatgaccaatagcgagatg 
Q  S  I  L  N  P  P  G  N  P  K  A  R  Y  M  T  N  S  E  M 
ccgctggacccgaaagcctggcaggaaagctcgaccaagcatgccgactcctggtggctg 
P  L  D  P  K  A  W  Q  E  S  S  T  K  H  A  D  S  W  W  L 
cattggcaaagctggctggccgagcgctcgggcgaaaccaagaatgctccacgggcgctg 
H  W  Q  S  W  L  A  E  R  S  G  E  T  K  N  A  P  R  A  L 
ggcaacaagaaattcccggccggcgaagccgcaccgggcacctatgtacacgaacgctga 
G  N  K  K  F  P  A  G  E  A  A  P  G  T  Y  V  H  E  R  - 
Figure 3.6. Sequencing results obtained from phaC1 gene cloned into pHCMC04 shuttle 
vector. The highlighted position shows the mutation observed.  
 
Further, B. subtilis 1604 was transformed with the pHCMC04-phaC1 construct by 
electroporation as described in section 2.2.1.8. Transformed colonies were selected in 5 
µg/mL chloroamphenicol. In addition, B.subtilis1604 strain was transformed with pHCMC04 
without insert, to be used as control in further experiments. B. subtilis containing the 
pHCMC04-phaC1 construct and B. subtilis containing the vector without insert were named 
B. subtilis-phaC1 and B.subtilis-vector, respectively. In order to confirm the presence of 
phaC1 in the chloroamphenicol-resistant B. subtilis-phaC1, the isolated plasmid was 
amplified by PCR using specific primers flanking the last 301 bp of the phaC1 gene. Figure 
3.7 shows the results obtained. The first and the last lanes show the PCR product of negative 
controls where no template or the plasmid extracted from B.subtilis-vector, respectively, were 
used. The second lane shows the PCR product obtained when the plasmid extracted from 
B.subtilis-phaC1 was used as template.   
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Figure 3.7. Confirmation of transformation of B. subtilis 1604 with pHCMC04-phaC1. MK 
represents the 1Kb ladder. The picture shows results from PCR reactions using primers 
flanking the last 301 bp of phaC1 sequence. Lane 1: PCR without template; Lane 2: PCR 
with B.subtilis-phaC1 extracted plasmid as template; Lane 3: PCR with B.subtilis-vector 
extracted plasmid as template. The arrow in the figure indicates the PCR amplification 
product obtained. 
 
3.2.2. Expression of the phaC1 gene in the recombinant Bacillus subtilis 1604 
Recombinant B. subtilis was tested for phaC1 gene expression (section 2.2.2). The plasmid 
construct contained the xylA constitutive promoter, inducible by xylose. It was important to 
identify the various growth phases during xylose induction for the recombinant B. subtilis 
1604 in order to determine the correct induction time using xylose. Hence, the recombinant 
strain was grown in LB broth at 30 °C in the presence of chloramphenicol. The OD600nm was 
measured every 30 minutes. Figure 3.8 shows the resulting growth profile and the chosen 
OD600nm values for the xylose induction. 
 
MK     1     2     3       
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Figure 3.8. B. subtilis recombinant growth curve. LogOD600nm of 1.5 (mid-log phase) was 
chosen for induction using xylose. 
 
B. subtilis 1604 recombinant bacteria were grown in duplicate in LB media at 30 °C and one 
of the duplicates was induced with a solution of 0.5 % xylose as described in literature at Log 
OD600nm 1.5 (Nguyen et al., 2005). Aliquots of the growth cultures were taken at different 
time points after induction (min.): 0, 15, 30, 60, 90 and 120. The same procedure was carried 
out for B. subtilis wild type. Whole cell extracts were prepared for SDS-PAGE and run in 
12% SDS-PAGE gel at 140 V. Figure 3.9 shows the resulting gels. The phaC1 protein is  
62.4 KDa in size. Results show that no distinct band of this size was found in either the 
induced or uninduced samples. However, there was appearance of a band at around 66 KDa 
when compared with the wild type bacteria at the different time points, which might indicate 
phaC1 expression. In this case, the fact that the bands appear in both induced and uninduced 
conditions, may indicate the “leaky” characteristics of the plasmids. In order to enhance the 
levels of protein expression, this protocol was repeated using xylose solutions of various 
concentrations (0.2%, 0.8% and 1,1%) at mid-log phase (Log OD600nm 1.5), early-log phase 
(Log OD600nm 1.1) and late-log phase (Log OD600nm 2.2), but no differences were observed 
compared with the 0.5% xylose induction (results not shown). A Western blot could have 
been carried out to determine the presence of phaC1, however, due to the lack of availability 
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       t=120                      t=90                     t=60              t=30                       t=15                     t=0 
    I      UI     WT       I      UI     WT      I      UI      WT   MK     I       UI    WT      I       UI    WT      I       UI     WT  MK 
Figure 3.9. SDS-PAGE of B.subtilis 1604 recombinant and wild type at different time points 
after induction with xylose 0.5%.WT: wild type B.subtilis 1604, UI: uninduced recombinant 
B.subtilis, I: xylose induced recombinant B.subtilis. 
Hence, for the purpose of confirming that the recombinant B. subtilis expresses the phaC1 
gene, both B. subtilis-phaC1 and B. subtilis-vector were grown in PHA production media. A 
single colony was grown in nutrient broth until mid-log phase and used as inoculum for the 
PHA production media. Figure 3.10 shows the growth curve for the recombinant B. subtilis-
phaC1 strain at 30 °C, in PHA production media indicating the mid-log phase for the xylose 
induction.  
Figure 3.10. Growth curve for B. subtilis recombinant strain harbouring pHCMC04-phaC1 in 
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3.2.3. Production of PHAs from recombinant B. subtilis from carbohydrates 
The recombinant B. subtilis harbouring pHCMC04-phaC1 was grown in LB broth and the 
resulting culture in mid-log phase was used as a 10% inoculum for PHA production using the 
PHA production media described by Ramsay et al., (1990) with sucrose as a carbon source. 
The culture was grown at 30 °C in the PHA production media and induced with a 0.5 % 
xylose solution at an OD600nm of 0.385. After 30-hours of growth in the PHA production 
media, the cells were harvested and dried in a freeze-dryer for two days. As controls this 
protocol was repeated with B. subtilis wild type and B. subtilis-vector.  
Figure 3.11 shows a Gram-staining of the recombinant B. subtilis grown in LB broth after 
induction. The recombinant bacteria were seen to consistently form aggregates in contrast to 
the B. subtilis wild type. Such aggregates were previously observed by Babic et al., (2011) 
who showed that recombinant B. subtilis grow in chains in order to accelerate the spread of 
DNA within microbial communities and that DNA transference appeared to occur at a cell 
pole or along the lateral cell surface by conjugation (Figure 3.8).  
 
 
Figure 3.11. Gram-staining of recombinant B. subtilis grown in LB broth showing the 
aggregates formed.  
The cells obtained from these cultures were freeze dried and analysed by Fourier Transform 
Infrared Spectroscopy (FTIR) as described in section 2.2.4.1. Figure 3.12 shows the FTIR 
spectral analysis confirming the presence of a strong, distinct ester carbonyl band at         
  CHAPTER 3 
77 
1733 cm-1 in the case of the recombinant B.subtilis-phaC1 strain which was absent in B. 
subtilis-vector and B. subtilis wild type. These results indicated the successful production of 
PHAs by the recombinant B. subtilis harbouring pHCMC04-phaC1.   
Figure 3.12. FTIR spectra for B. subtilis wild type (—) B. subtilis-phaC1 (—) and B. 
subtilis-vector (—). The arrow in the figure indicates the presence of a distinct ester carbonyl 
band at 1733 cm-1 for B.subtilis-phaC1. 
In order to analyse the polymer produced by the recombinant B. subtilis-phaC1, the growth 
and induction conditions were repeated in large scale. The cells were harvested immediately, 
dried in a freeze-dryer for two days and the polymer was extracted and analysed by FTIR and 
GC. The resulting polymer is shown in Figure 3.13. 
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Figure 3.13. Polymer produced by recombinant B. subtilis-phaC1. 
In order to determine the nature and amount of polymer, B. subtilis wild type, B. subtilis-
phaC1 and B. subtilis-vector were subjected to fermentation in 2 L PHA production media in 
quadruplicates. Polymer was extracted from the resulting cells, quantified and characterized 
by GC-MS (described in section 2.2.4.2) and NMR (described in section 2.2.4.3). Figure 
3.14(A) and 3.14(B) shows the GC-MS and NMR results, respectively, of the obtained 
polymer. These results showed the presence of the P(3HB) homopolymer. 
3.14 (A) 
(3HB) 
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Figure 3.14. (A) GC-MS spectra of the extracted polymer produced from B. subtilis-phaC1. 
Note the presence of a peak at RT: 6.67 and the corresponding mass spectra for P(3HB) (the 
peak obtained at RT: 9.56 corresponded to methyl benzoate used as the internal control) and 
(B) 1H NMR on the left, 13C NMR on the right. This spectrum is characteristic of the P(3HB) 
homopolymer.  
 
Figure 3.15 shows the dry cells weight (A), PHA content (B) and amount of polymer 
normalized per gram of dry cells (C) of B. subtilis wild type (wt), B. subtilis wild type, B. 
subtilis-vector and B. subtilis-phaC1 after fermentation. According to these results B. subtilis-
phaC1 shows a significant higher dry cell weight, PHA production and polymer content 









Figure 3.15. PHA production by B. subtilis wild type (wt), B. subtilis-vector and B. subtilis-
phaC1. (A) Dry cell weight (B) Total PHA content and (C) PHA yield in % dry cell weight.  
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3.2.4. Production of PHAs from the recombinant B. subtilis in fatty acids 
In order to test the capability of the recombinant B. subtilis-phaC1 to produce mcl-PHAs via 
the fatty acid degradation pathway, a range of carbon sources including oils (groundnut oil, 
corn oil and coconut oil) and a series of alkanoic acids (monomer length from five to twelve 
carbons) were used. Presence of PHAs was detected only when pentanoic, hexanoic and 
heptanoic acids were used. The produced polymers were characterized by GC-MS and results 
show the production of Poly(3-hydroxyvaleric acid), P(3HV), with small amounts of P(3HB) 
in all the three cases (Figure 3.16).  
Figure 3.16. GC-MS spectra of the extracted polymer produced from B. subtilis-phaC1 when 
heptanoic acid was used as a sole carbon source. Note the presence of a peak at RT: 5.68 and 
(3HB) 
(3HV) 
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6.31 and the corresponding mass spectra for (3HB) and (3HV), respectively (the peak 
obtained at RT: 7.15 correspond to methyl benzoate used as the internal control). 
 
3.2.5. Sequence analysis 
Results obtained in section 2.4 indicate that the phaC1 enzyme from P. mendocina has the 
capacity to catalyse the production of both scl-PHAs and mcl-PHAs. In order to understand 
the broad substrate specificity sequence comparison was carried out with phaC1 protein 
sequences from other Pseudomonas sp. including known mcl-PHA producers such as 
Pseudomonas aeruginosa, Pseudomonas putida and Pseudomonas oleovorans. From the 
multiple sequence alignment (Figure 8), the residues in the catalytic triad (Cys296, Asp451, 
His479) and residue Ser297, which plays an important role in the formation of an oxyanion 
hole during catalysis (indicated by a red asterisk, Wahab et al., 2006), were found to be 
conserved in phaC1P.mendocina and also in all other sequences, suggesting that they share a 
similar catalytic mechanism. Another conserved feature, the lipase-box like consensus motif 
(GACSG,) located at residues 294 – 298, was found in all the sequences used in this study 
(underlined in red, Figure 3.17).  
A closer look at the stretch of residues from position 267 to position 484 revealed some 
interesting differences in the protein sequence of phaC1P.mendocina which could potentially 
explain its broad substrate specificity. This region contained the conserved catalytic residues 
is referred to as the core region by Wahab et al., (2006) in their threaded 3D model of 
phaC1Pseudomonas sp. USM4-55..   
It is interesting to note that all phaC1 homologues used in this study have a conserved Ala-
Ala-Lys motif at positions 346-348 except in phaC1P.mendocina where it is substituted with Arg-
Gly-Gln. Similarly Gln314, a neutral amino acid residue, conserved in phaC1P.mendocina, 
phaC1Pseudomonas sp. USM4-55 and phaC1P.nitroreducens was substituted with a negatively charged 
Glu314 in all other sequences. Another charge alteration was observed at Gln417, a neutral 
amino acid residue, conserved in phaC1P.mendocina, phaC1Pseudomonas sp. USM4-55, 
phaC1P.nitroreducens, phaC1P.stutzeri and phaC1P.fulva were substituted with a positively charged 
Lys417 in all other sequences. The above mentioned substitutions are indicated by a blue star 
in Figure 3.17. 
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Figure 3.17. Multiple sequence alignment of phaC1 protein sequences from 10 different 
Pseudomonas sp. The catalytic triad and Ser297 are highlighted by a * and the lipase-box like 
consensus motif (GACSG) is underlined in red. Sequence variations between P. mendocina 
and the most common PHAs producers including P. oleovorans, P. aeruginosa and P. putida 
are indicated by a *. 
 
From the pairwise sequence alignment, the percentage identity between the phaC1P.mendocina   
protein sequence and phaC1 protein sequence from other Pseudomonas sp. was sequentially 
calculated (Table 3.1). Interestingly, phaC1P.mendocina shared a higher percentage identity to 
phaC1Pseudomonas sp. USM4-55 (98.39 %) and phaC1P.nitroreducens (97.85%) than the other known 
mcl-PHA producers such as phaC1P.aeruginosa (81.22%), phaC1P.putida (79.79 %) and 
phaC1P.oleovorans (80.68 %). Phylogenetic analysis further illustrates this divergence (Figure 
3.18).  
 












Species name Sequence identifier Pairwise percentage 
identity (%) 
P. mendocina AAM10544.1 100 
P. nitroreducens Q8RPZ6 97.85 
P. resinovorans AAD26365.2 84.26 
P. putida AAM63407.1 79.79 
P. stutzeri AAO59383.1 95.89 
P. mediterranea AAX92633.1 81.40 
P. sp_USM4-55 ABX64434.1 98.39 
P. fulva_12-X YP_004472487.1 83.01 
P. oleovorans AAA25932.1 80.68 
P. aeruginosa AFA46810.1 81.22 
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Figure 3.18. Phylogenetic relationship of the analysed Pseudomonas sp. based phaC1 protein 
sequence. The tree was constructed using the neighbour joining algorithm using the ClustalW 
Phylogeny from the ClustalW2 package at the EBI.  
A 3D model for phaC1P.mendocina was generated (Figure 3.19A) using the structure of the 
human gastric lipase (PDB code 1hlg) as template and PHYRE2, an automatic fold 
recognition server for structure prediction (Kelley and Sternberg 2009). The active site 
residues of the catalytic triad (Cys296, Asp451, and His479) are shown in Figure 3.19B. 
Also, the amino acid differences observed in phaC1P.mendocina, ArgGlyGln346-348, Gln315 
and Gln417, as compared to the most used Pseudomonas strains have been highlighted in the 
structure (Figure 3.19(C)). However in the absence of X-ray crystallographic data for type II 
PHA synthases, with and without the substrates, it would be difficult to evaluate the 
significance of the sequence divergence observed in phaC1P.mendocina with respect to the other 
known mcl-producing strains. 
3.19 (A) 
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Figure 3.19. (A) The predicted 3D model for phaC1P.mendocina generated using the structure of 
the human gastric lipase (PDB code 1hlg) as template on the PHYRE2 server (B) The active 
site residues of the catalytic triad (Cys296, Asp451, and His479) are highlighted (C) Amino 




acid differences identified in phaC1P.mendocina protein sequence as compared to the most used 




In this chapter, we investigated the phaC1 gene expression from P. mendocina in B. subtilis 
1604. The B. subtilis 1604-phaC1 recombinant strain was subjected to fermentation and 
showed PHA accumulation. The incorporation of the phaC1 gene in B. subtilis confirmed the 
potential of the host bacteria to produce significant levels of PHAs. In contrast to what was 
expected, GC-MS and NMR studies confirmed the presence of an scl-PHA homopolymer, 
P(3HB), when the B. subtilis 1604-phaC1 recombinant strain was grown in PHA production 
media with sucrose as the sole carbon source. This is a very unusual result and has not been 
reported before. P. mendocina phaC1 gene was expected to encode an enzyme that would 
polymerise mcl-PHA monomers units leading to the production of mcl-PHAs.   
Wang et al., (2006) have cloned and expressed the phaC1 gene from Pseudomonas 
aeruginosa in B. subtilis. The gas chromatography results showed that the expression of the 
phaC1 gene into B. subtilis DB104, in the presence of glucose as a carbon source, resulted in 
the production of Poly(3-hydroxydecanoate-co-3-hydroxydodecanoate), P(3HD-co-3HDD), a 
mcl-PHA copolymer. Furthermore, the inclusion of the phaA gene, encoding the  
β-ketothiolase and the phaB gene encoding the acetoacetyl-CoA-reductase from Ralstonia 
eutropha resulted in the production of a Poly(3-hydroxybutyrate-co-3-hydroxydecanoate-co-
3-hydroxydodecanoate P(3HB-co-3HD-co-3HDD), a scl-mcl copolymer. 
In contrast to Wang et al., (2006) our results showed that only the incorporation of the phaC1 
synthase gene from P. mendocina in B. subtilis 1604 resulted in the production of a scl-PHA, 
P(3HB), and no mcl-PHAs were observed. The fact that phaC1P.aeruginosa and phaC1P.mendocina 
showed only 81.22% of identity (table 3.1) can explain differences in PhaC1 substrate 
specificity. However, further experiments should be carried out by Wang et al. to confirm the 
nature of the produced PHAs. 
B. subtilis containing the phaC1 gene showed a higher amount of dry cells weight and a 
significant PHA production compared to B. subtilis containing the vector without the insert 




and the wild type. The amount of PHA produced, normalized per gram of cells (g of PHA/g 
dry cell weight) was 1.7%±0.43, 2.7%±0.45 and 32.3%±9.6 for B. subtilis wild type,            
B. subtilis-vector and B. subtilis-phaC1 gene, respectively. These results confirmed the role 
of the PhaC1 synthase in PHA accumulation in the recombinant B. subtilis. 
P. mendocina wild type produces a copolymer composed of short chain length and medium 
chain length PHAs when sucrose is used as the carbon source. In contrast to our results, 
previous reports showed production of only mcl-PHAs by P. putida, P. aeruginosa, 
P. resinovorans and P. mediterranea in the presence of carbohydrates confirming the 
different substrate specificity of P. mendocina PhaC1 enzyme (Ashby et al., 2001, Huijberts 
et al., 1992, Palmeri et al., 2012, Rosas et al., 2007).  
As described previously, mcl-PHAs can be produced via the fatty acid de novo biosynthesis 
pathway and the fatty acid β-oxidation pathway. When sucrose was used as a carbon source 
the mcl-PHA polymer production was expected to occur via the fatty acid de novo 
biosynthetic metabolic pathway. However, contrary to our expectations, a scl-homopolymer 
was obtained. In order to test the capability of the recombinant B. subtilis to produce mcl-
PHAs via the fatty acids degradation pathway, a range of fatty acids were screened. Only 
when pentanoic, hexanoic and heptanoic acids were used as carbon sources, PHAs were 
obtained. The resulting polymer was a scl-copolymer composed of Poly-(3-
hydroxybutanoate) and Poly-(3-hydroxypentanoate), (P3HB-co-HV). As previously reported 
by Valappil et al., (2007) within the Gram-positive genera, only Corynebacterium, Nocardia 
and Rhodococcus can naturally synthesize the commercially important co-polymer P(3HB-
co-3HV) from simple carbon sources such as glucose (Alvarez et al., 2000, Haywood et al., 
1991). In this case, the addition of the phaC1 gene from P. mendocina to B. subtilis allowed 
the strain to synthesize LPS-free P(3HB-co-3HV) copolymer. However, no mcl-PHAs 
production was observed. One of the main enzymes that play a pivotal role in the mcl-PHAs 
synthesis is the (R)-3-hydroxyacyl-ACP-CoA transacylase, which converts the (R)-3-
Hydroxyacyl-ACP precursor from the fatty acid de novo biosynthetic pathway to (R)-3-
hydroxyacyl-CoA, the substrate required by the PHA synthase for mcl-PHA production. As 
BLAST results revealed the presence of a hypothetical protein predicted to be a 
hydrolase/acyltransferase in B. subtilis 1604, it is not possible to attribute the incapability of 
the phaC1 synthase from P. mendocina to support mcl-PHA production in B. subtilis to the 
absence of (R)-3-hydroxyacyl-ACP-CoA transacylase. However, as this protein was not 
studied previously, further studies should be carried out to confirm the nature of the protein. 




No structural information for the class II PHA synthases is available. Threading models 
generated for phaC1 from Pseudomonas aeruginosa (Amara and Rehm, 2003) and 
Pseudomonas sp. USM 4–55 (Wahab et al., 2006) have provided insights into the residues 
critical for catalysis in these enzymes. Therefore, in order to understand the exceptionally 
broad substrate specificity of the phaC1 enzyme in P. mendocina, sequence analysis and 3D 
structure prediction was undertaken. Multiple sequence analysis and phylogenetic analysis 
was carried out with phaC1 protein sequences from other Pseudomonas sp. containing class 
II PHA synthases. Of the 9 sequences compared, phaC1P.mendocina shared the lowest sequence 
identity with other well established mcl-PHA producers such as the P. aeruginosa, P. putida 
and P. oleovorans. The phylogenetic analysis further emphasised this sequence divergence, 
as phaC1P.mendocina was placed in a distinctly different cluster along with phaC1 Pseudomonas sp. 
USM4-55 and phaC1P.nitroreducens. Previous reports has shown that surprisingly, Pseudomonas 
nitroreducens, that shares 97.85% of identity with P. mendocina in the phaC1 sequence 
(Table 3.1), produced P(3HB) homopolymer when hexanoate was used as a sole carbon 
source and Poly(3-hydroxyoctanoate-co-hydroxydecanoate) copolymer in the presence of 
butyrate, decanoate, lauric acid and tetradecanoic acid (Yao et al., 1999). These results 
confirm the broad substrate specificity of the PHA synthase in P. nitroreducens, very similar 
to that found in P. mendocina. 
Although the important residues such as the catalytic triad (Cys296, Asp451, His479), Ser297 
and the lipase-box like consensus motif are conserved in all the sequences used in this study, 
certain amino acid substitutions were observed in the core region (residue 267- 484) of the 
phaC1protein sequence from P. mendocina, which were otherwise conserved in other mcl-
PHA producers such as the P. aeruginosa, P. putida and P.  oleovorans. As described 
previously, some of these amino acid changes result in charge alterations, for example the 
change from neutral amino acid Gln314 in phaC1P.mendocina, phaC1Pseudomonas sp. USM4-55 and 
phaC1P.nitroreducens  to a negatively charged Glu at the same position in all other Pseudomonas 
species. There is no information on the functional significance of these amino acid 
differences. A 3D model was generated for phaC1P.mendocina using human gastric lipase as the 
template. From the predicted model, the catalytic residues and structural position of the 
observed amino acid differences in phaC1P.mendocina could be mapped. However without a 
crystal structure it is difficult to exactly predict the structural effect of these amino acid 
changes on the active site of the enzyme and their role in the catalytic mechanism of the 
phaC1. It is possible that the catalytic core of phaC1P.mendocina is different from the other mcl-




PHA producers in its charge distribution and side chain composition and therefore exhibits 
broader substrate specificity. 
Hence, in conclusion, this work confirms the capability of a Gram-positive GRAS organism 
to express a Gram-negative gene from P. mendocina. Additionally, our results demonstrate 
the unusually broad substrate specificity of the PHA synthase from P. mendocina, which was 
found to be able to catalyse production of both mcl-PHA and scl-PHA production depending 
on the metabolic pool available in the host organism. Such a PHA synthase can therefore be 
used for the production of the entire range of PHAs (both scl and mcl-PHAs) by simply 
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4.1. INTRODUCTION 
Medium chain length PHAs are gaining importance due to their adjustable flexible material 
properties that are suitable for a range of biomedical applications. The type of mcl-PHA 
produced and hence their properties can be varied with the type and relative quantity of 
carbon sources supplied to the growth media, the organism used and the culture conditions 
provided (Ojumu et al., 2004). In addition to the different properties obtained with different 
mcl-PHAs, the production of co-polymers, blends and composites further increase the range 
of applications allowing the fabrication of tailor made materials. However, despite the varied 
applicability of these polymers, widespread use of the mcl-PHAs remain limited, mainly 
because of the lack of availability of these materials in large quantities (Rai et al., 2011b). 
Awareness of the need of industrialization of these polymers has reinforced the interest in 
scientists to develop different strategies for their production in large scale.  
Although there are many microorganisms that are able to produce PHAs, mcl-PHA 
production has been restricted to different strains of Pseudomonas (Prieto et al., 2007). In 
order to achieve a high productivity and high yield of mcl-PHAs, fermentation processes 
using these strains need to be optimized. To this end, in the first part of this chapter, P(3HO) 
polymer production in P. mendocina was optimized in 2 L bioreactors and the effect of 
different parameters such as pH, and carbon/nitrogen ratio was analyzed.  
As no work has been carried out in the scaling-up of P(3HO) production using P. mendocina, 
in the second part of the chapter we have studied the capacity to scale-up the polymer 
production from 2 L to 20 L and 72 L bioreactors using the constant oxygen transfer 
coefficient technique. In aerobic bioprocesses, the oxygen transfer rate (OTR) in the media is 
a key factor that will influence a culture performance. Therefore, it is important to ensure an 
adequate delivery of oxygen to the media. In a stirred tank bioreactor, the OTR is mainly 
affected by the stirrer speed, the type and number of stirrers and the gas flow rate used. 
Accurate estimation of the OTR in bioreactors is essential in order to establish aeration 
efficiency at different scales under different stirrer speeds and airflow rates. In stirred tank 
bioreactors, the stirrer is the main gas dispersing tool and stirrer speed and airflow rate are the 
main factor that will determine the kLa values. In this project, the P(3HO) polymer 
production was scaled up from the 2 L to the 20 L and 72 L bioreactors based on the constant 
oxygen transfer coefficient, kLa. The oxygen transfer from air to liquid phase is controlled by 
the liquid phase mass transfer resistance, described by the following equation: 
 [dCL/dt] = kLa x (C*-CL)                                                   (4. 1) 




where C* is the saturation concentration of oxygen in liquid, CL is the dissolved oxygen 
concentration in liquid, t is time and dCL/dt is the volumetric rate of mass transfer. The -kLa 
value can be obtained from the slope of ln(C*-CL) against time.                  
In this project, kLa values were determined by the dynamic method. The dynamic method 
involves the elimination of oxygen in the liquid, followed by the supply of air. The variation 
in oxygen concentration in the water is measured through time. Firstly, the kLa value of the   
2 L bioreactor was determined under the condition that produced maximum polymer in the 
optimization work. Then, in order to keep the same oxygen transference in the 20 L and 72 L 
bioreactors, the kLa values of both bioreactors were calculated at different sets of impeller 
speeds and airflow rates. P. mendocina was grown under the obtained condition for a 
constant kLa in the 20 L and 72 L bioreactors and P(3HO) was extracted at different scales. 
The evaluation of the scaling-up process was carried out by the comparison of the amounts of 











4. 2. RESULTS 
4. 2. 1. Production of P(3HO) in P. mendocina 
The P(3HO) production from P. mendocina with sodium octanoate as a sole carbon source 
was optimized in 2 L bioreactors as described in section 2. 2.7.1 Four conditions were tested 
where the pH and carbon/nitrogen ratio were varied (Table 2.5). To enhance P(3HO) 
production, the C/N ratios of 20:1, 15:1 and 10:1 and pH of 6.8, 7.15 and 7.5 in mineral salt 
medium production media were compared in order to determine the optimal conditions.  
Figure 4. 1 shows the fermentation profile obtained for condition 1 (pH 7.15, carbon/nitrogen 
20:1 and stirrer speed 200 rpm). Under this condition the organism reaches exponential phase 
after 3 hours of growth. At this point, the DOT reaches zero, as a consequence of the oxygen 
consumption of the growing bacteria in the media. At 29 hours, stationary phase is achieved 
and as a result of the cell death, the DOT starts to increase. The maximum OD450nm achieved 
during the fermentation was 4.7. PHAs were extracted at 24 hr, 36 hr and 48 hr and these 
time points were at the exponential phase, stationary phase and death phase, respectively. The 
maximum PHA yield of 20.6 % DCW was obtained during the stationary phase, at 36 hr.  
 
 
Figure 4. 1. Fermentation profile of P. mendocina and P(3HO) accumulation obtained under 
condition 1 (pH 7. 15, carbon/nitrogen 20:1 and stirrer speed 200 rpm). OD450nm (—) , DOT 
(—) and PHA yield (grey bars). 




Figure 4.2 shows the fermentation profile obtained under condition 2 (pH 7. 5, 
carbon/nitrogen 15:1 and stirrer speed 200 rpm). In this condition the organism reached 
exponential phase before 3 hours of growth. As a consequence, the oxygen consumption by 
the organism decreased to zero in 1.2 hr. The stationary phase was achieved at 23 hr, when 
the DOT increased drastically. The maximum OD450nm achieved during the fermentation was 
4.5. PHAs were extracted at 24 hr, 36 hr and 48 hr with the first two values at the stationary 
phase and the last one at the death phase. The maximum PHA yield of 12.3 % DCW was 
obtained during early stationary phase, at 24 hr.  
 
 
Figure 4. 2. Fermentation profile of P. mendocina and P(3HO) accumulation obtained under 
condition 2 (pH 7.5, carbon/nitrogen 15:1 and stirrer speed 200 rpm). OD450nm (—) ,  DOT  
(—) and PHA yield (grey bars).  
Figure 4. 3 shows the fermentation profile obtained for condition 3 (pH 6. 8, carbon/nitrogen 
15:1 and stirrer speed 200 rpm). Under this condition the organism achieved exponential 
phase after 3 hours of growth with a slower growth than condition 1, represented by the 
smaller slope of the OD450nm and DOT graph. At 23 hr, the stationary phase was achieved and 
as a result of the cell death, the DOT started to increase. The maximum OD450nm achieved 
during the fermentation was 4.2. PHAs were extracted at 24 hr, 36 hr and 48 hr at the 
stationary phase. The maximum PHA yield of 10.5 % DCW was obtained during early 
stationary phase, at 24 hr.  





Figure 4. 3. Fermentation profile of P. mendocina and P(3HO) accumulation obtained under 
condition 3 (pH 6. 8, carbon/nitrogen 15:1 and stirrer speed 200 rpm). OD450nm(—) , DOT  
(—) and PHA yield (grey bars)  
 
Figure 4.4 shows the fermentation profile obtained under condition 4 (pH 7.15, 
carbon/nitrogen 10:1 and stirrer speed 200 rpm). In this condition the exponential phase is 
achieved before conditions 1, 2 and 3. As a consequence, the organism’s oxygen 
consumption in the media decreased to zero within 1 hr. The stationary phase was achieved 
between 9 hr and 23 hr and as a result, the DOT increased drastically at 15 hr. The maximum 
OD450nm achieved during the fermentation was 3.3. PHAs were extracted at 24 hr, 36 hr and 
48 hr, at the stationary phase. The maximum PHA yield of 2.3 % DCW was obtained at 24 
hrs.  
 





Figure 4. 4. Fermentation profile of P. mendocina and P(3HO) accumulation obtained under 
condition 4 (pH 7. 15, carbon/nitrogen 10:1 and stirrer speed 200 rpm). OD450nm(—) ,      
DOT (—) and PHA yield (grey bars) 
 
4. 2. 2. Scaling-up production of P(3HO) from Pseudomonas mendocina 
4. 2. 2. 1. Determination of kLa and scaling-up conditions 
The condition in which the highest PHA yield was obtained was scaled-up to 20 L and 72 L 
bioreactors as described in section 2.2.7.2. For this, condition 1, when pH is 7.15, 
carbon/nitrogen 20:1 and stirrer speed 200 rpm was used. In a first step, the kLa of the 2 L 
bioreactor, at an airflow rate of 1 vvm and stirrer speed 200 rpm was determined by the 
gassing out method. For this, the bioreactor was filled with 1.4 L of distilled water and the 
oxygen of the liquid was removed with nitrogen. Then, air was supplied to the bioreactor and 
the increment in DOT with time was measured. Equation 4.1 shows that kLa can be obtained 
from the inverse of the slope of ln(C*-C) vs. time and the obtained value was 0.256 (Figure 
4.12).   
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CHAPTER	  4	  
98	  
Figure 4. 5. Ln (C*-C) vs. time for the 2 L bioreactor at 1vvm and 200 rpm. Note that the 
inverse of the slope is the kLa.  
In the second part, in order to determine the condition to be used in the 20 L bioreactor for 
constant oxygen transfer, the kLa values were determined at a range of air flow rates (from 
0.5 vvm to 1. 25 vvm) and stirrer speed (from 100 rpm to 250 rpm), in the 20 L bioreactor. 
Figure 4. 6 shows the plot of the ln(C*-C) vs. time at different stirrer speeds of 100, 150, 200 
and 250 rpm and A) 0.5 vvm B) 0.75 vvm C) 1 vvm D) 1.25 vvm constant air flow rates.  
A) 
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D) 
Figure 4. 6. Ln (C*-C) vs. time for the 20 L bioreactor at 100, 150, 200 and 250 rpm at A) 
0.5 vvm B) 0.75 vvm C) 1 vvm and D) 1. 25 vvm. Note that the inverse of the slope for each 
condition is the kLa.  
The kLa obtained at 200 rpm and 1 vvm in the 2 L bioreactor was 0.256. Table 4.1 
summarizes the kLa values obtained at the different air flow rates and stirrer speeds in the 
20 L bioreactor. The results obtained show that the kLa value obtained with the 2 L bioreactor 
is within the range of the kLa values obtained at 0.5 vvm in the 20 L bioreactor (Table 4.1). 
Hence, in order to determine the stirrer speed to be used in the 20 L bioreactor for a kLa of 
0.256, a plot of the kLa vs. stirrer speed at 0.5 vvm was carried out and the stirrer speed was 
calculated from the obtained linear regression (Figure 4.7). The obtained stirrer speed was 
186 rpm.  




Table 4. 1. kLa values obtained in the 20 L bioreactor at different air flow rates and stirrer 
speeds 
 0.5 vvm 0.75 vvm 1 vvm 1. 25 vvm 
100 rpm 0.193 0.259 0.307 0.360 
150 rpm 0.219 0.287 0.340 0.405 
200 rpm 0.254 0.330 0.379 0.461 




Figure 4.7. kLa vs. stirrer speed at 0.5 vvm and linear regression for the 20 L bioreactor.  
The same procedure was repeated to determine the condition to be used in the 72 L bioreactor 
in order to maintain constant the oxygen transference. Figure 4.8 shows the plot of the    
ln(C*-C) vs. time at different stirrer speeds of 100, 150, 200 and 250 rpm and A) 0.5 vvm B) 





y	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  0.0008	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Figure 4. 8. ln (C*-C) vs. time for the 72 L bioreactor at 100, 150, 200 and 250 rpm at A) 0.5 
vvm B) 0.75 vvm C) 1 vvm and D) 1. 25 vvm. Note that the inverse of the slope for each 
condition is the kLa.  
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Table 4. 2 summarizes the kLa values obtained at the different air flow rates and stirrer speeds 
in the 72 L bioreactor. Results showed that the kLa value obtained with the 2 L bioreactor is 
closer to the kLa values obtained at 0.5 vvm in the 72 L bioreactor. Hence, in order to 
determine the stirrer speed to be used in the 72 L bioreactor for a kLa of 0.256, a plot of the 
kLa vs. stirrer speed at 0.5 vvm was carried out and the stirrer speed was calculated from the 
obtained linear regression by interpolation (Figure 4.9). The obtained stirrer speed was 143 
rpm.  
Table 4. 2. kLa values obtained in the 72 L bioreactor at different air flow rates and stirrer 
speeds  
0.5 vvm 0.75 vvm 1 vvm 1. 25 vvm
150 rpm 0.261 0.313 0.340 _ 
200 rpm 0.336 0.318 0.417 0.409 
250 rpm 0.416 0.480 0.476 0.502 
Stirrer speed (rpm)














Figure 4. 9. kLa vs. stirrer speed at 0.5 vvm and linear regression for the 72 L bioreactor. 
y	  =	  0.0016	  x	  –	  0.0277	  




4. 2. 2. 2 Scaling-up 
The scale-up studies based on a constant oxygen transfer coefficient, kLa from 2 L to 20 L 
and 72 L of aerated and agitated bioreactors were performed. Table 4.3 summarizes the 
conditions obtained for a constant kLa of 0.256. All the fermentations were carried out with 
an initial carbon/nitrogen ratio 20:1 and pH 7. 15.  
Table 4. 3. Scaling-up conditions for the 2 L, 20 L and 72 L bioreactor for a constant kLa of 
0.256  
Bioreactor scale Stirrer speed (rpm) Air flow rate (vvm) 
2 L 200 1 
20 L 186 0.5 
72 L 143 0.5 
 
P. mendocina was grown in the 2 L bioreactor at 200 rpm and 1 vvm. Figure 4.10 shows the 
fermentation profile obtained. Under this condition, within 7 hr of fermentation, a decrease in 
the dissolved oxygen tension, from 100% to zero was observed. After 27 hr the oxygen 
concentration in the media started to increase. The maximum OD450nm achieved during the 
fermentation was 5. 9. PHAs were extracted at 36 hr and 48 hr, during the stationary phase. 
The maximum PHA yield was 26.84±0.35 %DCW, obtained during early stationary phase, at 
36 hrs.  
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Figure 4. 10. Fermentation profile of P. mendocina and P(3HO) accumulation obtained in the 
2 L bioreactor with an initial carbon/nitrogen ratio of 20:1 and pH of 7.15, stirrer speed 200 
rpm and air flow rate 1 vvm. OD450nm(—) , pH (—), DOT (—) and PHA yield (grey bars). 
P. mendocina was grown in the 20 L bioreactor at 187 rpm and 0.5 vvm. Figure 4.11 shows 
the fermentation profile obtained. Under this condition the amount of oxygen in the media 
were zero between 4 hrs and 64 hrs of fermentation. The maximum OD450nm achieved during 
the fermentation was 6. PHAs were extracted at 66 hr and 78 hr during the stationary phase. 
The maximum PHAs yield was 23.17±1.47 %DCW, obtained during the late stationary phase 
at 36 hr.  





Figure 4. 11. Fermentation profile of P. mendocina and P(3HO) accumulation obtained in the 
20 L bioreactor with an initial carbon/nitrogen ratio of 20:1 and pH of 7. 15, stirrer speed 186 
rpm and air flow rate 0.5 vvm. OD450nm (—) , pH (—), DOT (—) and PHA yield (grey bars).  
 
P. mendocina was grown in the 72 L at 143 rpm and 0.5 vvm. Figure 4.12 shows the 
fermentation profile obtained. In this condition, within 8 hr of fermentation, a decrease in the 
amounts of oxygen from 100% to zero was observed. After 46 hr, the oxygen concentration 
in the media started to increase. The maximum OD450nm achieved during the fermentation 
was 5.6. PHAs were extracted at 48 hr and 65 hr during the stationary phase. The maximum 
PHA yield of 13.80 ± 2.82 %DCW was obtained during the early stationary phase at 48 hr.  





Figure 4. 12. Fermentation profile of P. mendocina and P(3HO) accumulation obtained in the 
72 L bioreactor with an initial carbon/nitrogen ratio of 20:1 and pH of 7. 15, stirrer speed 143 
rpm and air flow rate 0.5 vvm. OD450nm(—) , pH (—), DOT (—) and PHA yield (grey bars). 
 




4. 3. DISCUSSION 
4. 3. 1. Optimization of P(3HO) production in P. mendocina 
Studies were carried out to assess the effect of pH and carbon:nitrogen (C:N) ratio on the 
P(3HO) yield. Four conditions were studied (Table 2. 5): pH 7.15 and C:N 20:1 (condition 1), 
pH 7.5 and C:N 15:1 (condition 2), pH 6.8 and C:N 15:1 (condition 3) and pH 7.15 and C:N 
10:1 (condition 4). From the comparison of the four conditions it was observed that the 
smallest lag phase and consequently a faster achievement of exponential phase occurred 
under condition 4, at pH 7.15 and C:N 10:1. It has been assumed that lag phase allows the 
adaptation required for bacterial cells to begin to grow under new environmental conditions 
(Madigan et al., 2000). The main reason for this observation might be that long chain fatty 
acids have been proven to have a toxic effect on bacterial growth and condition 4 represents 
the lowest amount of sodium octanoate (10mM), used as a carbon source (Dubos 1946). 
Additionally, we have observed that lower concentrations of sodium octanoate results in 
shorter exponential phases. For example, condition 4, containing the lowest amounts of 
sodium octanoate has the shortest exponential growth phase and condition 1, containing the 
highest amounts of sodium octanoate, the longest one. It is expected that the lower 
concentration of carbon source leads to shorter times of bacterial growth. By comparing 
conditions 2 and 3, we observed that pH values of 7.5 resulted in a smaller lag phase and 
consequently a quicker adaptation of the bacteria to the media than pH values of 6.8. 
However, similar durations of the exponential phase were obtained in both cases. Upon 
nutrient starvation or entry into the stationary phase, some bacteria develop different 
mechanisms that allow stress tolerance and starvation survival, including PHAs production 
(Ruiz et al., 2001). PHAs were extracted in the four conditions at 24, 36 and 48 hr. As 
expected, our results show that the highest PHA accumulation occurred during the early 
stationary phase. By comparing condition 1 and 4, where only the C:N ratio differed, we 
observed that when the ratio C:N is increased from 10:1 to 20:1 the PHA yield (%DCW) 
increased from 2.3 to 20.6 %DCW. Also, by comparing condition 2 and 3, where only the pH 
differs, we can conclude that no significant differences in terms of PHA accumulation 
occurred when the pH varied from 6. 8 to 7. 5, suggesting that within this pH range there is 
no significant effect of pH on PHA production. The highest PHA accumulation of 20.6% 
DCW was observed under condition 1 at 36 hr, during the early stationary phase.   
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4. 3. 2. Scaling-up production of P(3HO) from Pseudomonas mendocina 
With a product development there is a need to achieve successful scale-up strategies in order 
to convert laboratory results to industrial scale. Despite much research that has been carried 
out for the development of strategies to allow an efficient scale-up, no common strategies 
were described and hence, for each individual product, process and facility a suitable scale-up 
strategy has to be elaborated (Schmidt et al., 2005). It is not possible to maintain all the 
parameters constant between scales and hence, different characteristics are suggested to be 
maintained constant during scale-up processes (Ju and Chase 1992). As oxygen transfer is 
often a limiting factor in aerobic bioprocesses due to the low solubility of this gas in the 
medium, the oxygen supply in bioreactors is a decisive factor in microorganism growth and 
plays a pivotal role in the scale-up of aerobic biosynthesis systems (Amaral et al. , 2008, 
Galaction et al. , 2004). As a result, one of the most common strategies used for scaling-up 
aerobic systems is based on maintaining the volumetric oxygen transfer, kLa, constant 
through the different scales (Puthli et al., 2005). The determination of kLa in bioreactors is 
essential in order to establish the aeration efficiency and to quantify the effects of the 
operating variables on the oxygen provision. In this project, the production of PHAs from 
P. mendicina was scaled-up from 2 L to 20 L and 72 L bioreactors based on a constant kLa. 
The kLa value was determined by employing the gassing out technique and the obtained value 
was kept constant upon scale-up to maintain similar mass-transfer of oxygen at the larger 
production scale. The chosen volumetric oxygen transfer coefficient was the one obtained 
with the 2 L bioreactor at 200 rpm stirrer speed and 1 vvm air flow rate. For this, as a first 
step, the kLa of the 2 L bioreactor, at 200 rpm and 1 vvm of air flow rate was determined 
from the slope of the ln(C*-C) vs. time. The kLa value obtained under this condition was 
0.256. In order to find the condition in the 20 L and 72 L bioreactors that gave the same kLa, 
the kLa values for the 20 L and 72 L bioreactors were calculated at different set of impeller 
speeds and air flow rates. Due to the fact that the stirrer speed can be regulated with more 
precision, the aeration rate was kept constant and the estimation of the stirrer speed for a 
constant oxygen transfer in the 20 L and 72 L bioreactors was carried out from the 
extrapolation of the kLa vs. stirrer speed plot. As expected, an increment in the kLa values 
was observed with an increment in the stirrer speed or air flow supply for both 20 L and 72 L 
bioreactors. For the 20 L bioreactor, a kLa of 0.256 was among the values obtained at 0.5 vvm 
air flow rate. The stirrer speed was obtained from the linear regression of kLa vs. stirrer speed 
at 0.5 vvm. The obtained stirrer speed was 186 rpm. Note that although a kLa of 0.254 was 




obtained at 200 rpm (Figure 4.7), a lower stirrer speed of 186 rpm was obtained for a kLa of 
0.256 from the linear regression and this is due to the fact that the values did not follow a 
perfect linear trend. For the 72 L bioreactor, a kLa of 0.256 was close to the values obtained at 
0.5 vvm air flow rate. The stirrer speed was obtained from the interpolation of kLa vs. stirrer 
speed at 0.5 vvm. The obtained stirrer speed was 143 rpm. The conditions obtained for a 
constant kLa in the 2 L, 20 L and 72 L bioreactors showed that bigger bioreactors supply 
more oxygen at the same stirrer speeds and air flow rates. The main reason of this 
observation is that bigger bioreactors require more power input to achieve the same air flow 
rate and, hence, more oxygen is supplied at a certain air flow rate. In this work, the kLa at 
different scales was determined experimentally and, hence, differences in the dimensions of 
the bioreactors, the aspect ratio, the ratio diameter bioreactor and the number of impellers and 
buffers are contemplated in the final kLa obtained for each bioreactor.  
The conditions obtained for the scale-up work in the 2 L, 20 L and 72 L bioreactors were 
evaluated by the PHA yield obtained at different scales. From the profiles obtained we 
observed that the stationary phase, in which we expected the highest PHA production, was 
achieved at different times for the different bioreactors. Surprisingly, the stationary phase was 
achieved after around 27 hr of fermentation for the 2 L bioreactor, after 64 hr of fermentation 
for the 20 L bioreactor and after 46 hr of fermentation for the 72 L bioreactor. PHAs were 
extracted during the stationary phase for each of the different scales; hence, the extraction 
times were modified accordingly. The highest PHA yield was 26.84±0.35 % DCW for the     
2 L bioreactor, 23.17±1.47 % DCW for the 20 L bioreactor and 13.80±2.82 % DCW for the 
72 L bioreactor. Our results showed that similar values were obtained in terms of PHA yield 
with the 2 L and 20 L bioreactors, and hence we can conclude that based on a constant kLa it 
was possible to scale-up the PHA production from the 2 L to the 20 L bioreactor. However, 
the PHAs amount obtained for the 72 L bioreactor were considerably lower than the amount 
obtained with the 2 L and 20 L bioreactors. Our results showed that based on a constant kLa it 
was not possible to scale-up the PHA production to 72 L bioreactor. The reason of this 
observation is that by maintaining the kLa constant, other parameters such as the specific 
power input and the superficial air velocity will change and can thus produce undesired 
effects on the polymer yield (Ju and Chase 1992). The manipulation of specific power input 





Characterization of P(3HO) 
for cardiac tissue 
engineering applications 





There is an increasing interest in the development of biomaterials for regenerative medicine 
and tissue engineering. Certain requisites are crucial for a successful material in cardiac tissue 
engineering applications. The material’s physical and mechanical characteristics should be 
similar enough to those of the natural tissue in order to support the organ during the 
regeneration process, and its composition should allow it to degrade as the new tissue takes 
over its function (Neal et al., 2012). Biodegradable materials have attracted significant 
interest since further surgery is not required to remove the implanted material. Although most 
of the currently investigated materials are biodegradable, many of these have toxic             
by-products and poor mechanical properties that are not compatible with the injured tissue. 
As a result of the enormous clinical need, myocardial tissue engineering has become a special 
area of focused research within the field of tissue engineering. In this project, medium chain 
length polyhydroxyalkanoates, mcl-PHAs, were studied as potential materials for cardiac 
tissue engineering. These biopolymers are promising materials for various applications due to 
their mechanical properties, biodegradability and biocompatibility.  
In this chapter, P(3HO), a mcl-PHA, produced by Pseudomonas mendocina, was fully 
characterized and assessed for cardiac tissue engineering applications. As discussed 
previously, the material’s mechanical properties are crucial for supporting the organ during 
the new tissue regeneration. In the first part of this chapter, the mechanical properties of 
P(3HO) were determined using dynamic mechanical analysis and the values obtained were 
compared with the values required by the native cardiac structures. The mechanical 
properties of the myocardium are as follows: Young’s modulus 0.02-0.5 MPa, tensile 
strength 3-15KPa, and elongation at break between 100-300% (Nagueh et al., 2004, 
Watanabe et al., 2006).  In order to define the processability of the material, the thermal 
properties of the material were determined by differential scanning calorimetric analysis. 
Surface roughness and wettability have been known to play a crucial role in cell adhesion and 
proliferation, hence, P(3HO) films were formed by the solvent casting method and the 
surface topography, roughness and water contact angle were determined using Scanning 
Electron Microscopy (SEM), white light interferometry and contact angle analysis, 
respectively. 
An appropriate level of cardiomyocyte contraction is a crucial factor for a highly regulated 
mechanical system such as the heart, in order to maintain its accurate pumping function.       




In vivo, cardiomyocytes’ interaction with the extracellular matrix during contraction is the 
main factor in determining the heart’s performance (Tracqui et al., 2008). In a preliminary 
study, the effect of the P(3HO) polymer on contracting cardiomyocytes was studied by 
seeding freshly isolated cardiomyocytes from rat on P(3HO) films and the viability of the 
cardiomyocytes was studied over time. 
The change in cardiomyocyte contraction in response to a change in electrical stimulation is a 
general property of the cardiac muscle and in most species the contraction increases with the 
frequency of the electrical stimulation (Antoos et al., 2002). Intracellular Ca2+ is the central 
trigger factor for cardiomyocyte contraction and in most species, larger intracellular 
Ca2+concentrations result in higher cardiomyocyte contraction (Knollmann et al., 2008). In 
this project, the contraction of individual fresh adult rat cardiomyocytes on the P(3HO) 
polymer was studied at different frequencies of electrical pulses and calcium concentrations. 
For this, cardiomyocytes were seeded on glass cover slips coated with P(3HO) and glass 
cover slips without coating were used as positive controls. 
Finally, in order to understand and compare the properties of P(3HO) with materials available 
in the market being used as basic cardiac patches, in the last part of the chapter we have 
characterized two types of biological membranes currently used as patches by surgeons, i.e. 












5.2.1. Characterization of P(3HO) from Pseudomonas mendocina 
5.2.1.1. P(3HO) chemical characterization 
P. mendocina was grown in shaken flask under nitrogen limiting conditions in MSM growth 
media. As a carbon source, sodium octanoate was used. The obtained polymer was extracted 
and the nature of the polymer was determined by FTIR, GC-MS and NMR. Figure 5.1 shows 







Figure 5.1. Polymer produced by P. mendocina with sodium octanoate as a sole carbon 
source.  
 
FTIR analysis was carried out in order to determine the functional groups present in the 
obtained polymer, as described in section 2.2.8.1. Figure 5.2 represents the FTIR absorbance 
spectrum, which shows the presence of the characteristic ester band at 1728 cm-1. The bands 
corresponding to O-H stretching groups from carboxylic acids and C-H stretching groups 
from alkyl side chains were observed at 2955 cm-1 and 2928 cm-1, respectively. The bands at 
1466 cm-1 and 1379 cm-1 occurred due to CH3 stretching and the band at 1095 cm-1 describes 
the methylene C-H vibration. According to Ramalingan et al., 2011, four bands are 
characteristic of mcl-PHAs: 1740, 2859, 2924 and 1069 cm-1. The polymer FTIR spectrum 
showed the presence of bands in the range of these characteristic bands, suggesting that the 
PHA produced was indeed a mcl-PHA. 
 





Figure 5.2. FTIR spectra of the polymer produced by P. mendocina. Note the four 
characteristic bands of mcl-PHAs highlighted in red. 
 
In order to confirm the exact chemical nature of the sample, GC-MS and NMR were carried 
out as described in section 2.2.8.2 and 2.2.8.3, respectively. The GC-MS spectrum of the 
methanolysed polymer shows the presence of a main band with a retention time of 10.49-
10.51 (Figure 5.3). The mass spectrum of the compound obtained at this retention time 
corresponded to the octanoic acid 3-hydroxy-methyl ester, confirming the presence of poly-
(3-hydroxyoctanoate) homopolymer, P(3HO). The band obtained at a retention time of 9-9.8 
belonged to the methyl ester of benzoic acid, used as a positive control. Peaks obtained at 
9.83 and 15.13 corresponded to other ester forms of the P(3HO) and benzoic acid. Finally, 
other peaks at retention time 11.87 and 12.11 corresponded to impurities that had co-purified 
with the polymer.  





Figure 5.3. GC-MS spectra of the polymer produced from P. mendocina. Note the presence 
of a peak at RT: 10.49-10.51 and the corresponding mass spectra for P(3HO)  (the peak 
obtained at RT: 9-9.8 correspond to methylbenzoate used as the internal control). 
 
Figure 5.4 shows the (A) 13C and (B) 1H NMR spectra. The 13C spectra showed the presence 
of nine main peaks corresponding to the eight different carbon environments of P(3HO) plus 
one at 77.15 ppm corresponding to the carbon present in CDCl3 used as solvent. The eight 
peaks that belong to the P(3HO) molecule are: 169.56, 70.94, 39.17, 33.84, 31.61, 25.17, 
22.60 and 13.91. These peaks correspond to the different carbon atoms present from the 
carboxylic group of the P(3HO) molecule to the last carbon present in the alkyl group of the 
side chain. The proton spectra showed the presence of five main peaks that correspond to the 
five different types of protons in the P(3HO) molecule. The five peaks obtained were: 5.17, 
2.50, 1.56, 1.27 and 0.82 ppm. The first two peaks correspond to the protons present in the     
-CH groups and -CH2 groups of the main carbon chain. The last three peaks are from the 
different types of protons of the alkyl group in the side chain, starting from the first -CH2  
group bonded to main carbon chain and following to the -CH2 and -CH3 groups present in the 
side chain. 
(3HO)	  
























                                                                                                                                                                                                              
Figure 5.4. (A) 13C and (B) 1H NMR spectra for the polymer produced by P. mendocina. The 
chemical structure of the P(3HO) molecule indicating the position of the different 
environments for Carbon or Proton atoms in the molecule is shown in the figures.   




5.2.1.2. P(3HO) mechanical and thermal characterization  
P(3HO) films were fabricated by solvent casting as described in section 2.2.9.1 and 
characterized in terms of the mechanical and thermal properties as described in section 
2.2.10.1 and 2.2.10.2, respectively. The mechanical properties were determined by dynamic 
mechanical analysis. Results are represented in a static strain vs. stress plot (Figure 5.5). The 
initial slope of the plot corresponds to the Young’s modulus and the obtained value was 
3.7±0.3 MPa. The % elongation at break and the tensile strength, obtained at the maximum 
elongation before the material is broken was 299±29 % and 3.4±0.2 MPa, respectively. 
 
 
Figure 5.5. Static strain vs. Stress profile of the P(3HO) polymer. The initial slope and the 
maximum elongation are indicated with a black line. 
 
The thermal properties of the material were determined by the differential scanning 
calorimetry analysis. The thermograms show the presence of two peaks corresponding to the 
melting temperature and glass transition temperature (Figure 5.6). The melting temperature 
obtained was 43.7±4.1 ºC and the glass transition temperature was -32.9±3.8 ºC.  
 





Figure 5.6. Thermal profile of the P(3HO) polymer. The peaks corresponding to the Tg and 
Tm are indicated with arrows.  
 
5.2.1.3. P(3HO) surface characterization  
In order to analyze the surface structure of the P(3HO) polymer, P(3HO) films were created 
by the solvent casting technology. The surface wettability of the P(3HO) films was studied 
with a contact angle meter as described in section 2.2.10.3. The water contact angle on the 
P(3HO) films was 101.1±0.8 º, indicating a hydrophobic surface. The surface roughness of 
the P(3HO) film was determined using white light interferometry, as described in section 
2.2.10.5. Results showed that the average surface roughness of the P(3HO) film was 0.17 µm 
(Figure 5.7). Finally, the surface morphology and microstructure of the P(3HO) films was 
studied using scanning electron microscopy, as described in section 2.2.10.4. Figure 5.8 
shows the smooth surface properties obtained.  
Tg 
Tm 






Figure 5.7. Surface roughness analysis of two typical P(3HO) films. Ra describes the average 
surface roughness, Rmax the maximum roughness depth, RZDIN is the average peak to valley 
height minus Rtm and Rtm is the average distance between the highest peak and lowest valley 
in each sample. 
 
Figure 5.8. SEM images obtained from P(3HO) films showing the smooth surface of the 
films at different magnifications. 
Ra =        0.17 µm 
Rmax =     2.79 µm 
RZDIN =  2.32 µm 
Ra =        0.17 µm 
Rmax =     3.56 µm 
RZDIN =  2.42 µm 




5.2.1.4. In vitro cytocompatibility studies 
5.2.1.4.1. Cardiomyocyte viability on P(3HO) films 
In a preliminary study, the effect of the P(3HO) polymer on cardiomyocyte viability was 
studied. Fresh isolated adult rat cardiomyocytes were seeded on the P(3HO) films as 
described in section 2.2.11.1. Based on the shape, the number of live and dead cells were 
determined with an inverted microscope at the following times after seeding: 0, 1, 2, 24, 25 
and 26 hours. Figure 5.9 shows the rod shape of a live cardiomyocyte vs. the round shape of 






Figure 5.9. Live vs. dead cardiomyocytes. The picture on the left shows a live cardiomyocyte 
and the picture on the right shows dead cardiomyocytes (Gonzalez-Granillo et al., 2012). 
The ratios of live/dead cells at the different time points are illustrated in Figure 5.10. These 
results show a significant slightly higher viability on the polymer than in the control at 0, 2, 
25 and 26 hr .  
 
Figure 5.10. Live/dead rat cardiomyocytes seeded on the P(3HO) film vs. control at  0, 1, 2, 
24, 25, 26 hours (n=6; error bars=±SD).  




5.2.1.4.2. Cardiomyocytes’ contraction on P(3HO) films 
The effect of the P(3HO) polymer on the contraction of the cardiomyocytes was studied. 
Fresh isolated adult rat cardiomyocytes were seeded on P(3HO) coated cover slips and 
superfused in a Krebs-Henseleit solution at 37◦C and bubbled with 95% O2, 5% CO2 as 
described in section 2.2.11.2. Cover slips without coating were used as controls. For the 
study, rod shaped cardiomyocytes with regular and no spontaneous contraction without 
stimulation were selected. Cells were stimulated with pulses of 50 V for a period of 2ms with 
2 seconds intervals. The contraction amplitude (% shortening), ʻtime to peak 90%ʼ and time 
to ʻrelaxation 50%ʼ were recorded with a video and analyzed with the Inoptix program.  
 
5.2.1.4.3. Effect on cardiomyocyte contraction at different intervals of electrical 
impulses  
The effect on cardiomyocyte contraction at a range of electrical impulse frequencies was 
analyzed. Cells were stimulated with pulses of 50 V for during 2 ms at the following time 
intervals: 2, 5, 2, 1 and 0.5 seconds. Figure 5.11 shows the profile of one representative 
experiment obtained. 
 
Figure 5.11. Effect of 50 V pulses for 2 ms at 2, 5, 2, 1 and 0.5 seconds intervals on 
cardiomyocyte contraction. 




Figure 5.12 and 5.13 show the effect of 50 V electrical pulses for 2 ms at 2, 5, 2, 1 and 0.5 
second intervals on the ʻtime to peak 90%ʼ and ʻtime to baseline 50%ʼ, on the P(3HO) 
polymer, respectively. Results show differences when the frequency of electrical pulses 
increases from 5 to 0.5 seconds, where the time to peak 90% decreases in both polymer and 
control (Figure 5.12). Additionally, differences were significant only in control when the 
intervals of electrical pulses decreased from 5 to 2, 1 and 0.5 seconds (Figure 5.13). 
 
 
Figure 5.12. Effect of 50 V pulses for 2ms at 2, 5, 2, 1 and 0.5 seconds intervals on the ʻtime 
to 90% peakʼ of rat cardiomyocytes for cardiomyocytes contraction on P(3HO) polymer and 
control glass slides (n=5; error bars=±SD). The data were compared using the t-test and the 
differences were considered significant when **p < 0.01. 





Figure 5.13. Effect of 50 V pulses for 2m at 2, 5, 2, 1 and 0.5 seconds intervals on time from 
peak to 50% relaxation of rat cardiomyocytes on P(3HO) polymer and control glass slides 
(n=5; error bars=±SD). The data were compared using the t-test and the differences were 
considered significant when **p < 0.01. 
 
Figure 5.14 shows the effect on cardiomyocyte contraction (% shortening) of electrical pulses 
of  50 V for 2 ms at 2, 5, 2, 1 and 0.5 seconds interval on P(3HO) polymer. The data was 
normalized against 2 second interval pulses. Results show that no differences were observed 
between the cardiomyocyte on the control and polymer. Only when the frequency of 
electrical pulses was increased from 5 to 2, 1 and 0.5 seconds, the percentage of shortening 
decreased significantly in the control but not in the polymer. 
 
 





Figure 5.14. Normalized contraction amplitude (% shortening) of rat cardiomyocytes on 
P(3HO) polymer with electrical pulses of 50 V for 2 ms at 2, 5, 2, 1 and 0.5 seconds intervals 
(n=5; error bars=±SD).The data was normalized against 2 seconds interval pulses and 
compared using the t-test and the differences were considered significant when *p < 0.01, 
***p < 0.001. 
 
5.2.1.4.4. Effect on cardiomyocyte contraction at different calcium concentrations 
In this section, the effect of calcium concentration on cardiomyocyte contraction was studied. 
For this, the calcium concentration in the Krebs-Henseleit solution was increased from 1 to 2, 
3 and 4 mM. The experiments were carried out as described in section 2.2.11.2. Figure 5.15 
shows the profile of one representative experiment. 





Figure 5.15. Effect of calcium concentration on cardiomyocyte contraction (the calcium 
concentration of the Krebs-Henseleit solution was increased from 1 to 2, 3 and 4 mM). 
 
Figure 5.16 and 5.17 shows the effect on ‘time to peak 90%’ and ‘time to baseline 50%’ of 
the cardiomyocytes on the P(3HO) polymer, when the calcium concentration in the Krebs-
Henseleit solution was increased from 1 to 2, 3 and 4 mM, respectively. Results show that no 
differences were observed between the data obtained for the polymer and control at different 
calcium concentrations. An increment in the ‘time to baseline 50%’ was observed in the 
control but not in the polymer when the calcium concentration was increased from 2 to 3 and 
4 mM. 





Figure 5.16. Response on cardiomyocyte beat duration, ‘time to peak 90%’, to an increment 
in Ca2+ concentration from 1 to 2, 3 and 4 mM on P(3HO) films (n=5; error bars=±SD). The 
data were compared using t-test. 
 
Figure 5.17. Response on cardiomyocyte beat duration ‘time from peak to 50% relaxation’ to 
an increment in Ca2+ concentration from 1 to 2, 3 and 4 mM on P(3HO) films (n=5; error 




bars=±SD). The data were compared using the t-test and the differences were considered 
significant when *p < 0.05, **p < 0.01. 
Figure 5.18 shows the effect on cardiomyocyte contraction (% shortening) at 1, 2, 3 and        
4 mM calcium when grown on P(3HO) polymer. Data were normalized against 1 mM 
calcium. The results showed that no differences were observed between the control and 
polymer. A slightly higher response in the % of shortening is observed when the calcium 
concentration is increased from 1 to 2 and 3 mM in the polymer. 
 
 
Figure 5.18. Normalized contraction amplitude (% shortening) of rat cardiomyocytes on 
P(3HO) polymer at different calcium concentrations (n=5; error bars=±SD). The data were 









5.2.2. P(3HO), SIS and pericardium   
The SIS and pericardium were characterized in terms of mechanical properties, thermal 
properties, wettability, protein adsorption and surface roughness. The SIS and pericardium 
properties were then compared with the properties of P(3HO). Mechanical properties were 
determined using Dynamic Mechanical Analysis as described in section 2.2.10.1. The 
pericardium and SIS mechanical profile are represented in a static strain vs. stress plot shown 
in Figure 5.19 and Figure 5.20, respectively. The initial slope of the plot corresponds to the 
Young’s modulus and the obtained value was 0.4 ±0.1 MPa and 329.9±2.2 MPa for the 
pericardium and SIS, respectively. Section 5.2.1.2. shows that the P(3HO) Young’s modulus 
was 3.7±0.3 MPa. These results indicate that P(3HO) stiffness is more similar to the 
pericardium than SIS. In the case of the pericardium the tensile strength was 6.33 MPa and 
elongation at break 114.5%. For SIS the obtained tensile strength was 10.5 MPa and 
elongation at break 10%. The tensile strength and elongation at break for P(3HO) was 
3.4±0.2 MPa and 299±29 %, respectively. Comparison of the values showed that P(3HO) had 




Figure 5.19. Static strain vs. stress profile of pericardium. 





Figure 5.20. Static strain vs. stress profile of SIS 
 
The thermal properties of the two biological membranes were studied by Differential 
Scanning Calorimetry, as described in section 2.2.10.2. Figure 5.21 and 5.22 show the 
thermal profiles obtained for the pericardium and SIS, respectively. As collagen is the main 
constituent of both membranes, the thermograms showed a typical denaturation peak starting 
at 70 ºC, which corresponds to the collagen denaturation temperature as found in literature 
(Samouillan et al., 2011). The peak observed at 5 ºC for the pericardium belongs to the 
solvent in which the tissue was preserved. As described in section 5.2.1.2, P(3HO) showed a 
melting temperature of 43.7±4.1 ºC, indicating a lower processability of the polymer respect 
to the two biological tissues. 





Figure 5.21. Thermal profile of the pericardium. The arrow shows the typical denaturation 
peak starting at 70 ºC. The first peak observed at 5 ºC corresponds to the solvent used to 
preserve the tissue. 
 
Figure 5.22. Thermal profile of SIS. The arrow shows the presence of one main peak starting 
at 70 ºC which shows the denaturation of the membrane.  




Wettability studies were carried out with a contact angle meter as described in section 
2.2.10.3. The contact angle obtained for the pericardium was 41.6±9.6 º and for SIS was 
96.2±6.6 º. These results show that the pericardium surface is hydrophilic, while SIS surface 
is hydrophobic. The P(3HO) water contact angle was 101.1±0.8 º, hence, the P(3HO) 
wettability is similar to that of SIS. The thicknesses of both biological membranes and the  
5 wt% P(3HO) were measured and results were as follows: P(3HO) 0.18 mm, SIS 0.16 mm 
and pericardium 0.58 mm. Hence, the thickness of the P(3HO) film used in this study was 
similar to SIS and less than that of the pericardium. Surface roughness analysis was carried 
out by SEM and white light interferometry as described in section 2.2.10.4 and 2.2.10.5, 
respectively. Figure 5.23 shows the SEM images for pericardium. These pictures reveal an 
uneven surface. Figure 5.24 shows the SEM images obtained for SIS. In these pictures it is 
possible to recognize the presence of some cells and veins that were not removed from the 
membrane which would increase the roughness of the surface. 
 
Figure 5.23. SEM images of pericardium at different magnifications. 
 
Figure 5.24. SEM images of SIS at different magnifications. 




The surface roughness results for both membranes are shown in Figure 5.25. The values 
obtained for the membranes were 1.51 µm for pericardium and 2.20±0.01 µm for SIS. As 
expected, the surface roughness values for both membranes were higher than the surface 






Figure 5.25. Surface roughness analysis of (A) pericardium and (B) SIS. Ra describes the 
average surface roughness, Rmax, the maximum roughness depth, RZDIN, the average peak to 
valley height minus Rtm and Rtm is the average distance between the highest peak and lowest 
valley in each sample. 
 
It is well known that as soon as a foreign body is implanted in the body, proteins are adsorbed 
onto the surface of the implant. As a result, it is expected that cells interact with the 
biomaterial surface rather than directly with the material itself. Hence, the initial protein 
adsorption onto a biomaterial surface is a key factor that will determine how the body will 
Ra =          1.51 µm 
Rmax =     18.35 µm 
RZDIN =  12.54 µm 
Ra =          2.02 µm 
Rmax =     20.19 µm 
RZDIN =  15.91 µm 
Ra =           1.75 µm 
Rmax =      15.22 µm 
RZDIN =   12.98 µm 
Ra =          1.51 µm 
Rmax =     15.19 µm 
RZDIN =  12.64 µm 
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react to an implanted material (Anderson et al., 1990, Tang et al., 1995). The protein 
adsorption on both biological membranes and the P(3HO) film were measured as described in 
section 2.2.10.6 and results are represented in Figure 5.26. For this, films were incubated in 
foetal bovine serum and the total adsorbed protein was quantified. Results showed that 
protein adsorption on P(3HO) films is considerably lower than the SIS and the pericardium. 
Figure 5.26. The concentration of proteins adsorbed on the surface of the P(3HO) films vs. 
SIS and pericardium (n=3; error bars=±SD). The data were compared using ANOVA and the 
differences were considered significant when ***p < 0.001. 
In order to confirm the integrity of the proteins adsorbed on the surface of the structures and 
to verify the origin of these proteins, adsorbed proteins were run on a SDS-PAGE gel. Figure 
5.27 shows the gels. As albumin is the main protein present in the serum the presence of the 
band at 66 KDa in all the samples confirms the integrity of this protein. In the case of the 
pericardium and SIS, results show that not only albumin but also other proteins were eluted 
(Figure 5.27 (B) and (C)). The fact that some bands appear in the negative control, in which 
the membranes were not treated with FBS, indicates that proteins that were originally present 
on the surface of the pericardium and SIS were not completely removed. In the case of SIS 
(Figure 5.27 (C)), the membrane showed a high concentration of protein that eluted from the 
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membrane and a low concentration of albumin. Some of these proteins did not appear either 
in the negative control in which PBS was used instead of FBS or the positive control where 
FBS was loaded, hence, it was not possible to confirm the origin of these proteins. However, 
it is possible that these proteins were present in the serum and due to the fact that the 
concentration of albumin in the serum in significantly higher than other proteins they are not 
visible in the positive control. Hence, we can suggest that SIS has higher affinity for other 
proteins as compared to albumin. 
 
Figure 5.27. SDS-PAGE showing the integrity of the proteins adsorbed on the surface of A) 
P(3HO) films B) Pericardium and C) SIS. MK: Bio-rad® reference protein ladder; C-: 
negative control that contains the proteins eluted from the membranes without FBS treatment; 
FBS: whole serum; PHO1, PHO2 and PHO3: proteins eluted from the P(3HO) film after FBS 
treatment; P1,P2 and P3: proteins eluted from pericardium after FBS treatment; S1, S2 and S3: 
proteins eluted from SIS after FBS treatment. 
Table 5.1 summarizes the results obtained from the various analyses carried out on P(3HO), 
pericardium and SIS.  




	  75	  -­‐-­‐-­‐-­‐-­‐-­‐	  
	  66	  -­‐-­‐-­‐-­‐-­‐-­‐	  
	  50	  -­‐-­‐-­‐-­‐-­‐-­‐	  
	  37	  -­‐-­‐-­‐-­‐-­‐-­‐	  
	  25	  -­‐-­‐-­‐-­‐-­‐-­‐	  
	  20	  -­‐-­‐-­‐-­‐-­‐-­‐	  
	  15	  -­‐-­‐-­‐-­‐-­‐-­‐	  














100	  -­‐-­‐-­‐-­‐-­‐-­‐	  	  	  
	  	  	  75	  -­‐-­‐-­‐-­‐-­‐	  
	  	  	  66	  -­‐-­‐-­‐-­‐-­‐	  
	  	  	  50	  -­‐-­‐-­‐-­‐-­‐	  
	  	  	  37	  -­‐-­‐-­‐-­‐-­‐	  




Table 5.1. A summary of the results obtained from the characterization of the P(3HO) film, 

















Although the biomaterial’s surface properties have been extensively described to have an 
effect on cell adhesion and proliferation, no general principles that allow the prediction of 
cell behaviour have been established and this has to be specifically determined in each 
particular case. In the following experiment the effect of the polymer and the two biological 
membranes on cell attachment and proliferation was assessed. To this end, myoblast cells 
(C2C12) were seeded on the P(3HO) films, pericardium and SIS, as described in section 
2.2.11.3.3. The cell adhesion and proliferation were measured after 24 hr of cell seeding with 
the MTT colorimetric assay (section 2.2.11.3.4). The results obtained were normalized 
against the cell proliferation observed on tissue culture plates. The results showed no 
significant difference in the % cell proliferation observed on P(3HO) and SIS, at 24 hr 
(Figure 5.28). A 14 % higher cell proliferation was observed on the pericardium in 
comparison to P(3HO) or SIS.  
 
 
 P(3HO) Pericardium SIS 
Young'smodulus (MPa) 3.7±0.3  0.4 ±0.1 329.9±2.2 
Tensile strength (MPa) 3.4±0.2 6.3 10.5  
Elongation at break (%) 299±29 114.5 10 
Melting temperature (ºC) 43.8±4.1 60 60 
Water contact angle 101.1±0.8 41.6±9.6 96.2±6.6 
Thickness  (mm) 0.18 0.58 0.16 
Surface roughness (µm) 0.17 1.51 2.20±0.01 
Protein adsorption (µg/mL) 108.61±40.30 648.06±80.30 954.17±150.70 
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Figure 5.28. % Cell proliferation of C2C12 cell line at 24 hr on P(3HO), SIS and 
pericardium (n=4; error bars=±SD). The data were compared using ANOVA and the 
differences were considered significant when *p < 0.05. 
SEM was carried out to visualize myoblast cells grown on the different materials. Sample 
preparation for the SEM analysis was performed as described in section 2.2.10.4. SEM 
images are shown in Figure 5.29. Although the % cell proliferation is compared between a 
P(3HO) neat structure and two 3D structures, similar proliferation was observed between 
P(3HO) and SIS and comparable values were obtained with the pericardium. 
*
*





















Figure 5.29. SEM images of C2C12 cells after 24 hr at different magnifications growing on 
A), B) and C) P(3HO) neat film; D), E) and F) SIS membrane and G), H), I) pericardium. 
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Medium chain length PHAs, with a typical monomer chain length from 6-16 carbon atoms, 
are polymers produced in Gram-negative bacteria, mainly Pseudomonas sp. Mcl-PHAs are of 
great interest because according to the number of carbons in the side chain, the physical 
properties of these biodegradable polymers can be varied, allowing the production of tailor 
made materials. Previous reports have shown that mcl-PHAs are flexible elastomeric 
polymers, with low crystallinity, low glass transition temperature, low tensile strength, and 
high elongation to break (Zinn et al., 2001). In this chapter we studied poly(3-
hydroxyoctanoate), a mcl-PHA, as a potential material for cardiac tissue engineering. P(3HO) 
was known to be produced as an homopolymer by P. medocina, as described by Rai et al., 
(2011a).  
5.3.1. P(3HO) properties 
P. mendocina was grown in 2 L bioreactors, in MSM media, with sodium octanoate as the 
sole carbon source and PHAs were extracted and characterized. Structural characterization of 
the polymer was carried out by FTIR, GC-MS and NMR and results showed that, as 
expected, the produced polymer was the P(3HO) homopolymer. 
The mechanical properties of the material will play an essential role in supporting the injured 
organ during regeneration. The P(3HO) mechanical properties were measured using dynamic 
mechanical analysis. As myocardial stiffness is considered to be an essential myocardial 
property, especially during the diastole, P(3HO) stiffness was quantified by examining the 
relationship between stress and strain (Watanabe et al., 2006). According to our results the 
Young’s modulus of the P(3HO) neat film was 3.7±0.3 MPa. This value shows that the 
P(3HO) stiffness is approximately one order of magnitude higher as compared to that of 
myocardial structures (human myocardium stiffness 0.02-0.5MPa). Further experiments will 
include production of P(3HO) structures that will decrease the material’s Young’s modulus. 
The ability to resist breaking under tensile stress is one of the most important properties of 
materials used in structural applications. The tensile strength obtained for P(3HO) was 
3.4±0.2 MPa. Although this value is higher than myocardial structures (human myocardium 
tensile strength 3-15 KPa), a higher tensile strength might have a positive effect as after a 
myocardial infarction, the abrupt loss of myocardium triggers a ventricular remodeling that 




includes dilatation, hypertrophy, and the formation of a collagen scar that increases the load 
of the infarcted region. Furthermore, it has been described that negative ventricular 
remodeling continues for weeks or moths until the distending forces the cardiac tissue are 
counterbalanced by the tensile strength of the collagen scar, hence, a higher tensile strength 
could have a positive effect after a myocardial infarction (Sutton et al., 2000). The percentage 
elongation at break of P(3HO) recorded at the moment of rupture of the specimen, expressed 
as a percentage of the original length was 299±29 %. This value is similar to the upper limit 
of myocardial structures (human myocardial elongation at break is between 100-300 %). 
Thermal analyses of P(3HO) showed two peaks corresponding to the glass transition 
temperature and melting temperature observed at -32.9±3.8 ºC and 43.7±4.1 ºC during the 
first heat scan, respectively. A glass transition temperature below room temperature and the 
low melting temperature, which reflects the low crystallinity of the polymer imparts to the 
material an elastomeric behavior. No melting temperature peaks were observed during the 
second heat scan as P(3HO) polymer chains were unable to rearrange again into ordered 
structures during the cooling run after the melting process.   
The surface of the biomaterials plays a significant role in determining the outcome of the 
biological system and biomaterial interaction (Flemming et al., 1999). Biomaterials interact 
with the biological environment at their surface, making the characterization of the surface 
crucial for understanding subsequent biological effects. In order to study the surface 
properties of the P(3HO) polymer, films were created by the solvent casting technology. The 
hydrophobicity of a biomaterial surface is directly related to cell adhesion. The cell adhesion 
to a surface occurs by adhesion receptors present in the cell that binds to proteins adsorbed on 
the surface and the conformation of these proteins depends on the surface wettability (Lee et 
al., 2003). It has been described that the water contact angle of hydrophobic surfaces is 
higher or equal to 90º (Li, 2011). The P(3HO) water contact angle was 101.1 ± 0.8º. This 
value showed that the P(3HO) film surface is hydrophobic, however, the value is not much 
higher than the upper limit of 90o, known for hydrophilic surfaces. In general, hydrophilic 
surfaces display better affinity for cells but lower affinity for many proteins as compared to 
hydrophobic surfaces (Lampin et al., 1997).  
Finally, SEM analysis and surface roughness studies revealed that the P(3HO) neat films 
present a smooth surface. With regard to roughness of the surface affecting the growth of 
different kinds of cells, most researchers have shown that increased surface roughness has a 




positive effect on cell adhesion (Richert et al., 2008). Further experiments in this thesis will 
include surface functionalization of the P(3HO) film in order to promote cell adhesion and 
growth. 
 
5.3.2. Use of P(3HO) in cardiac tissue engineering 
The interaction of cardiomyocytes with the extracellular matrix is essential for the proper 
functioning of cardiomyocytes since the extracellular matrix provides an adhesive surface for 
cells and a structural organization to the tissue (Gupta et al., 2006). In the second part of this 
chapter, the effect of P(3HO) on freshly isolated cardiomyocytes was assessed. In a 
preliminary study, cardiomyocytes were seeded on P(3HO) polymer films and the number of 
live vs. dead cells was measured at different time points. Results were compared to the 
control in which plastic tissue culture was used. Results showed a slightly higher number of 
live cells on P(3HO) than in the control (tissue culture plastic) at different time points. These 
results suggest that P(3HO) is not toxic and a good cell adhesive surface for the 
cardiomyocytes.   
The proper contraction of individual cardiomyocytes is essential for the normal functioning 
of the heart. Intracellular calcium is the main factor that regulates cardiomyocyte contraction. 
First, an action potential leads to the opening of L-Type calcium channel present in the 
membrane of the cells. Second, the calcium entering the cells triggers the release of calcium 
from the sarcoplasmatic reticulum, leading to a marked increase of cytosolic calcium 
concentration. High concentrations of intracellular calcium initiate the interaction of 
contractile filaments and subsequent contraction. Relaxation occurs by the removal of 
calcium from the cytosol by calcium transporters. It has been described that Gap junctions 
coordinate the contraction of individual cardiomyocytes and this force is transduced to the 
extracellular matrix, which coordinates the overall contraction of the heart (Harvey et al., 
2011). Engler et al., (2008) have shown that the culturing of embryonic cardiomyocytes on a 
series of substrates of different elasticity has a significant effect in the transmission of 
contractile work and that cells in a rigid matrix are deficient in the assembly of contractile 
proteins and their beating frequency slows down over time. As a result, the extracellular 
matrix to which cardiomyocytes attach is a key factor for a highly regulated system such as 
the heart. In order to analyze the effect of P(3HO) on isolated cardiomyocyte contraction, 
fresh cardiomyocytes were seeded on P(3HO) coated cover slips and the effect of a range of 




frequencies on the cardiomyocyte contraction was examined. Results show that no significant 
differences were observed between the polymer and the control (glass cover slips) in terms of 
‘time to peak 90%’, ‘time to baseline 50%’ and the amplitude of contraction (% shortening). 
As expected, increasing stimulation frequencies, leads to a progressive decrease in the 
amplitude of contraction in myocytes due to a shorter time for cytosolic calcium 
replenishment. Decreased function of individual cardiomyocyte contraction is known to lead 
to the deterioration of cardiac performance. Our results showed that the polymer is not 
reducing the effect of frequency on cardiomyocytes. Differences were observed with ʻtime to 
peak 90%ʼ when the frequency of stimulation was increased from every 5 to 0.5 seconds in 
both polymer and control. When the frequency of stimulation was increased from every 5 to 
2, 1 and 0.5 seconds, a significant diminution in ‘time to baseline 50%’ was observed in the 
control but not on the polymer. Additionally, when the frequency of the electrical impulse 
was increased from 5 to 0.5 seconds, the cardiomyocyte contraction decreased significantly in 
the control but not on the polymer. The decrease in time to relaxation might lead to a 
decrease in the contraction amplitude for the control. There is a usual negative effect at high 
frequencies due to a reduction in the time for calcium replenishment, which leads to a 
diminution in the contraction amplitude performance. However, this negative effect on the 
contraction performance with increment in electrical impulse frequency was not observed in 
the case of P(3HO).  
As described before, calcium is a central regulator of cardiac contractibility. We have studied 
the effect of increasing calcium concentrations on cardiomyocyte contraction. It has been 
reported that an intracellular calcium increment leads to an increment in the force of 
contraction that results in a higher contraction amplitude until a saturation point at which no 
further increment in contraction occurs (Bers 2000). Our results show that no significant 
differences were observed between the polymer and the control in terms of ‘time to peak 
90%’, ‘time to baseline 50%’ and amplitude of contraction (% shortening). As expected, an 
increment in cardiomyocyte contraction was observed when the concentration of calcium was 
increased from 1mM to 2mM on both the polymer sample and the control, reaching a point of 
maximum contraction. Additionally, a slight increment was observed in ‘time to baseline 
50%’ when the concentration of calcium was increased from 2 to 3 and 4 mM in the control 
but not on the polymer. These results showed that the polymer is not reducing the effect of 
calcium.  




In agreement with Engler et al., (2008), who observed a reduced contraction ability of 
cardiomyocytes in rigid surfaces, our results showed a reduction in the contraction amplitude 
at high frequencies of electrical impulses in the rigid surface of the control in contrast to the 
constant contraction amplitude observed on the surface of the P(3HO) elastomeric polymer. 
Our results showed that P(3HO) did not have a deleterious effect on the contraction of adult 
cardiomyocytes and hence P(3HO) is a potential material that can be effectively used in 
myocardial tissue engineering. 
 
5.3.3. P(3HO), SIS and pericardium 
Over the past years, different materials have been proposed to support and regenerate the 
myocardial infarcted tissue as adult cardiomyocytes lack the capacity for self-repair or 
regeneration. Among these materials are porcine small intestinal submucosa (SIS) and bovine 
pericardium. SIS is an extracellular matrix rich in collagen, glycosaminoglycans and 
fibronectin (Perla et al., 2006). This membrane has been used as a biomaterial for soft tissue 
engineering in different tissues including the artery, abdominal body wall, skin and the 
urinary tract (Badylak et al., 1989, Campodonico et al., 2004, Kim et al., 2005 and Zhang et 
al., 2003). On the other hand, bovine pericardium is an extracellular membrane mainly 
composed of collagen and elastin. Bovine pericardium is commonly used in the repair of 
vascular tissue, cardiac tissue, the urinary tract and in thoracic surgery (Li et al., 2011, 
Provencher et al., 2003, Us et al., 2004). In order to understand and compare the properties of 
SIS and the pericardium with P(3HO), in the first part of the chapter we have focused on the 
characterization of these two biological membranes available in the market. As discussed 
previously, mechanical properties play a key role in supporting the organ during the 
regeneration process. Mechanical properties of SIS and the pericardium were determined by 
dynamic mechanical analysis. Figure 5.19 and 5.20 show the mechanical profiles obtained for 
each membrane. The initial slope of the plot corresponds to the Young’s modulus and the 
obtained values were 0.4 ±0.1 MPa and 329.9±2.2 MPa for pericardium and SIS, 
respectively. These results showed that stiffness of these two materials, used as cardiac 
patches by different groups, differs in three orders of magnitude (Pires et al., 1999, Rosen et 
al., 2005). It is important to mention that an unusual mechanical profile was obtained in the 
case of pericardium. The reason of this observation could be related to the dehydration of the 
membrane at room temperature during the measurement. Section 5.2.1.2 shows that the 




Young’s modulus of P(3HO) was 3.7±0.3 MPa and hence, the P(3HO) stiffness is closer to 
pericardium. In order to achieve a contraction in unison with the heart, it is important that the 
biomaterial has similar mechanical properties to the heart tissue. As described previously, the 
Young’s modulus of the human myocardium is 0.02-0.5 MPa. Consequently, we can 
conclude that only the bovine pericardium stiffness is in the range of myocardial structures. 
In case of the pericardium, the tensile strength was 6.33 MPa and elongation at break was 
114.5%. For SIS the obtained tensile strength was 10.50 MPa and elongation at break 10%. 
The tensile strength and elongation at break of myocardial structures have been found to be 
3-15 KPa, and 100-300%, respectively. The tensile strength of P(3HO) was 3.4±0.2 MPa and 
299±29 %, respectively. Therefore, these results confirmed that the P(3HO) and pericardium 
elongation at break values and the P(3HO) tensile strength value showed values closest to 
myocardial structures. Hence, our results suggest that P(3HO) mechanical properties are very 
similar to that of the pericardium, a material that is currently used in cardiac surgery. This 
confirms that P(3HO) has the potential to be used equally successfully in cardiac tissue 
engineering. 
The thermograms of the pericardium and SIS showed denaturation at 70 ºC, corresponding to 
collagen denaturation. Collagen is a major component of both membranes. The melting 
temperature for P(3HO) was measured to be 43.8±4.1 ºC, hence, both membranes can be 
predicted to have better processability/stability at higher temperatures as compared to 
P(3HO).   
Surface studies including wettability, surface roughness and protein adsorption for 
pericardium and SIS were also carried out. The contact angle obtained for the pericardium 
was 41.6±9.6 º and for SIS was 96.2±6.6 º. As described previously, the water contact angles 
smaller or equal to 90º are characteristic of hydrophilic surfaces (Li, 2011). In this case, the 
pericardium was found to have a hydrophilic surface, whereas SIS was found to have a 
hydrophobic surface. The P(3HO) filmʼs wettability properties were similar to SIS, indicating 
that the P(3HO) surface was hydrophobic in nature. The surface roughness values for the 
pericardium and SIS were 1.51 µm and 2.20±0.01 µm, respectively. Finally, protein 
adsorption/elution studies showed significantly higher proteins concentration on the SIS and 
pericardium surface as compared to neat P(3HO) films. However, SDS-PAGE results suggest 
that some of the eluted proteins from both the membranes were present on the membranes 
before the FBS treatment. It is important to point out that although adsorbed proteins on the 
surface have a positive effect in cell adhesion, the presence of proteins on the membranes is 




much less desirable because it can elicit adverse host responses such as blood coagulation and 
complement activation (Hlady et al., 1996).  
Due to the continuous contractile activity of myocytes, cardiac tissue has high oxygen and 
nutrient’s demand and hence, a high level of vascularization is essential. It has been found 
that absence of vasculature in tissues thicker than 300 µm can be a limiting factor in the 
selection of a material for cardiac tissue engineering (Bronzino 2006). The thickness of the 
P(3HO) sample, pericardium and SIS were 0.18 mm, 0.58 mm and 0.16 mm, respectively. 
These results show that the thickness of the pericardium is higher than desired values. 
The cell proliferation on P(3HO), SIS and the pericardium was studied using the C2C12 
myoblast cell line. Results showed that at 24 hr, the % cell proliferation on both P(3HO) and 
the pericardium were similar. Higher % cell proliferation was observed for the pericardium at 
24 hr as compared to SIS and P(3HO). As P(3HO) was processed in to a neat film, lower cell 
proliferation on its surface was expected, hence surface modifications of P(3HO) were 
carried out in future experiments. However, contrary to expectation, P(3HO) as a neat film 
showed similar cell proliferation values as SIS and values comparable to that of the  
pericardium. In conclusion, our results showed that P(3HO) is a promising material for the 




Production of P(3HO) based 
cardiac patches 




6. 1. INTRODUCTION 
Myocardial tissue engineering is based on the regeneration of cardiac tissue by the 
implantation of cells, capable of forming cardiomyocytes and grown on a biocompatible and 
biodegradable scaffold, which eventually will be implanted onto the injured site of the heart. 
The combination of living cells seeded onto a biomaterial has been proposed as an alternative 
option to replace the scarred non-contractile fibrous tissue caused post-infarction (Jawad et 
al., 2008). 
Williams et al., (1999) defined six key requirements for a biomaterial to succeed in cardiac 
tissue engineering: (1) biocompatible, (2) support cell adhesion and growth, (3) guide and 
organize the cells, (4) allows cell ingrowth and passage of nutrients and waste products (5) 
biodegradable and (6) mechanical properties to support the organ during regeneration.     
Engineering biomaterials to promote cell adhesion and direct cellular behavior is crucial for 
the development of materials capable of restoring tissue function. Several reports have 
proven that cells are sensitive to the physical and chemical environment which determines 
cell specific migration, proliferation, differentiation and production of proteins which in turn 
influences tissue organization and regeneration (Jell et al., 2009). This chapter is devoted to 
the production of cardiac patches using P(3HO). Our first approach was the design of 
permeable porous structures with an appropriate surface structure for cell attachment that 
permits the ingress of cells and guides their growth, leading to tissue regeneration in three 
dimensions. Eventually, the polymer matrix would be degraded leaving behind new tissue. 
The diameter of the cardiomyocytes dictated the minimum pore size (Yang et al., 2001). The 
size of the fabricated porous structures were comparable to cardiomyocytes (250-300 µm) in 
order to allow cell permeation. Additionally, the mechanical properties were adjusted to 
match myocardial structures.  
Several reports have shown that the appropriate modification of the biomaterial’s surface can 
have a high impact on the biocompatibility, cell adhesion and cell interactions (Williams et 
al., 2011). As collagen is the main constituent of the extracellular matrix and exhibits a 
distinct fibrous architecture, in order to mimic such fibrous structure, the neat P(3HO) and 
porous film surfaces were modified using P(3HO) fibres, which were produced using 
electrospinning. In this technique, a syringe fitted with a nozzle is filled with polymer 
solution and an electric field is applied to the nozzle. As the electric field increases, a charge 
builds on the polymer solution. When the force due to the charge in the polymer solution 
exceeds the surface tension of the solution, a charged jet of polymer solution is released 




(Doshi et al., 1995). P(3HO) fibres were deposited on neat and porous P(3HO) films. Curtis 
et al., (1999) have shown that cell adhesion, morphology and orientation can be highly 
affected by the size and shape of the topographical features on a polymer surface (Curtis et 
al., 1999). In order to find the optimal fibre size, myoblast cells were seeded on a range of 
fibres with different diameters. Optimal fibre size was selected according to the highest cell 
affinity and proliferation observed. Finally, P(3HO) neat and porous surfaces were modified 
with the optimal fibre size and the resulting cardiac patch prototypes were characterized. In 










6.2.1. P(3HO) porous patches 
Controlled porosity in biomaterials is a key factor when they are used as a physical support 
for cell adhesion and growth (Lebourg et al., 2008). In this study, porous P(3HO) films were 
created by the particle leaching method according to section 2.2.9.1 and the effect of porosity 
on the mechanical properties and on cell adhesion and proliferation were studied. For this, 
0.5% sucrose with controlled particle size ranging from 250 to 300 µm was used as porogen. 
Mechanical properties of the resulting porous films were measured using dynamic 
mechanical analysis, according to section 2.2.10.1. Figure 6.1 shows the mechanical profile 
of the porous films. It is expected that mechanical strength decrease with increasing porosity. 
In this case, the obtained Young’s modulus was 0.41±0.03 MPa. The Young’s modulus of 
neat P(3HO) film was measured to be 3.7±0.3 MPa (section 5.2.1.2). Hence, the stiffness of 
the material decreases by one order of magnitude. The obtained tensile strength and 
elongation at break were 0.7±0.1 MPa and 447±5 %, respectively. The tensile strength of the 
neat P(3HO) film was 3.4±0.2 MPa and the elongation at break was 299±29 % (section 
5.2.1.2). Hence, the incorporation of porosity in the film resulted in a decrease in its tensile 
strength and an increase in the elongation at break, as compared to the neat film.   
 
 
Figure 6.1. Static strain vs. stress profile of the P(3HO) porous films. The initial slope and 
the maximum elongation are indicated with a black line.   
 




The surface wettability of the P(3HO) porous films was studied with a contact angle 
measuring device as described in section 2.2.10.3. The obtained water contact angle was 
104.9 ± 6.0 º. No differences were observed in terms of the surface wettability as compared to 
the neat film which also had a contact angle of 101.1±0.8 º. The surface roughness of the film 
was measured using the white light interferometry technique, as described in section 2.2.10.5. 
The results obtained showed that the surface roughness of the P(3HO) porous films was 
0.9±0.2 µm (Figure 6.2). The average surface roughness of the neat film was 0.17 µm and, 
hence, the incorporation of porous structures increases the surface roughness by 
approximately five times. Figure 6.3 shows the SEM images of the porous structures 




Figure 6.2. Surface roughness analysis of two representative samples of P(3HO) porous films 
created by the particle leaching method. Ra describes the average surface roughness, Rmax the 
maximum roughness depth, RZDIN the average peak to valley height minus Rtm and Rtm is 
the average distance between the highest peak and lowest valley in each sample. 
 
Ra =          0.90 µm 
Rmax =     23.15 µm 
RZDIN =  15.58 µm 
Ra =          0.82 µm 
Rmax =     22.80 µm 
RZDIN =  10.88 µm 
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Figure 6.3. SEM images of the P(3HO) porous films showing the structure of the pores at 
different magnifications. 
 
The protein adsorption of the P(3HO) porous films was measured as described in section 
2.2.10.6. The obtained values were compared with neat P(3HO) films. No significant 
differences were observed in terms of the protein adsorption properties with the incorporation 
of porous structures (Figure 6.4).  
 
 
Figure 6.4. Concentration of proteins adsorbed on the neat P(3HO) film vs. P(3HO) porous 
film (n=3; error bars=±SD). The data was compared using the t-test. 
 
In order to study the effect of porous structures on cell adhesion and proliferation, C2C12 
cells were seeded on the P(3HO) porous films and the % cell proliferation was measured at 
24 hr after seeding. Figure 6.5 compares the % cell proliferation observed on the surface of 




neat P(3HO) and porous films, where the proliferation observed on tissue culture plates was 
considered to be 100%. The results showed that the % cell proliferation increased 2.5 fold 
when porous structures were incorporated on the P(3HO) films.  
 
 
Figure 6.5. The % cell proliferation of C2C12 cell line at 24 hr on neat P(3HO) films and on 
porous films normalized with respect to tissue culture plastic (n=4; error bars=±SD). The data 
were compared using the t-test and the differences were considered significant when ***p < 
0.001. 
 
SEM analysis was carried out in order to visualize the C2C12 myoblast cell line on the 
P(3HO) porous films. Samples were prepared as described in section 2.2.11.4. Figure 6.6 
shows typical SEM images observed for samples after 24 hr of cell growth. It was observed 













 Figure 6.6. SEM images of C2C12 cells at 24 hr on porous P(3HO) films at different 
magnifications. 
 
6.2.2. P(3HO) fibres 
In order to mimic the fibrillar structure of the extracellular matrix which provides essential 
guidance for cell organization, survival and function, P(3HO) fibres were created by 
electrospinning, as described in section 2.2.9.2. Electrospinning is a process based on the 
production of fibres by the application of a high voltage source to a polymer solution in a 
suitable solvent. For the optimization of the electrospinning conditions, a range of P(3HO) 
solutions were created in acetone (0.2 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 1 wt% and 1.2 
wt%). Additionally, two sizes of inner diameter nozzles (330µm and 660µm) were tested at a 
range of flow rates (from 30 µl/min to 250 µl/min). A stable jet and homogeneous fibres were 
obtained when the 330 µm needle and 30 µl/min flow rate were used and the electric potential 
was adjusted (Figure 6.7). Higher electric potentials were required with lower polymer 




concentrations. The electric potential used for the 1.2 wt%, 1 wt%, 0.7 wt%, 0.6 wt%, 0.5 
wt% and 0.2 wt% polymer solution were 8.9 KV, 10.9 KV, 11.4 KV, 11.6 KV 13.4 KV and 
13.8 KV, respectively. A distance of 15 cm between the needle and collector was used in all 







Figure. 6.7. The stable jet obtained with a 330 µm needle at a flow rate of 30 µl/min was 
employed for electrospinning. The arrow indicates the single stable jet obtained. 
 
The size of the fibres obtained in each condition was measured by optical microscopy and the 
results are shown in Table 6.1. It was observed that the fibre diameters decreased with 
decreasing P(3HO) concentration and particles rather than fibres were obtained with the 
lowest concentration. In, the case of 0.5 wt% P(3HO) solution, a transition between fibre 
formation and particle formation occurred, hence, both fibres and particles were obtained. 
Figure 6.8 shows optical images of the material obtained with different polymer 
concentration solutions. 
 
Table 6.1. Fibre and particle diameters obtained by electrospinning of different solutions of 
P(3HO) in acetone. Values are shown ± standard deviation. 
 
P(3HO)	  concentration	  (wt%)	   Fibre	  diameter	  (nm)	   Particle	  diameter	  (nm)	  
1.2	   750	  ±	  130	   -­‐	  
1	   700	  ±	  100	   -­‐	  
0.7	   630	  ±	  100	   -­‐	  
0.6	   370	  ±	  90	   -­‐	  
0.5	   340	  ±	  100	   660	  ±	  60	  
0.2	   -­‐	   	  	  580	  ±	  120	  
 
 




A)                                                       B) 
           
C)                                                        D) 
           
 E)                                                         F) 
           
 
Figure 6.8. Optical microscopy images of P(3HO) electrospun fibres/particles obtained with 
varying concentrations of P(3HO) solutions in acetone, after 10 seconds of collection: A) 1.2 
wt%, B) 1 wt%, C) 0.7 wt%, D) 0.6 wt%, E) 0.5wt% and F) 0.2wt%. 
In order to determine the most suitable fibre or particle size to be used for the design of 
cardiac patches, fibres or particles were collected from the 1.2 wt%, 1 wt%, 0.7 wt%, 0.6 
wt%, 0.5 wt% and 0.2 wt% polymer solution on glass slides for 10 minutes in order to ensure 




that the full surface of the slides were covered. Contact angle measurements were performed 
on the glass slides coated with different P(3HO) fibre diameters, in order to determine 
differences in surface properties that would influence cell adhesion and proliferation. No 
differences were observed in terms of water contact angle between the 750 nm fibres, 700 nm 
fibres, 630nm fibres, and 340 nm fibres + particles (Figure 6.9). Smaller water contact angles 
were obtained with 580 nm particles than with the other fibres or particle diameters.  
 
Figure 6.9. Surface wettability properties of the different fibres or particles of different 
diameters, obtained by electrospinning (n=3; error bars=±SD).The data was compared using 
ANOVA and the differences were considered significant when ***p < 0.001. 
 
In the following experiments cell proliferation on the P(3HO) fibres was assessed with the 
C2C12 myoblast cell line. Cells were seeded on the glass slides coated with different sizes of 
P(3HO) fibres or particles. Cell adhesion and proliferation were determined after 24 hr using 
the MTT colorimetric assay, as described in section 2.2.11.3.4. Figure 6.10 shows the results 
obtained. Our results showed that an increment in fibre diameter resulted in a higher % cell 
proliferation, achieving the highest value of 196.8± 16.0 with 750 nm fibres. Also, cells 
showed preference for fibrous structures as compared to particle structures.  
***	  






Figure 6.10. The % cell proliferation of C2C12 cell line normalized against cell growth on 
tissue culture plastic (n=4; error bars=±SD). The data were compared using ANOVA and the 
differences were considered significant when *p<0.05 and **p<0.01. 
 
Figure 6.11 shows the C2C12 myoblast cell line growing on glass slides coated with 750 nm 
electrospun P(3HO) fibres (Figure 6.20 (A), (C) and (E)) vs. slides coated with 370 nm 
electrospun P(3HO) fibres (Figure 6.20 (B), (D) and (F)) collected for ten seconds. In the 
case of cells growing on 750 nm fibres it was possible to identify cells attaching through their 












A)                                                                            B) 
                   
C)                                                                           D) 
                
E)                                                                            F) 
                     
Figure 6.11. Optical microscopy images of C2C12 myoblast cell line grown on glass slides 
coated with: (A), (C) and (E) 750 nm electrospun P(3HO) fibres vs. (B), (D) and (F) 370 nm 




electrospun P(3HO) fibres collected for ten seconds. A), B), C), D) 100x and E), F) 400x 
magnification. The cell’s focal adhesions attaching to the fibres are indicated with black 
arrows.  
 
Several studies have shown that fibrous matrices, which allow cell infiltration into their 
porous structure, are attractive substrates as tissue engineering scaffolds (Lee et al., 2011, 
Kurpinski et al., 2012). Pores in an electrospun fibrous structure are formed by differently 
oriented fibres and the size and shape of those pores will be directly related to the fibre 
concentration. In order to find the optimal concentration of fibres that will allow cell 
infiltration, in the next experiment, the collection times for the 750 nm fibres on glass slides 
were varied and the fibre concentration was evaluated by optical microscopy. Figure 6.12 
shows optical microscopy images of the 750 nm fibres at (A) 1 second, (B) 10 seconds, (C) 
30 seconds, (D) 60 seconds and (E) 90 seconds collection times. The selected collection time 
was 30 seconds (Figure 5.12 C), in which the fibres covered the entire surface, leaving some 
gaps for the cells to infiltrate. 




     A)                                                         B) 
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              E)    F) 
Figure 6.12. Optical microscopy images of the 750 nm P(3HO) electrospun fibres at (A) 
1 second, (B) 10 seconds, (C) 30 seconds, (D) 60 seconds and (E) 90 seconds collection 
times.   
6.2.3. P(3HO) cardiac patches 
In this section the fabrication of cardiac patches is described. 750 nm fibres were collected 
for 30 seconds on neat and porous 5 wt% P(3HO) films. The surface of the resulting film was 
analyzed in terms of the wettability, surface roughness and protein adsorption. The 
visualization of the fibres by SEM was not possible due to the high temperature sensitivity of 
the P(3HO) fibrous structures which melted under the SEM focused beam of high-energy 
electrons. In order to confirm that fibres were collected on the P(3HO) film surface, the 
patches were observed under the optical microscope (Figure 6.13).  
40µm	   40µm	  
40µm	   40µm	  





Figure 6.13. Optical microscopy image of the 750 nm P(3HO) electrospun fibres at 30 
seconds collection time on the 5 wt% P(3HO) film. 
 
The surface wettability analysis was carried out as described in section 2.2.10.3. The water 
contact angles measured were 110.2± 3.7 for neat P(3HO) films containing 750 nm fibres and 
99.8 ± 1.9 for porous films containing 750 nm fibres. The water contact angle measured for 
the neat P(3HO) film was 101.1±0.8 (section 5.2.1.3) and for porous P(3HO) film was    
104.9 ± 6.0 (section 6.2.1). Surprisingly, an increment in the surface hydrophobicity was 
observed when neat films were functionalized with fibres and a decrease in the surface 
hydrophobicity was observed when porous films were functionalized with fibres. 
The surface roughness of the cardiac patches was measured according to section 2.2.10.5. 
The obtained values were 0.90±0.01 µm for neat films with 750 nm fibres and 1.1±0.1 µm 
for porous films with 750 nm fibres. The surface roughness of the neat P(3HO) film was  
0.17 µm and for the porous film was 0.9±0.2 µm (section 5.2.1.3 and section 6.2.1, 
respectively). As expected, an increment is the surface roughness was observed when films 
were functionalized with fibrous structures, achieving the maximum roughness when porous 



















Figure 6.14. Surface roughness analysis of two representative samples of A) P(3HO) neat 
film modified with 750nm fibres and B) P(3HO) porous films modified with 750nm fibres. 
Ra describes the average surface roughness, Rmax the maximum roughness depth, RZDIN the 
average peak to valley height minus Rtm and Rtm is the average distance between the highest 
peak and lowest valley in each sample. 
 
The protein adsorption capacity of the patches was assessed according to section 2.2.10.6. 
Results were compared with the neat P(3HO) and porous films (Figure 6.15). No significant 
differences were observed in terms of the protein adsorption capacity between the P(3HO) 
neat and porous films and the P(3HO) neat and porous films coated with fibres.  
 
Ra =        0.89 µm 
Rmax =     7.78 µm 
RZDIN =  6.60 µm 
Ra =         1,03 µm 
Rmax =    18,20 µm 
RZDIN =   9,71 µm 
Ra =         1,23 µm 
Rmax =    16,72 µm 
RZDIN = 11,98 µm 
Ra =        0,90 µm 
Rmax =     8,21 µm 
RZDIN =  6,68 µm 





Figure 6.15. Concentration of proteins adsorbed on the surface of neat P(3HO) films, porous 
P(3HO) films, neat P(3HO) films + 750 nm fibres and porous P(3HO) films + 750 nm fibres 
(n=3; error bars=±SD). The data were compared using ANOVA. 
 
As the structure of the P(3HO) fibres was intended for cardiac tissue engineering, its 
suitability was evaluated in vitro using C2C12, a myoblast cell line. Cells were seeded on the 
cardiac patches as described in section 2.2.11.3.3 and the % cell proliferation was assessed at 
24 hr with the MTT colorimetric assay according to section 2.2.11.3.4. Cell proliferation 
results on the patches were compared with the values obtained for neat P(3HO) and porous 
films (Figure 6.16). Our results showed that a significant increment in the % cell proliferation 
was obtained when fibre structures were incorporated on the surface of the neat P(3HO) films 
and porous films. Similar values for cell proliferation were observed with the porous films 
and neat films modified with fibres, suggesting that both structures contribute in a similar 
way to cell proliferation. Finally, P(3HO) porous films containing the P(3HO) fibrous 
structures showed the highest cell proliferation rate and hence this was the best matrix for cell 
adhesion and proliferation.  
 





Figure 6.16. The % cell proliferation of C2C12 cell line on neat P(3HO) films containing 
porous structures, fibrous structures and both fibrous and porous structures. Results were 
normalized against cell growth results on tissue culture plastic, used as a control (n=4; error 
bars=±SD). The data were compared using ANOVA and the differences were considered 
significant when **p<0.01 and ***p<0.001. 
 
SEM analysis was carried out to visualize the C2C12 myoblast cell line on the neat and 
porous P(3HO) films modified with fibres. Samples were prepared as described in section 
2.2.11.4. Figure 6.17 shows the SEM images obtained at 24 hrs. These results show that at  
24 hr the surface of the cardiac patches is covered with cells and new cells growing on top of 
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E)                                                                    F) 
    
Figure 6.17. SEM images of C2C12 cells at 24 hr on A), B) and C) neat P(3HO) and C), D) 




6.3.1. P(3HO) porous patches 
In order to provide more space for incorporation of cells and to allow the formation of a three 
dimensional structure, pores were incorporated in to the cardiac patches. As P(3HO) is a 
biodegradable material, it is anticipated that the biomaterial structure will reabsorb leaving 
behind new tissue. P(3HO) based porous films were fabricated by the solvent cast particle 
leaching method. The average diameter of the porous structures were 250-300 µm, which is 
the size of human myocytes. It is important to mention that although porous structures 
provide more surface for cell residence, the number of porous structures that can be created 
are limited by the desired mechanical properties of the biomaterial. Materials with high 
porosities displayed diminished mechanical properties (Goldstein et al., 1995). As one of the 
main requirements for a biomaterial in cardiac tissue engineering is to support the high 
mechanical demands of the organ during regeneration, the porogen concentration, which 
would determine the porosity in the patch, was chosen to allow some cell ingrowth without 
substantial deterioration of the mechanical properties. For this, P(3HO) porous films were 
created with 0.5 wt% sucrose and the mechanical properties of the constructs were assessed. 
The Young’s modulus value of the porous film was 0.41±0.03 MPa. The Young’s modulus of 
the P(3HO) neat film was 3.7±0.3 MPa. These results show that with a 0.5 % porogen, the 
stiffness of the material decreases by one order of magnitude.  The Young’s modulus of the 
human myocardium is 0.02-0.5 MPa, hence, the stiffness of the P(3HO) porous film matches 
this range very well. As the lower value of myocardial stiffness is 0.02 MPa, it is possible to 
further increase the number of porous structures, decreasing the stiffness of the construct. 
However, after a myocardial infarction, the abrupt loss of myocardium triggers a ventricular 
remodeling which includes dilatation, hence increasing the load on the infarcted region. 
Hence we hypothesized that among the range of cardiac patches, the one with a higher 
stiffness is convenient for myocardial support (Sutton et al., 2000). The tensile strength and 
elongation at break measured for the porous material was 0.7±0.2 MPa and 447±5 %, 
respectively. The tensile strength of the P(3HO) neat film was 3.4±0.2 MPa and the 
elongation at break 299±29 %. With the incorporation of porous structures, the tensile 
strength of the cardiac patch was closer and elongation at break was a bit higher to that of 
myocardial structures. As, expected, an increment in the surface roughness was obtained with 
the incorporation of porous structures. Finally, although no differences were observed in 
terms of surface wettability and protein adsorption between the neat and porous P(3HO) 




films, the % cell proliferation increased 2.5 times as compared to the neat film, when porosity 
was incorporated.  
 
6.3.2. P(3HO) fibres 
The extracellular matrix provides not only structural support to the cells but also regulatory 
cues for cells assembling into tissues, for growth and communication. As a result, one of the 
main goals in tissue engineering is to develop a tailored in vitro environment that mimics the 
intricate and organized meshwork of native extracellular matrix. As the extracellular matrix is 
mainly composed of collagen fibrils, the structure and topography of the fibres were recreated 
by electrospinning. Electrospinning is a versatile technique which allows the fabrication of 
nano and micro scale fibres or particles which mimic the extracellular matrix architecture. 
Different P(3HO) concentrations ranging from 0.2 wt% to 1.2 wt% were used to create 
electrospun fibres. The results obtained showed an increment in the fibre diameter from 340 
nm to 750 nm when the polymer concentration was increased from 0.6 wt% to 1.2 wt% 
(Table 6.1). These results were in agreement with Boland et al., (2001) who showed a direct 
relation between polymer concentration and electrospun fibre diameter. When the P(3HO) 
concentration was 0.5 wt%, both fibres and particles were obtained. Only particles where 
obtained with 0.2 wt% polymer solution.   
In order to find out the most suitable matrix for cells to grow, glass slides were coated with 
the different fibre sizes obtained. The surface wettability analyses of the samples showed no 
differences between 750 nm fibres, 700 nm fibres, 630 nm fibres, and 340 nm fibres + 
particles (Figure 6.9). Smaller water contact angles were obtained with the 580 nm particles 
than with other fibres or particle diameters, which indicated a more hydrophilic surface. 
C2C12 myoblast cells were seeded on the electrospun coated slides. The results obtained 
showed that the fibre diameter has a direct effect on cell adhesion and proliferation, with an 
increment in cell density with fibre size. In contrast to our results, Chen et al., (2007) 
observed an increment in fibroblast adhesion as a function of decreasing electrospun 
polycaprolactone fibre diameter from 1051 to 428 nm. Optical microscopy images revealed 
that the cell’s focal adhesions attach to the 750 nm fibres. It has been demonstrated that 
differences in fibre diameter result in highly significant differences in focal adhesion 
formation and cell proliferation (Hsia et al., 2011).  
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It is important to mention that fibre diameter also has a crucial role in controlling the pore 
diameter of the networks. It has been proven that increasing fibre diameter results in an 
increase in mean pore radius and hence cellular ingrowth (Eichhorn et al., 2005). Previous 
findings have shown that nanofibre structures impede cell migration into the scaffolds as they 
act as a sieve, keeping cells on the surface of the scaffold (Balguid et al., 2009). In order to 
allow cell migration into the interior of the electrospun fibres and porous structures, different 
collection times were assessed. The selected collection time was 30 seconds (Figure 6.12 C), 
the one in which the fibres have covered the full area leaving gaps for the cells to infiltrate. 
Note that the although some pores are smaller than myocardial cells, they should not impede 
cell migration as the fibres are lying loosely upon each other and cells can perform amoeboid 
movements to migrate through the pores by pushing adjacent fibres (Li et al., 2002).    
6.3.3. P(3HO) cardiac patches 
P(3HO) cardiac prototypes were fabricated by modifying the P(3HO) neat and porous films 
with 750 nm fibres. The surface of the construct was characterized by measuring the water 
contact angle, surface roughness and protein adsorption. It has been described that the 
wettability depends on the type of material as well as the surface treatment of the material 
(Lu et al., 1998). Our experiments showed an increment in the surface hydrophobicity when 
neat cardiac patches were functionalized with fibres. The reason is assumed to be an increase 
in the roughness of the surface. However, in contrast to our expectations, a decrease in the 
surface hydrophobicity was observed when porous cardiac patches were functionalized with 
fibres. The surface roughness of the cardiac patches was 0.90±0.01 µm for neat films with 
750 nm fibres and 1.13±0.14 µm for porous films with 750 nm fibres. The surface roughness 
of the neat P(3HO) film was 0.17 µm and hence with the incorporation of fibrous and porous 
structures, as expected, it was possible to increase the surface roughness by 6.5 fold. 
Although it could be expected an increment in the protein adsorption due to the structure of 
the patches, especially when porous structures were combined with fibres, no significant 
differences were observed between the different cardiac patches in terms of protein 
adsorption. 
Several reports show the influence of surface wettability, surface roughness and protein 
adsorption in the cell-biomaterial interaction, however, no general principles that can help in 
the prediction of cellular behavior by the combination of these parameters are known. 




Therefore, cell adhesion and proliferation were assessed. Myoblast (C2Cl2) cell proliferation 
was analyzed and compared on neat P(3HO) patches, porous patches, neat P(3HO) cardiac 
patches with 750 nm diameter fibres and porous cardiac patches with 750 nm diameter fibres 
on their surface. The proliferation observed on these patches were 21.11±1.85 %, 53.83±3.05 
%, 41.60±2.40 % and 109.20±1.50 %, respectively, when proliferation observed in tissue 
culture plates was considered to be 100 %. Results showed that both porous and fibrous 
structures increased the % cell proliferation due to their higher surface area-to-volume ratio 
as well as their topographical features that can enhance cellular adhesion and proliferation. A 
higher cell proliferation was observed when porous structures were incorporated than with 
fibrous structures. P(3HO) porous films modified with 750 nm fibres resulted in the best 
matrix for cells to proliferate .  
Thus results from this study suggests that the P(3HO) porous cardiac patches functionalized 
with 750 nm fibres are promising materials to support the infarcted myocardium, due to their 
mechanical properties and to deliver cells in order to allow efficient tissue regeneration due to 
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Cardiac tissue engineering aims to create constructs that can re-establish the structure and 
function of the infarcted myocardium. The basic strategy of tissue engineering includes the 
combination of living cells and a biocompatible material that mimics the structure of the 
extracellular matrix leading to the proliferation and differentiation of the seeded cells (Jawad 
et al., 2008). In addition to the engineered matrix, the cardiac cell microenvironment can be 
improved by the addition of adhesion, growth, migration or differentiation signals. In this 
chapter we have focused on the incorporation of protein based active factors capable of 
inducing vascularisation, modulating cell adhesion, favouring cell migration and 
differentiation, in the PHA based cardiac patches.  
The arginine-glycine-aspartic acid RGD tripeptide sequence is a cell attachment motif 
recognized by several adhesion receptors (Ruoslahti et al., 1996). Due to the widespread 
distribution of the RGD peptide, its use in a range of organisms and its high biological effect 
on cell adhesion, cell behaviour and cell survival, the RGD sequence is one of the most 
effective active molecule used in tissue engineering (Hersel et al., 2003). In the first part of 
this chapter, RGD motifs were immobilized on the P(3HO) film surfaces. The immobilization 
was carried out in two stages. First, the P(3HO) polymer was aminated and films were cast 
using solvent casting. Then, surface immobilization of the RGD peptide was carried out on 
the aminated solvent cast films. The presence of RGD motifs on the P(3HO) film surface was 
confirmed by FTIR, water contact angle studies and SEM.  
As cardiac tissue requires high oxygen levels due to the continuous contractile activity of the 
myocytes, the lack of vasculature in the engineered cardiac patches is the main cause of 
failure after implantation (Bronzino 2006, Cohen et al., 2012).  In order to promote 
angiogenesis and vascularisation, in this work, vascular endothelial growth factor (VEGF) 
was incorporated into the P(3HO) films (Neufeld et al., 1999).  
 
P(3HO) cardiac patches containing the immobilized RGD motifs or VEGF were 
characterized in terms of the mechanical, thermal and wettability properties. Cell 
proliferation studies were carried out using C2C12 myoblast cells on modified cardiac 
patches to determine the effect of RGD and VEGF effects on the biocompatibility of the  
P(3HO) based cardiac patch.  




Finally, as VEGF has a short biological half-life and high tumorigenic potential, a sustained 
and controlled release is desirable (Faranesh et al., 2004). VEFG can be incorporated into the 
constructs or engineered and supplemented in microspheres separately for a controlled 
release. Biocompatible and biodegradable P(3HB) microspheres have shown a high loading 
efficiency and a controlled release with a high potential to be used in biomedical applications 
(Francis et al., 2011). In order to create a controlled release system, P(3HB) microspheres 
containing VEGF were produced from the polymer obtained from the recombinant  
B. subtilis phaC1-pHCMC04 described in Chapter 3.TheVEGF release from P(3HO) cardiac 
patches and P(3HB) microspheres was measured and compared over a period of a month.   
 






7.2.1. RGD immobilization 
The cell-polymer and cell-cell interactions play a key role in controlling cell adhesion, 
proliferation, migration and differentiation. Several reports show the role of the RGD peptide 
in controlling these interactions (Hersel et al., 2003, Rezania et al., 2008, Yoon et al., 2004). 
In order to improve the properties of the P(3HO) cardiac patches, RGD peptides were 
immobilized onto the surface of the patch. The RGD peptide immobilization protocol used in 
this project was adapted from Yoon et al., 2003, where RGD motifs were immobilized on 
PLGA (section 2.2.9.4). Firstly, the carboxylic acid terminal group of P(3HO) was aminated 
by reacting the polymer with hexaethyleneglycol-diamine. FTIR was carried out to confirm 
that the amination had occurred as described in Section 2.2.9.4.3. The FTIR spectrum 
obtained from the modified P(3HO) patch was compared with the neat P(3HO) patch (Figure 
7.1). Results show the presence of a band at 3400 cm-1, which corresponds to the N-H bond. 
Additionally, a band was observed at 1000 cm-1 confirming the presence of a C-N bond. 
These absorbance peaks were missing in the neat patch. This result confirmed that the 
P(3HO) patch had been successfully aminated.          
 
 
Figure 7.1. FTIR spectra of as synthesized P(3HO) polymer vs. aminated P(3HO) (P(3HO)-
NH2). The arrows at 3400cm-1 and 1000 cm-1 indicate the N-H and C-N bonds, respectively. 
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The aminated P(3HO) polymer was blended with P(3HO) 50:50 and films were fabricated by 
the solvent casting technique. The resultant patches were modified with RGD tripetides on 
one side of the structure. In order to verify the presence of RGD motifs covalently linked to 
the membrane, FTIR was carried out according to section 2.2.9.4.3. The FTIR spectra 
obtained from the RGD immobilized P(3HO) film was compared with the as synthesized 
P(3HO) film (Figure 7.2). Results showed the presence of a strong band at 1287 cm-1 
corresponding to the C-N bonds present on the RGD-P(3HO) polymer. Also, other bands 
were observed at 825 cm-1, 1047 cm-1 and 1226 cm-1 due to the bend of the N-H bond and the 
stretch of C-O and C-O-C bonds from the PEG group linked to the structure, respectively. 
Note that, as expected, the band observed at 3400 cm-1corresponding to the –NH2 functional 
group in Figure 7.1 was not observed in this case. This is due to the fact that this terminal 
amine group would have reacted with the RGD sequence and hence the new terminal group is 
the carboxylic group from the RGD peptide.  
Figure 7.2. FTIR spectra of P(3HO) polymer vs. P(3HO)-RGD. The arrow at 1200 cm-1 
indicates the C-N bond. 
Several reports have shown the relation between RGD immobilization and surface 
wettability. It was observed that the incorporation of RGD structures on the surface of the 




polymer has a direct effect in decreasing the hydrophobicity of the structure. In order to 
confirm the presence of RGD motifs linked to P(3HO) cardiac patches the surface wettability 
of the cardiac patches was analysed according to section 2.2.9.4.3 The water contact angle 
obtained for the P(3HO)-RGD film was 93.44±0.09°. P(3HO) water contact angle was 
101.12±0.82º (section 5.2.1.3). Our results show a significant decrease in the water contact 

























Figure 7.3. Surface wettability properties of P(3HO) vs. P(3HO)-RGD cardiac patches (n=3; 
error bars=±SD).The data were compared using t-test and the differences were considered 
significant when **p < 0.01. 
As described previously, mechanical properties of the cardiac patch play an essential role in 
the patch function supporting the heart during regeneration.  In order to study the possible 
influence of the P(3HO) modification on the patch mechanical properties, Dynamic 
mechanical analysis was carried out on P(3HO)-RGD cardiac patches according to section 
2.2.10.1. The Young’s modulus of the RGD modified film was 3.9 MPa. Section 5.2.1.2 
shows that P(3HO) Young’s modulus was 3.7±0.3 MPa, hence no differences were observed 
in terms of the material stiffness after the RGD modification. The tensile strength for 
P(3HO)-RGD was 0.66 MPa and elongation at break 426.53%. The tensile strength and 
elongation at break for P(3HO) was 3.4±0.2MPa and 299±29 %, respectively. These results 
show a decrease by 19% in tensile strength and an increase by 42% in elongation at break 
after the RGD modification. In order to visualize the surface of the modified cardiac patches, 
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SEM was carried out as described in section 2.2.10.4. Figure 7.4 shows the SEM images of 
P(3HO)-RGD cardiac patches. These pictures revealed that the incorporation of RGD 
peptides structures changed the surface morphology by introducing a rough topography to the 
surface. 
   A)                                                                   
 
B) 
    
Figure 7.4. SEM images of A) neat and B) RGD immobilized P(3HO) film at different 









7.2.2. VEGF incorporation in P(3HO) films 
As vascularisation and angiogenesis are key factors in cardiac tissue engineering, VEGF was 
incorporated into the P(3HO) films. The mechanical properties of the resulting cardiac 
patches were measured as described in section 2.2.10.1. The Young’s modulus obtained for 
the VEGF modified film was 6.82 MPa, the tensile strength was 0.56 MPa and the elongation 
at break was 449.32%. The tensile strength and elongation at break for P(3HO) was        
3.4±0.2 MPa and 299±29 %, respectively. These results show a decrease in tensile strength 
by 17% and an increase by 50% in elongation at break after the VEGF incorporation. The 
surface of the VEGF modified cardiac patches was analysed by water contact angle and 
SEM. The water contact angle of P(3HO) cardiac patches containing VEGF factor 
incorporated was 102.49 ± 1.40°. P(3HO) water contact angle was 101.1±0.8 ° (section 
5.2.1.3). These results show no differences in the surface wettability with the VEGF 
incorporation. The surface of the cardiac patches was visualized by SEM (Figure 7.5). SEM 
images show qualitatively a slight increment in the surface roughness compared to P(3HO) 
plain films.  
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Figure 7.5.SEM images of A) P(3HO) neat film and B) P(3HO) containing VEGF at 
different magnifications showing the surface of the films.  
 
7.2.3. Cell proliferation 
In this part of the study, the effect of P(3HO)-RGD immobilized cardiac patches and 
P(3HO)-VEGF on cell proliferation as compared to the neat polymer patch was studied. To 
this end, C2C12 myoblast cells were seeded on P(3HO) modified cardiac patches according 
to section 2.2.12.3.3 and cell proliferation was measured by the MTT colorimetric assay, as 
described in section 2.2.11.3.4. Figure 7.6 shows the % cell proliferation on P(3HO), 
P(3HO)-VEGF, P(3HO)-RGD and P(3HO)-VEGF+RGD cardiac patches when proliferation 
observed on tissue culture plastic was considered to be 100%. The % cell proliferation on 
P(3HO) films was 21.11±5.29 %. A significant increase in cell proliferation was observed 
when VEGF and RGD were incorporated into the P(3HO) cardiac patches. However, a higher 
cell proliferation was achieved with VEGF. A synergistic effect was observed when both 
VEGF and RGD were incorporated together, showing a highly significant effect on cell 
proliferation.   






Figure 7.6. The % cell proliferation of C2C12 cell line at 24 hr on P(3HO), VEGF, RGD and 
VEGF+RGD modified P(3HO) patches (n=4; error bars=±SD).The data were compared using 
ANOVA and the differences were considered significant when *p<0.05,**p<0.01 and 
***p<0.001. 
 
7.2.4. VEGF encapsulation in P(3HB) microspheres 
VEGF was encapsulated in P(3HB) microspheres anticipating that this approach could lead to 
localised and controlled delivery. P(3HB) microspheres were fabricated according to section 
2.2.12.1. Fabricated microspheres containing VEGF were visualized with SEM. Figure 7.7 
shows the obtained images. SEM images reveal the spherical shape with a smooth surface 
morphology.The average size of the P(3HB) fabricated microspheres was 127.69±16.41 µm. 
As microsphere porosity plays an important role in determining the encapsulation efficiency 
and release kinetics, the porosity of the microspheres were determined using equation 2.4 
described in section 2.2.12.2 (Cai et al., 2013). The porosity of the microspheres was 








Figure 7.7.SEM images of P(3HB) microspheres, containing VEGF, at different 
magnifications showing the spherical and smooth surface of the microspheres. 
In order to confirm drug encapsulation and possible drug-polymer interactions, FTIR and 
DSC (described in section 2.2.12.4) were carried out. Unloaded microspheres were used as a 
negative control. The FTIR spectrum for VEGF loaded and unloaded microspheres are shown 
in Figure 7.8. The appearance of a band at 2978 cm-1 corresponding to the benzene ring of the 
tyrosine and phenylalanine aminoacids present in VEGF protein, indicate the presence of 
VEGF. No other differences were observed between the spectra of VEGF loaded and 
unloaded microspheres which indicated that either no covalent interaction had occurred 




Figure 7.8. FTIR spectra of P(3HB) unloaded microspheres vs. VEGF loaded P(3HB) 
microspheres. The arrow at 2978 cm-1 indicates the aromatic groups present in the VEGF 
protein. 
The DSC thermograms for unloaded and VEGF loaded micrspheres are shown in Figure 7.9 
(A) and (B), respectively. The thermal properties of P(3HB) crude polymer obtained from 
the recombinant B. subtilis phaC1-pHCMC04 described in Chapter 3 were determined. The 
Tm and Tc values were 169.81ºC and 119.51ºC, respectively. For the unloaded microspheres 
the Tm was 167.07 ºC and Tc was 62.90 ºC. Finally, for VEGF loaded microspheres the Tm 
was 157.74 ºC and Tc was 92.33 ºC. These results showed a shift in the Tm towards lower 
temperature with crude P(3HB) ˃ unloaded microspheres ˃ VEGF loaded microspheres. On 
the other hand, a decrease in Tc was also observed when comparing crude polymer with 
unloaded and loaded microspheres. Note that VEGF does not appear as a separate peak and 
this might be due to the low amount of protein compared to the polymer. However, a change 
in the Tm and Tc values between the loaded and unloaded microspheres indicates the presence 
of VEGF in the VEGF loaded microspheres. Also, in the next section VEGF release was 
quantitatively measured using ELISA from the VEGF loaded microspheres confirming the 
successful encapsulation of VEGF. 








Figure 7.9. Thermal profile of (A) unloaded P(3HB) microspheres and (B) VEGF loaded 
P(3HB) microspheres. The arrows in the pictures indicate the Tm and Tc obtained.  
 
7.2.5. VEGF release 
The cumulative in vitro release of VEGF from P(3HB) microspheres and P(3HO) cardiac 
patches was studied over 30 days, as described in section 2.2.12.5. The amount of VEGF 
released in the medium was measured using the Invitrogen® VEGF human ELISA kit. The 







loaded within the microsphere. The encapsulation efficiency was calculated using equation 
2.5 described in section 2.2.12.3.1. The obtained value was EE%= 34.98 %. The release 
profile is shown in Figure 7.10. Our results showed a biphasic VEGF release for both P(3HB) 
microspheres and P(3HO) cardiac patches with an initial burst release followed by a period of 
sustained release. Significant differences were observed at days 1 and 3 between P(3HB) 
microspheres and P(3HO) patches. The VEGF released from the microspheres was 
10.78±1.79 % and 21.71±1.95 % on day 1 and 3 respectively, whereas from the cardiac 
patches was 21.92±1.58 % and 30.02±1.78 % on day 1 and day 3 respectively. Note that in 
addition, both in the cardiac patches and the microspheres, the VEGF release kinetics 
changed at day 7, showing a slower release rate. 
Figure 7.10. Release profile of VEGF from P(3HB) microspheres and P(3HO) cardiac 
patches (n = 3; error bars=±SD). 
**
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7.3.1. RGD immobilization 
The fabrication of biodegradable constructs in tissue engineering is essential to provide a 
matrix for cell proliferation, migration and differentiation and to act as a support for the organ 
during regeneration. In addition to the biomaterial matrix, the control of cardiac cell 
environment can be enhanced by the design of biomaterials that provide adhesion, growth, 
migration or differentiation signals. In this chapter, the cardiac patch was further 
functionalised via the incorporation of active factors. It has been observed that proteins that 
contain the Arg-Gly-Asp (RGD) sequence are recognized by several different integrins in 
their adhesion protein ligands (Ruoslahti et al., 1996). In order to allow efficient host cell 
recruitment and adhesion, in the first part of the chapter RGD motifs were immobilized on 
the films. For the RGD immobilization a series of chemical reactions were carried out to 
incorporate active amino terminal structures on the carboxyl terminal end of the P(3HO) 
molecule, followed by the reaction of the terminal amine with the RGD sequence. The 
incorporation of the amino terminal group into the P(3HO) molecule was carried out through 
the addition of  hexaethyleneglycol-diamine to the P(3HO) carboxylic acid end. The 
incorporation of the hexaethyleneglycol-diamine group to the P(3HO) was confirmed by 
FTIR. The appearance of a band at 3400 cm-1 which corresponded to the N-H bond and the 
appearance of a band at 1000 cm-1 showing the presence of a C-N bond suggested the 
presence of the hexaethyleneglycol-diamine in the P(3HO) film. In a second step, the 
covalent linkage of the RGD peptide to the hexaethyleneglycol-diamine present on the 
P(3HO) film was studied by FTIR. Results showed the presence of a strong band at  
1200 cm-1 corresponding to the C-N bonds that should be present in the RGD-P(3HO) 
polymer due to the linkage of the hexaethyleneglycol-diamine with P(3HO) and with the 
RGD peptide. In addition, the disappearance of the band corresponding to the NH2 primary 
amine group further confirmed the formation of the RGD-hexaethyleneglycol-diamine- 
P(3HO) linkage. 
With the incorporation of RGD structures in the P(3HO) cardiac patches, an increment in the 
hydrophilicity of the surface was expected (Lin et al., 1992, Lin et al., 1994). As polar 
molecules interact better with water than non-polar molecules, an increment in the molecular 
hydrophilicity is usually detected when RGD motifs are immobilized (Lin et al., 1992, Lin et 
al., 1994). The water contact angle of the P(3HO)-RGD immobilized cardiac patches was 




93.44±0.09º. P(3HO) water contact angle was 101.1±0.8 º (section 5.2.1.3). These results 
thus showed a significant decrease in the water contact angle. Hence, the expected increase in 
the surface hydrophilicity after the modification with RGD peptides reconfirmed the 
incorporation of the RGD peptide onto the P(3HO) film.   
In order to study any possible effect of the RGD immobilized peptides on the mechanical 
properties of the P(3HO) cardiac patches, dynamic mechanical analysis under static 
conditions was carried out. No differences were observed in terms of the polymer stiffness 
after the RGD incorporation. However, a decrease in the tensile strength was observed with 
the RGD immobilization. As the linkage of the RGD motifs to the surface of the P(3HO) 
cardiac patches were carried out through hexaethyleneglycol-diamine molecules incorporated 
to the polymer, differences in the mechanical properties can be attributed to the presence of 
these molecules which perhaps embedded themselves between the chains of the polymer, 
spacing them apart. In agreement with our results, previous reports have shown a decrease in 
the tensile strength and an increment in the elongation at break when polyethylene-glycol was 
incorporated into cellulose acetate films as a plasticizer (Yuan et al., 2001). Finally, SEM 
images show an increment in the surface roughness after the RGD modification. 
 
 
7.3.2. VEGF incorporation 
As vascularisation is crucial in cardiac constructs, VEGF was incorporated in order to assist 
cell growth and tissue vascularisation. Mechanical properties of the P(3HO)-VEGF cardiac 
patches were determined and compared with P(3HO) films. Similar stiffness was obtained 
after the VEGF incorporation. However, a decrease in the tensile strength and an increment in 
the elongation at break were observed with VEGF. It has been observed that the addition of 
different molecules on a polymer reduce the molecular weight of the material and a decrease 
in the molecular weight is directly related with a decrease in tensile strength (Barron 2013, 
Odian 1991). The elongation at break may be influenced by water used as VEGF solvent, 
which may have decreased the interaction of the polymer chains when the polymer was 
mixed with the VEGF solution, making them more stretched due to interactions of water with 
the hydrogen bonds of the polymer (Wang et al., 2005). Although an increment in the surface 
hydrophilicity can be expected with the incorporation of VEGF molecules, due to an 
increment in the surface polarity, no significant differences were observed in terms of the 
surface wettability after the VEGF incorporation. The reason of this observation can be 
related to the amount of VEGF incorporated, which was too low to have an effect on the 
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surface wettability. SEM images show a slight increment in the surface roughness in P(3HO) 
VEGF cardiac patches. Surface roughness studies should be carried out for a quantitave 
analysis.   
7.3.3. In vitro cell proliferation in P(3HO) cardiac patches containing VEGF and RGD 
peptide 
C2C12 myoblast cells were seeded on P(3HO) cardiac patches containing VEGF, P(3HO) 
cardiac patches containing RGD and P(3HO) cardiac patches containing both VEGF and 
RGD. Cell proliferation was evaluated at 24 hr with the MTT colorimetric assay. Results 
showed a significant increment in the cell proliferation when VEGF or RGD were 
incorporated in comparison to P(3HO) films. In terms of RGD, these results suggested that as 
previously reported in literature, the increased cell-polymer interactions play a pivotal role in 
simulating cell proliferation (Neff et al., 1999). Yoon et al., (2004) showed a significant 
increment in cell attachment when bone marrow stem cells isolated from rat were seeded on 
PLGA films immobilized with RGD motifs. On the other hand, VEGF has also been shown 
to have a positive effect in cell proliferation. These results are in agreement with previous 
reports that show the presence of VEGF receptors, which were thought to be present 
exclusively in endothelial cells, in a number of different cell types (Couper et al., 1997, 
Pancholi et al., 2000, Shen et al., 1993). Sipahigil et al., (2012) showed a significant 
increment in L-929 cell line proliferation with VEGF incorporationinpoly(lactic-co-glycolic 
acid) microspheresand a direct relation between VEGF concentration and % cell 
proliferation. Additionally, our results showed a slightly higher increment in cell proliferation 
with VEGF than with RGD incorporation. However, from these results it is not possible to 
conclude if the higher effect on cell proliferation with VEGF is due to the difference in the 
actual effects of this factor on the cells or due to the different amounts of VEGF and RGD 
used in this study as the VEGF amount incorporated in each film was 2µg and in the case of 
the RGD, each film was reacted with a 1.5 nm/ml RGD solution. Finally, when both VEGF 
and RGD were incorporated, a synergetic effect was observed, with an increment in cell 
proliferation by 7 times with respect to P(3HO) films. These results suggested that there is no 
interference of VEGF with RGD proteins and, hence, both can be incorporated together to 
achieve better conditions that mimic the extracellular matrix structure in the tissue 
encouraging cell attachment and proliferation. 




7.3.4. VEGF encapsulation in P(3HB) microspheres 
Several advantages have been described with the development of controlled release systems 
including temporal and spatial presentation of the active factor in the target tissue, protection 
of the active factor from physiological degradation or elimination and patient compliance 
(Siegel and Rathbone, 2012). In order to achieve a controlled release of VEGF, VEGF was 
encapsulated in P(3HB) microspheres. SEM images confirmed the spherical shape of the 
constructs with a smooth surface morphology and with an average diameter of      
127.69±16.41 µm. The importance of porous microspheres is widely reported in tissue 
engineering. A highly porous structure with interconnected pores is crucial to achieve 
sufficient drug absorption and drug release kinetics, large specific surface area, and low 
density (Cai et al., 2013). In this work, the porosity of the microspheres was found to be 
85±13 %, showing a highly porous structure. It is widely known that differences in drug 
release between different constructs were not only attributed to the matrix porosity, but also 
to the polymer composition, the solubility of the drug in the media and amount of drug 
loaded (Gould et al., 1987, Dash et al., 1992). As a result, the optimal porosity should be 
determined in each case by drug release studies. FTIR and DSC analysis were carried out to 
confirm the presence of the VEGF in the microspheres and to study possible VEGF–polymer 
interactions. The FTIR spectra showed the appearance of only one band at 2978 cm-1 that was 
not present in the unloaded microspheres. This band showed the presence of the aromatic 
group of tyrosine and phenylalanine present in VEGF, confirming the presence of VEGF in 
the microspheres. Additionally, FTIR spectral studies showed no other differences between 
VEGF loaded and unloaded microspheres suggesting no significant covalent interactions 
between the drug and the polymer or the relative amount of VEGF being too low to be 
detected by FTIR. DSC studies showed a reduction of 10ºC in the melting temperature for 
VEGF loaded microspheres with respect to unloaded microspheres similar to the observations 
previously made by Bidone et al., (2009) with the incorporation of ibuprofen in 
P(3HB):mPEG-PLA blend microspheres. Our results indicate that the crystalline structure of 
the polymer was affected in the presence of the VEGF. No separate peaks were observed for 
the active factor, which might be due to the low concentration of the VEGF in the sample 








7.3.5. VEGF release 
The drug release profiles of VEGF were measure during VEGF loaded P(3HO) cardiac 
patches and P(3HB) microspheres for a period of 30 days. The results obtained showed a 
biphasic VEGF release profile for both P(3HB) microspheres and P(3HO) film, with an initial 
burst release followed by controlled release. However, the results showed that the P(3HB) 
microsphere drug release, during the initial phase, was half of that obtained using the P(3HO) 
films. These results indicated that a better initial controlled release is obtained with P(3HB) 
microspheres. Note that due to the fact that the structure of the constructs and the nature of 
the polymer used are different, the differences in the release profile must be attributed to both 
these factors. However, due to the more crystalline structure of P(3HB), lower degradations 
rates leading to lower drug release rates are expected, as compared to P(3HO). Hence, the 
more controlled release in microspheres cannot be attributed only to the structure of the 
constructs due to the different nature of the polymer. Although differences in the % 
cumulative release were observed in the P(3HB) microspheres and P(3HO) cardiac patches, 
at day 1 and 3, similar VEGF release rates were obtained from day seven until day 30. On 
day 30 only 50 % of the drug was released in both microspheres and cardiac patches 
indicating a sustained drug release during longer periods than 30 days as is suggested by the 
slope pendant, an advantage for long term release. Sipahigil et al., (2012) have worked on 
VEGF encapsulation in PLGA microspheres. A similar release profile was obtained in 
P(3HB) microspheres with an initial burst release of 10 %, following by a controlled release. 
However, for PLGA microspheres at the end of 30 days, the cumulative release achieved was 
around 75 %. In this study, P(3HB) microspheres showed a slower release rate than PLGA 
microspheres which can be attributed to differences in the VEGF-polymer interaction and 
slower degradation times of PHAs as compared to PLGA that allow drug release for longer 
periods of time. 
A sustained release of VEGF over a 30 day period is crucial for because of a short biological 
half-life of VEGF and its high tumorigenic potential. This was successfully achieved with 
both P(3HB) microspheres and P(3HO) cardiac patches with a more controlled initial burst 
release in microspheres (Faranesh et al., 2004). In conclusion, functionalised patches 
containing RGD and VEGF proteins can create a perfect microenvironment that would 
induce vascularization and improve cell-matrix and cell-cell interactions to promote the 





















8.1. CONCLUSIONS  
 
In the first part of this study we investigated the phaC1 gene expression from P. mendocina 
in B. subtilis 1604. The B. subtilis 1604-phaC1 recombinant strain showed PHA 
accumulation in Ramsay media, when sucrose was used as a sole carbon source. B. subtilis 
wild type and B. subtilis containing the pHCMC04 vector with no phaC1 insert were used as 
controls. Results showed that PHA accumulation in B. subtilis wild type and B. subtilis 
containing the vector with no insert was lower than 3% DCW. In contrast, PHA accumulation 
in B. subtilis containing the phaC1 gene from P. mendocina, was more than 32 %DCW. 
These results confirmed the role of the phaC1 gene in PHA accumulation in the recombinant  
B. subtilis. The chemical characterization of the produced polymer was carried out showing 
the presence of the P(3HB) homopolymer in both the controls and the recombinant strain. In 
order to understand the substrate preference of the phaC1 encoded PHA synthase from  
P. mendocina, when sucrose was used as the carbon source, wild type P. mendocina was 
grown in MSM media with sucrose as the carbon source. In contrast to results obtained with 
other Pseudomonas strains, where mcl-copolymers were accumulated, P. mendocina showed 
the presence of the scl-mcl-PHA copolymer, P(3HB-co-HO). Although it is not possible to 
observe the sole effect of the phaC1 gene due to the presence of other genes related with 
PHA metabolism, this result showed the capability of the phaC1 encoded PHA synthase from        
P. mendocina to utilize coenzyme A thioesters of scl- and mcl-3-hydroxyalkanoates when 
sucrose was used as the carbon source. As previously described, the particular pathway used 
for PHA production was found to depend on the particular metabolic pathways that are 
operating in a particular microorganism and the carbon source provided. Additionally, the 
synthesis of mcl-3-hydroxyacyl-CoA units can occur mainly by two different pathways, one 
involving with the fatty acid degradation pathway from fatty acids and other involved with 
the fatty acid biosynthetic pathway from carbohydrates (Kim et al., 2007, Doi et al., 1990, 
Poirier et al., 1995, Steinbüchel et al., 1991). When the recombinant B. subtilis strain was 
growth on sucrose, mcl-PHA production was expected to occur via the fatty acid biosynthetic 
pathway. However, as no mcl-PHAs were obtained with sucrose as the carbon source, the 
recombinant B. subtilis was grown in a range of fatty acids to test the capability of the strain 
to utilize mcl-3-hydroxyacyl-CoA monomers for mcl-PHA production using the fatty acid 
degradation pathway. In this case PHA production was only observed when pentanoic, 
hexanoic and heptanoic acids were used and the polymer produced was poly(3-
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hydroxybutanoate-co-3-hydroxyvalerate), P(3HB-co-3HV), copolymer in all the three cases. 
As previously reported by Valappil et al., (2007) from the Gram-positive genera, only 
Corynebacterium, Nocardia and Rhodococcus can naturally synthesize this commercially 
important co-polymer P(3HB-co-3HV) from simple carbon sources such as glucose 
(Haywood et al., 1991, Alvarez et al., 2000). In this case, incorporation of the phaC1 gene 
from P. mendocina to B. subtilis allowed the strain to synthesize LPS-free P(3HB-co-3HV) 
copolymer a useful process. However, no mcl-PHA production was observed. Multiple 
sequence alignment showed certain amino acid differences in the core region of the phaC1 
encoded protein sequence from P. mendocina, which were otherwise conserved in other mcl-
PHA producers such as the P. aeruginosa, P. putida and P. oleovorans. These differences 
may explain the different outcomes observed. Our results, however, showed the capability of 
a Gram positive GRAS organism, B. subtilis, to express a gene from a Gram negative 
bacterium, i.e. Pseudomonas mendocina, and the low specificity of the phaC1encoded PHA 
synthase from P. mendocina, which can utilize both mcl- and scl-3-hydroaxyl CoA units for 
PHA production.  
As no P(3HO) was obtained from the recombinant strain, for this project, P(3HO) was 
produced using wild type P. mendocina and rigorously purified by sequential washing with 
acetone, ethanol, and methanol. Rai et al., (2011a) showed that an effective LPS removal was 
observed after strict purification steps, achieving 0.35 EU/mL, which complies with the 
endotoxin requirements of the FDA for biomaterials to be used for biomedical applications 
(Kato et al., 1996). P(3HO) production by P. mendocina was optimized in 2 L bioreactors. 
Four conditions with different carbon nitrogen ratios, and pH were tested. The highest PHA 
yields were obtained when pH 7.15, carbon/nitrogen 20:1 and stirrer speed of 200 rpm was 
used. Scaling-up studies were carried out for P(3HO) production in 20 L and 72 L 
bioreactors, based on the constant oxygen transfer method. The highest PHA yield (% DCW) 
was 26.84±0.35 for the 2 L bioreactor, 23.17±1.47 for the 20 L bioreactor and 13.80±2.82 for 
the 72 L bioreactor.  Comparable results obtained from both 2L and 20L bioreactors 
suggested that it is possible to scale-up PHA production from 2 L to 20 L bioreactors based 
on a constant oxygen transfer. Considerably lower values of PHA yield was obtained with the 
72 L bioreactor, suggesting that other parameters needed to be considered at this scale, such 
as specific power input or superficial air velocity, which cannot be maintained when kLa is 
maintained.   
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The purified P(3HO) was studied as a potential material for cardiac tissue engineering 
applications. In a first experiment, fresh ventricular cardiomyocytes from adult rats were 
seeded on P(3HO) films and the cell viability was compared with that on tissue culture 
plastic. Results showed a slightly higher viability on the polymer than in the control and 
confirmed the non-toxic nature and good cardiomyocyte adhesive property of the P(3HO) 
surface. In the following experiment, the effect of P(3HO) on cardiomyocyte contraction was 
studied using a range of frequencies of electrical impulses and calcium concentrations. The 
results obtained showed that the polymer did not reduce the effect of frequency or calcium on 
cardiomyocyte contraction when compared to the control. Moreover, the negative effect on 
the contraction performance with increment in electrical impulse frequency usually observed, 
was not observed with P(3HO). Results from these experiments confirmed that P(3HO) was a 
potential material to be used as an extracellular matrix in cardiac tissue engineering 
applications.  
It is widely accepted that the most promising materials that will allow efficient beating of the 
heart and proper matrix for new cardiac tissue regeneration will be the materials that most 
resemble the native myocardium. For this reason P(3HO) engineered constructs that attempt 
to mimic cardiac tissue were produced. In a first approach, 5%wt P(3HO) films were 
fabricated by solvent casting. The films were studied in terms of mechanical, thermal and 
surface studies. Due to the contractile function of the heart, one of the pivotal factors that will 
dictate the success of a material in tissue engineering applications is the mechanical 
properties of the engineered construct. As previously described, the mechanical properties of 
myocardium are as follows: Young’s modulus 0.02-0.5 MPa, tensile strength 3-15 KPa, and 
elongation at break between 100-300 % (Nagueh et al., 2004 and Watanabe et al., 2006). The 
stiffness of the P(3HO) film was 3.7±0.3 MPa, tensile strength 3.4±0.2 MPa and elongation 
at break 299±3 %. In order to reduce the stiffness and tensile strength, to provide more 
structural space for cell infiltration and to allow the formation of a three dimensional 
structure by permitting cell ingrowth, P(3HO) porous films were created by solvent cast 
particle leaching using 0.5% sucrose particles ranging from 250-300 µm diameter as the 
porogen. The stiffness of the porous film achieved with 0.5 % sucrose particles was 
0.41±0.03 MPa, tensile strength 0.7±0.2 MPa and elongation at break was 447±5 %. In this 
case, the desirable stiffness was achieved, the tensile strength was closer to myocardial 
structures and elongation at break was a bit higher than plain P(3HO) films, when porous 
structures were incorporated. Although the tensile strength was still higher than myocardial 
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structures, this may have a positive effect as it would prevent negative myocardial 
remodelling. The comparison of the mechanical properties of the P(3HO) film with most 
studied materials which is summarised in Table 1.1 (Chapter 1) indicates that (P3HO) porous 
film is the most promising candidate from the mechanical compatibility point of view. As 
collagen fibrils are the main constituent of the extracellular matrix and since we aimed to 
achieve an extracellular matrix like topography, electrospinning was used to produce P(3HO) 
fibres which were then used to functionalize P(3HO) plain and porous films. Different fibre 
sizes were created by electrospinning and optimal fibre size was selected according to cell 
proliferation studies. Significantly higher cell proliferation values were obtained with 750 nm 
fibre diameter. Final constructs were assessed in vitro with C2C12 myoblast cell line. The 
results obtained showed that cell adhesion and proliferation was improved when porous or 
fibrous structures were incorporated on the surface of the P(3HO) films and was highly 
improved when both fibrous and porous structures were incorporated simultaneously.   
Concluding remarks 
This study has shown the possibility of production of LPS-free PHAs by expressing the PHA 
synthase gene from a Gram-negative into a Gram-positive strain. In addition, results suggest 
the possibility of mcl-PHAs production in Bacillus subtilis using genes from P. mendocina. 
This study showed, for the first time, that Bacillus subtilis is as a potential candidate for 
producing PHAs. P(3HO) production based on constant oxygen transference was successfully 
scaled-up from 2 L to 20 L bioreactors for the first time. P(3HO) fibres were produced by 
electrospinning and used to surface functionalise the P(3HO) patches. Also, RGD tripeptide 
was immobilized on (3HO) patches. The final cardiac patches developed in this project 
exhibited enhanced cell adhesion and proliferation in vitro, and desirable mechanical 
properties, suggesting that P(3HO) is a promising material for future cardiac tissue 
engineering applications.  
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8.2. FUTURE WORK 
Based on the results obtained in this project the following investigations will provide a better 
understanding of the future potential of applying P(3HO) in cardiac tissue engineering: 
• The fact that B. subtilis containing the phaC1 gene from P. mendocina was unable to
synthesize mcl-PHAs can be attributed to the predominance of the scl-PHA metabolic
pathway operating in the organism or the lack of the enzymes from the mcl-PHA
metabolic pathway, including hydroxyacyl-ACP-CoA transferase which links the R-3-
Hydroxyacyl-ACP precursor from the fatty acid de novo biosynthesis metabolic pathway
to the PHA synthase for the mcl-PHA production. Although BLAST analyses suggested
the presence of a hypothetical protein, which is predicted to be a
hydrolase/acyltransferase, this protein has not been studied in detail, hence, further
studies should be carried out to confirm its presence and activity. Additionally, metabolic
engineering techniques with the obstruction of the scl-PHAs metabolic pathway to
facilitate the mcl-PHA biosynthesis should be carried out.
• As one of the main factors that limits the use of mcl-PHAs in different applications is the
limited capacity to produce high yields of mcl-PHAs and relatively low P(3HO) yields
were obtained in this work using P. mendocina, future studies should be carried out to
find optimal fermentation conditions based on a full factorial study with pH, C/N and rpm
as varying parameters.
• As similar yields results were not obtained when P(3HO) production was scaled-up from
20 L to 72 L bioreactors based on a constant oxygen transfer coefficient, further
experimentation is required to achieve a comparable operating condition in both  these
scales based on a range of other conditions including volumetric power input and
superficial air velocity.
• Confirmation of VEGF functional activity after incorporation on the P(3HB) patches
should be carried out by ligand-receptor assay for VEGF (Leopol’d et al., 2012).
• Determination of the optimal amounts of RGD peptide and VEGF to be incorporated on
the surface of the patch, should be carried out based on cell proliferation studies
combined with active factor release studies. To assess cell proliferation and active factor
release, MTT or neutral red and ELISA assays should be carried out, respectively.
Immobilization of optimal amounts of the RGD peptide and incorporation of optimal
amounts of VEGF should be carried out in the final cardiac patches.
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• The capacity of the engineered P(3HO) patch as an extracellular matrix to allow
cardiomyocyte differentiation should be assessed in vitro. For this, cells capable of
forming cardiomyocytes should be seeded and differentiated in vitro with signal
molecules such as ascorbic acid or retinoic acid on the P(3HO) cardiac patches containing
RGD peptides and VEGF (Ling-Ling et al., 2006, Woubus et al., 1998). For this, viability
tests such as the MTT or neutral red or observation in light microscopy in order to assess
live cells, combined with gene expression profiling of cardiac specific RNA and proteins
to determine cell differentiation, should be carried out. Functional activity of the
engineered graft including continuous, rhythmic, and synchronized contractions can be
tested in spontaneously beating artificial myocardial tissues by electrocardiography
(Kofidis et al., 2002a).
• In vivo experiments on infarcted animals will be crucial to define the potential of the
engineered P(3HO) based cardiac patch. Myocardial infarction can be induced i.e. by
ligation of the left anterior descending coronary artery (Laake et al., 2007). In this case,
P(3HO) engineered cardiac constructs created by seeded and differentiated pluri- or
multipotent cells should be implanted in the infracted region of the heart and the
following parameters should be assessed at different periods of time:
1. Degradation studies of the final constructs should be carried out in order to assess the
capability of cells to synthesize new extracellular matrix before complete degradation
of the material. For this, histological analysis combined with collagen I, IV, laminin
and fibronectin expression patterns and SEM can provide useful information in terms
of material degradation and new extracellular matrix formation.
2. Adequate integration and coupling of implanted and host cells should be assessed by
cell junction expression molecules, including connexin 43 and cadherin.
3. Biocompatibility of the final constructs should be assessed by the expression of
inflammatory mediators and material encapsulation. Acute or chronic inflammation
and possible ultimate rejection of the biomaterial should be determined by studying
cell infiltration and bioactive molecule expression. For instance, occurrence of acute
inflammation could be determined by neutrophil infiltration and production of
histamine, nitric oxide, bradykinin, C3A, C3B, C5A, PAF, IL-1 and IL-8 among
others. Chronic inflammation can be assessed by lymphocyte and macrophage
infiltration and TNF-α and INF-γ expression. Material encapsulation should be
evaluated by determining the presence and origin of fibrotic tissue surrounding




P(3HO) grafts. Although secretion of fibrotic tissue could lead to separation of host 
and implanted cells, this would not necessarily exclude functional coupling 
completely, since electrophysiological signalling can be conducted through relatively 
thick layers of fibrotic tissue (Gaudesius et al., 2003). However, inappropriate or 
excessive secretion of fibrotic tissue can increase the occurrences of arrhythmias 
(Breithardt et al., 1989).  
4. Structural and biochemical properties in common with the native cardiac tissue can be 
assessed by histological analysis.   
5. The ability of the newly formed tissue to contribute to long-term contractile function 
should be assessed using long-term experiments.  
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